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Abstract 
In West Africa, Streptococcus pneumoniae remains a leading cause of deaths in 
young children and serotype 1 strains are particularly important in causing invasive 
pneumococcal disease (IPD) despite being rare in nasopharyngeal carriage. The S. 
pneumoniae ST217 clonal complex, consisting of ST217 and the various locus 
variants has been shown to be the predominant pneumococcal serotype 1 clone in the 
sub-region. It is unclear how the recent introduction of pneumococcal conjugate 
vaccine (PCV) in countries in the sub-region could affect patterns of pneumococcal 
disease. Improving our understanding of the unique nature of pneumococcal serotype 
1 strains within the context of other pneumococcal serotypes circulating in West 
Africa prior to introduction of PCV would be critical in interpreting any subsequent 
changes in patterns of disease in this region. This forms the basis for my research 
studies for this PhD thesis. Epidemiological studies on S. pneumoniae strains in The 
Gambia revealed that a new dominant clone of serotype 1, ST3081, a single locus 
variant of ST217, emerged and appeared to have spread across the whole country. 
ST3081 appeared to have replaced ST618, a triple locus variant of ST217 and the 
previously dominant pneumococcal serotype 1 lineage circulating in The Gambia for 
over a decade earlier. This thesis, which also evaluated antimicrobial resistance 
patterns, showed that ST3081 isolates were more resistant to co-trimoxazole than 
ST618 isolates. In addition, comparative genomic analysis highlighted the role of 
recombination in driving the evolution of serotype 1 STs in The Gambia. It also 
revealed important genetic differences between these two predominant STs in The 
Gambia, ST3081 and ST618, in antimicrobial genes such as tetM and virulence 
genes such as exist within the fucose metabolism operon. These findings would be 
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useful in informing strategies to improve the monitoring and control of 
pneumococcal serotype 1 disease. 
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1. Introduction 
1.1. Historical perspectives 
Streptococcus pneumoniae was first isolated in 1881, independently by George 
Sternberg, an American scientist and Louis Pasteur, a French scientist from 
experiments with human saliva injected subcutaneously into rabbits (Austrian, 
1981). In 1884, the pneumococcus was found to be the cause of pneumonia by 
Albert Fraenkel (Austrian, 1960). During this period, the Gram stain was described 
and used to differentiate pneumococcal pneumonia from other microbes causing 
pneumonia (Austrian, 1960). These discoveries led to more research aimed at 
improving our understanding of host defence mechanisms against pneumococcal 
infections. In 1902, Fred Neufeld discovered capsular swelling with specific 
antibodies which led to the pneumococcal Quellung reaction, a method that remains 
the gold standard for differentiating pneumococcus into various serotypes (Austrian, 
1981). He had also previously discovered the bile solubility of S. pneumoniae which 
is currently used in the rapid identification of the organism (Austrian, 1981). 
Building on these discoveries, Frederick Griffith in 1928 demonstrated bacterial 
transformation when he showed that a non-virulent strain of pneumococcus injected 
into mice became virulent by exposing it to heat killed virulent strains (Griffith, 
1928). This subsequently led to the discovery of deoxyribonucleic acid (DNA) in 
1944 as the transforming factor, when Oswald Avery, Colin MacLeod and Maclyn 
McCarty resolved Griffith’s observation (Avery et al., 1944). This discovery has 
since formed the basis of the field of molecular genetics.  
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1.2. Streptococcus pneumoniae – the organism 
S. pneumoniae is a Gram positive, alpha-haemolytic coccal-shaped bacterium that is 
usually found in pairs, described as lancet-shaped diplococci, but may also occur 
singly or in short chains (Figure 1.1). A non-motile, non-spore forming, and 
facultative anaerobic organism, it often appears on blood agar plates as round 
colonies, sometimes mucoid, ranging from 0.5 to 1.25 µm in diameter with smooth 
edges. Older cultures, 24-48hours, may appear as “draughtsman” colonies having 
depressed centres and raised edges. S. pneumoniae can be differentiated from other 
alpha haemolytic Streptococci by the optochin susceptibility and bile solubility tests, 
both of which are positive with S. pneumoniae.  
 
Figure 1.1 Morphological features of Streptococcus pneumoniae. 
A) An electron micrograph of S. pneumoniae cells appearing singly or in pairs. B) A Gram stain 
showing Gram positive S. pneumoniae cells 
 
The pneumococcal cell has a thick cell wall comprised of teichoic acid and 
peptidoglycan. A prominent feature of the cell surface of most pneumococcal strains 
is the capsule (White et al., 1938). Encapsulated pneumococci are known to be 
pathogenic and largely responsible for causing invasive pneumococcal disease to 
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varying extents based on their capsular type (Brueggemann et al., 2003). Several 
studies have shown the important role of the capsule in causing disease. The 
pneumococcal capsule is known to inhibit complement activity and phagocytosis as 
well as reducing mucus-mediated clearance from the human host (Hyams et al., 
2010, Nelson et al., 2007). In addition, molecular evidence for the role of the 
pneumococcal capsule in virulence was demonstrated by Watson and Musher in their 
experimental study using mutant strains of pneumococcal serotype 3 that lacked only 
a polysaccharide capsule (Watson and Musher, 1990, Briles et al., 1992). They 
showed that the 50% lethal dose for mutant strains was greater than 5 x 107 colony 
forming units (CFU), in comparison to a 50% lethal dose of 1 CFU for the wild-type 
strains. Evidence from these studies as well as the observed decline in vaccine type 
pneumococcal disease following introduction of conjugate vaccines, the formulation 
of which have been based on capsular polysaccharides of the leading invasive 
pneumococcal serotypes, highlight the importance of the pneumococcal capsule in 
virulence of the organism. However, some other studies have shown that factors 
other than the capsule, such as the genetic background of pneumococcal strains, 
could also be important for full virulence of pneumococci (Kelly et al., 1994). Even 
though encapsulated pneumococci are typically known to cause invasive disease, 
non-encapsulated pneumococci have also been shown to cause non-invasive diseases 
like conjunctivitis and otitis media and in rare instances, have been responsible for a 
few cases of invasive disease (Valentino et al., 2014, Hotomi et al., 2016, Park et al., 
2014). Based on the capsule, S. pneumoniae strains are divided into different 
serotypes that are serologically and biochemically different. Currently, there are over 
95 known serotypes of pneumococci (Calix and Nahm, 2010, Oliver et al., 2013, 
Park et al., 2015, van Tonder et al., 2015). The pneumococcal cell surface has 
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several proteins and other factors that aid in evading the host immune system. Earlier 
reports have demonstrated that the pneumococcus exhibits phase variation in colony 
morphology with differential expression of the polysaccharide capsule, varying 
between a transparent and an opaque form. Evidence from these studies suggests that 
these forms of the pneumococcus play an important role in the ability of the 
pathogen to adapt to different environments within the human host at different times. 
The transparent phenotype is seen predominantly in the nasopharynx and has been 
shown to be the non-virulent form in established mouse models. During this phase, 
there is a down regulation of the cps genes which results in low levels of capsular 
polysaccharide being produced and more teichoic acid. This reduced expression of 
the capsule and higher levels of teichoic acid seen in the transparent phase is thought 
to facilitate nasopharyngeal carriage as teichoic acid has been shown to be important 
for adherence of pneumococci to the nasopharynx. In contrast to the transparent 
phenotype, the opaque phenotype is associated with more expression of the capsule 
and is known to predominate in blood (Weiser et al., 1994, Weiser et al., 1996, 
Manso et al., 2014). Given that the serotype specific PCVs, rolled out for routine 
immunization over the last two decades, have been developed based on the 
pneumococcal capsular types, the phenomenon of phase shift in pneumococci could 
have implications for overall effectiveness of these vaccines. The possibility of 
emergence in nasopharyngeal colonization of non-encapsulated strains of the 
pneumococcus, demonstrated by some recent studies (Roca et al., 2015), highlights a 
need for the development of pneumococcal vaccines that are able to provide wider 
coverage than the currently deployed PCVs. Some on-going efforts in vaccine 
development that employ use of non-encapsulated whole cell vaccines which express 
immunogenic proteins or attenuated virulence factors common to encapsulated and 
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non-encapsulated strains of the pneumococcus appear to be addressing these 
concerns (Chen et al., 2015, Goncalves et al., 2014). 
 
The first complete pneumococcal genome was published in 2001, a serotype 4 strain 
comprising of 2.16 Mbps encoding 2236 predicted coding sequences (Tettelin et al., 
2001). Subsequently, the genome sequence of several other strains across different 
serotypes have been published (Lanie et al., 2007, Hahn et al., 2015, Ip et al., 2015, 
Cornick et al., 2015, Williams et al., 2012). Being a naturally transforming organism, 
high rates of recombination occur within the genome of pneumococcal strains 
causing variability even amongst pneumococcal strains belonging to the same 
serotype (Croucher et al., 2011).  
 
1.3. Epidemiology of S. pneumoniae diseases 
The epidemiology of S. pneumoniae relates in most part to its ability to cause 
invasive pneumococcal disease (IPD) and these diseases occur in all age groups 
although the risks are highest in young children and the elderly. IPD is the isolation 
of S. pneumoniae from a normally sterile body site such as blood, cerebrospinal 
fluid, pleural or pericardial fluid and has been estimated to be responsible for 
700,000 to 1 million deaths in young children each year (O'Brien et al., 2009). 
Global estimates for child deaths indicate that pneumococcal disease case fatality 
rates are highest in Africa and South Asia (Figure 1.2). The average year to year 
pneumococcal disease incidence varied between countries from as low as 188 (131-
284) to as high as 6387 (4937-7909) per 100,000 in children less than 5 years with 
the highest incidence rates in Africa (O'Brien et al., 2009).  
 
Chapter one Introduction 
 
28 | P a g e  
 
 
Figure 1.2 Pneumococcal deaths in HIV-negative children aged 1-59 months per 
100,000 children. Adapted from (O'Brien et al., 2009). 
 
Studies conducted previously in The Gambia prior to the introduction of 
pneumococcal conjugate vaccines showed incidence rates of IPD to be 224, 139 and 
82 per 100,000 child years for children aged 2-11, 12- 23 and 24-35 months 
respectively in a peri-urban setting (Usen et al., 1998). Another study done in a rural 
setting of The Gambia reported even higher IPD incidence rates of 554 and 
458/100,000 in children less than 1 and 2 years old respectively (O'Dempsey et al., 
1996).  
 
More recently, a population-based surveillance for IPD conducted in rural Gambia 
over several years during and after the implementation of PCVs showed a reduction 
in the incidence of IPD from the baseline values. Specifically, reductions in IPD 
incidence was observed across all age groups with rates dropping from 253 cases per 
100,000 to 113 cases per 100,000; 113 to 49 cases per 100,000; 12 to 10 cases per 
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100000 and 9 to 4 cases per 100,000 in children age 2-23 months, 2-4 years, 5-14 
years and adults ≥ 15 years respectively (Mackenzie et al., 2016). 
 
In addition to regional and age-related differences in the epidemiology of IPD, the 
different clinical syndromes caused by invasive pneumococcal disease also have an 
influence on its epidemiology. Pneumonia, septicaemia and meningitis have been 
reported more frequently as clinical syndromes of IPD and are important causes of 
deaths globally. 
 
1.3.1. Pneumonia 
Pneumonia, a lower respiratory tract infection that specifically affects the lungs, is 
the leading cause of child deaths globally. Pneumonia illness is classified clinically 
either as a non-severe or a severe pneumonia illness (WHO, 2013). Childhood 
pneumonia deaths are often due to a severe pneumonia illness with approximately 1 
in 5 of these childhood pneumonia deaths caused by S. pneumoniae (Black et al., 
2010). Global disease burden estimates indicate there were as many as 120 million 
episodes of pneumonia in 2011, including 14 million episodes of severe pneumonia 
in children less than 5 years (Walker et al., 2013). These estimates represent widely 
varying regional incidence rates with reported rates lowest in the European region 
and highest in the African and Southeast Asian regions. As many as 30% and 39% of 
all severe pneumonia episodes occurred during this period in the African and 
southeast Asian regions respectively. The distribution pattern of childhood 
pneumonia deaths across world regions mirrors rates observed for pneumonia 
incidence. The highest number of deaths was reported in sub-Saharan Africa, 
accounting for as much as 43% of all childhood pneumonia deaths in 2011. 
Estimates for the year 2013, showed that pneumonia was responsible for 
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approximately 935,000 deaths of children under the age of five years and that this 
accounted for 15% of all deaths of children under five years old globally (Figure 1.3) 
(Liu et al., 2015).  
 
 
Figure 1.3 Global causes of death in children less than 5 years in 2013. Adapted 
from (Liu et al., 2015). 
 
Bacterial pathogens have been identified more frequently than other pathogens in 
severe pneumonia cases with S. pneumoniae, H. influenzae and Staphylococcus 
aureus the leading bacteria (Adegbola et al., 1994) prior to the introduction of PCVs. 
Of these bacterial pathogens, S. pneumoniae has remained the predominant bacterial 
cause of pneumonia in aetiology studies conducted both before and after the 
introduction of routine vaccination with pneumococcal conjugate vaccines with non-
vaccine type pneumococci predominating in the post-PCV era (Rudan et al., 2008, 
Rudan et al., 2013, Carrol et al., 2011).  
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1.3.2. Meningitis 
 Bacterial meningitis has been known to be associated with very high fatality, with 
reported annual mortality incidence in developing countries of 98 per 100,000 in 
children less than 1 year (Gessner et al 2010). Outbreaks of epidemic meningitis are 
particularly frequent in the African meningitis belt, a region that extends from The 
Gambia, in the west, to Ethiopia and Eritrea in the east (Leimkugel et al., 2005, Yaro 
et al., 2006). Predominant bacterial causes of meningitis include Neisseria 
meningitidis, S. pneumoniae and Haemophilus influenzae type b (Hib) in the pre-Hib 
vaccine era. Traditionally, the meningococcus has been known to be a leading cause 
of epidemic meningitis, but reports from the West African sub-region have indicated 
that the pneumococcus plays a more significant role in causing meningitis than 
thought previously (Gessner et al., 2010, O'Brien et al., 2009). The public health 
significance of bacterial meningitis extends beyond the deaths caused by this disease. 
Survivors are frequently left with significant sequelae. Some reports indicate that 
approximately half of all surviving children have life-long neurologic impairment 
including deafness, learning disabilities and seizures (Edmond et al., 2010, 
Goetghebuer et al., 2000). A systematic review also showed that the risk of at least 
one major complication was highest following S. pneumoniae meningitis in 
comparison to outcomes in meningitis caused by N. meningitidis or Hib (median 
(IQR) risks of 24.7% (16.2-35.3%), 7.2% (4.3-11.2%) and 9.5% (7.1-15.3%) 
respectively) (Edmond et al., 2010).  
 
1.3.3. Sepsis 
Sepsis refers to the presence of rapidly dividing bacteria in the blood stream with 
manifest signs of illness in the individual. Global estimates for incidence of 
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pneumococcal sepsis is reported be as frequent as 87 per 100,000 persons with 
highest rates seen in Africa (O'Brien et al., 2009). The case fatality rates for sepsis 
across all age groups ranged from 22% in the Western Pacific region to 58% in 
Africa region with higher rates seen in very young children and the elderly (O'Brien 
et al., 2009).   
 
1.3.4. Non-invasive pneumococcal disease 
Pneumococci are also known to cause less severe and non-invasive forms of disease 
such as otitis media (middle ear infection), sinusitis and bronchitis. Pneumococci 
have been identified in as many as 57% of middle ear aspirates taken from cases 
with acute otitis media (Tamir et al., 2015). Other bacteria known to cause otitis 
media include H. influenzae and Moraxella catarrhalis (Tamir et al., 2015).  
 
1.4. Risk Factors for invasive S. pneumoniae disease 
The risk for IPD has been shown to be significantly higher in certain groups or 
associated with specific factors. 
1.4.1. Age 
The risk for IPD has been shown to be significantly higher in children younger than 
two years of age and elderly persons older than 65 years (Robinson et al., 2001, 
Trotter et al., 2010). This may be related to relative immaturity or reduced 
competence of the immune system in these individuals to combat infection S. 
pneumoniae. In addition, data from different parts of the world indicate that the 
influence of age on IPD risk varies across regions. Children in developing countries 
were reported to have a lower median age for IPD incidence than was seen in 
children in developed countries (Greenwood, 1999).  
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1.4.2. Sex 
Males have been shown to have a higher risk for IPD (Nuorti et al., 2000). Reports 
from IPD surveillance across different geographical regions indicate that higher rates 
of IPD in males have persisted through the pre-PCV era into the post PCV era (de St 
Maurice et al., 2016, Wagenvoort et al., 2017). A recent study that 
utilized  population and laboratory-based IPD surveillance data from 1998-2013 
showed that IPD incidence rates in male subjects were as much as 1.5- 2 times 
higher than rates seen in females, regardless of race or existing co-morbidities (de St 
Maurice et al., 2016). Earlier experimental studies using mice models also 
demonstrated higher susceptibility among males to respiratory and 
systemic pneumococcal disease (Kadioglu et al., 2011).This relationship remains to 
be clearly understood. A previous report suggested that this observation might be 
confounded by gender differences in dietary and alcohol intake in adults (Cortese et 
al., 1992).  
 
1.4.3. Seasonality  
Reports from different geographical regions of the world have provided evidence of 
the seasonal patterns in IPD incidence. Incidence of IPD peaks in the winter periods 
in Europe and the United States of America (Ampofo et al., 2008) (Trotter et al., 
2010) whilst in The Gambia, the peak occurs in the rainy season (O'Dempsey et al., 
1996) and in the cold dry months in Malawi (Gordon et al., 2001).  
 
1.4.4. Socioeconomic factors 
Socioeconomic status, as assessed using a variety of factors in different studies, has 
been shown to be consistently associated with the risk of IPD. Persons in the lower 
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socioeconomic class have higher risk of IPD. Indicators of low social class such as 
overcrowding, illiteracy, malnutrition and lower income have all been shown to 
increase pneumococcal disease incidence (Chen et al., 1998, Nuorti et al., 2000, 
Savitha et al., 2007, Ciruela et al., 2013). 
 
1.4.5. Chronic medical conditions and immunosuppression 
Chronic illnesses or underlying medical conditions such as diabetes mellitus, chronic 
lung disease including asthma or chronic heart disease, have all been shown to 
significantly increase the risk of IPD (Ortqvist et al., 2005, Frankel et al., 1996). 
Additionally, human immunodeficiency virus (HIV) infected persons have been 
reported to have significantly higher risks for IPD in comparison to HIV negative 
persons (Nunes et al., 2011, Yin et al., 2012).  
 
1.4.6. Genetic predisposition 
Evidence for the influence of genes on IPD risk have come from various research 
studies including research evaluating the role of the sickle cell gene. The sickle 
haemoglobin (HbS) is a variant of the normal adult haemoglobin (HbA) and the 
sickle cell gene is inherited as a recessive trait. Individuals who are homozygous for 
the gene (HbSS) are regarded as having sickle cell disease (SCD). Sickle cell disease 
patients are reported to have significantly higher risks, as much as a 600-fold 
increased risk for IPD and higher IPD incidence than the general population 
(Greenwood, 1999, Williams et al., 2009). This increased risk in SCD patients is 
thought to be related to defects in splenic function and complement deficiency. The 
increased risk for IPD in sickle cell disease patients is important given that the 
burden of sickle cell disease is known to be highest in Africa. Global estimates of 
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sickle cell disease burden indicate that in 2010, of 305,800 new-borns delivered 
annually with the sickle cell disease, 79% occurred in sub-Saharan Africa (Piel et al., 
2013).  It may not be surprising, therefore, that high rates of pneumococcal 
nasopharyngeal carriage and invasive disease have been reported in many African 
countries, in comparison to rates observed in other parts of the world (O'Brien et al., 
2009).     
The roles of some other genetic factors, such as single nucleotide polymorphisms in 
selected genes involved in the innate and adaptive immune response, in individual 
differences in susceptibility to pneumococcal disease have been evaluated by 
different studies but the results have been largely inconclusive (Brouwer et al., 
2009). 
 
1.5. Epidemiology of S. pneumoniae carriage  
S. pneumoniae is asymptomatically carried in the upper respiratory tract of human 
beings, known to be its major natural reservoir, hence its dependence on humans for 
survival. The nasopharynx is the preferred sampling site for pneumococcal carriage 
studies although some studies have also considered sampling from the oropharynx 
(Odutola et al., 2013). S. pneumoniae is carried simultaneously with a wide range of 
other organisms in the nasopharynx, constituting a complex microbial community. 
Some of these organisms include Haemophilus influenzae, Moraxella catarrhalis, 
Staphylococcus aureus and other Streptococcus species.  
 
Nasopharyngeal carriage of pneumococci is believed to be an important step that 
precedes invasive disease and has been used as a measure for efficacy of vaccines 
(Bogaert et al., 2004a). Carriage rates of S. pneumoniae have varied across different 
regions of the world with higher rates recorded in developing countries compared to 
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developed countries. For example, relatively low carriage rates of 8.6% in children 
less than 5 years of age have been reported in Italy (Marchisio et al., 2002). By 
contrast, higher carriage rates between 85 and 97% have been found in children less 
than 5 years of age in The Gambia (Hill et al., 2006, Cheung et al., 2009, Obaro et 
al., 1996). Also similar rates between 50 and 90% have been found across other 
countries in sub-Saharan Africa (Vallès et al., 2006, Adetifa et al., 2012, Woolfson et 
al., 1997, Joloba et al., 2001, Feikin et al., 2003). 
 
Pneumococcal serotypes found most frequently in nasopharyngeal carriage are 
serotypes in groups 19, 6, and 23 while those rarely found include serotypes 1, 5 and 
7F (Roca et al., 2011, Feikin et al., 2003, Ba et al., 2014). 
 
1.6. Risk factors for S. pneumoniae carriage 
Low socio-economic status has been shown to be a risk for pneumococcal carriage in 
some studies. Overcrowding and poor ventilation often fosters transmission of 
pneumococci. Also, lack of education has been identified as a risk factor for 
pneumococcal carriage in some studies. Carriage rates also vary across age groups 
with a decreasing carriage rate observed with increasing age. For example, in The 
Gambia and Kenya respectively, carriage rates of 93.4% and 57.7 % was reported in 
children less than 5 years; 86.3% and 41.0 % in children aged 5 – 15 years and 
60.6% and 6.4 % in individuals above 15 years (Abdullahi et al., 2008, Hill et al., 
2006). Seasonality is another factor affecting pneumococcal carriage. A recent study 
conducted in three different geographical regions; South East Asia, Africa and North 
America showed that S. pneumoniae are optimally transmitted during the cooler and 
driest months (Numminen et al., 2015). Also attendance of day care centres; 
smoking history of parents, use of wood for cooking fuel , antibiotic therapy have 
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also been identified as risk factors in different settings (Regev-Yochay et al., 2012, 
Cardozo et al., 2008). 
 
1.7. Pneumococcal population biology  
1.7.1. Definition and importance of pneumococcal population biology  
The concept of bacterial population biology deals with study of the differences and 
similarities of genetic expression of a bacterial species that exists within a local 
community. It also aims to provide insights into the evolutionary mechanisms behind 
the emergence of the existing variants of the bacteria over a period of time, including 
the effects of any interventions in the community on that bacterial population. Some 
bacterial strains are known to exist as commensals in the human body, whilst other 
strains have been associated with causing invasive disease. Bacterial population 
biology also explores the relationships between invasive bacterial strains and the rest 
of the bacterial population, including the specific factors driving the invasive 
potential of these bacterial strains. For the purpose of this thesis, this section focuses 
on the population biology of Streptococcus pneumoniae.  
1.7.2. Sampling approach and the relationship between pneumococcal 
carriage and disease 
Pneumococcal strains are known to reside in the human nasopharynx as part of the 
normal bacterial flora, but are also able to cause invasive disease. Nasopharyngeal 
carriage is known to precede onset of invasive pneumococcal disease (Bogaert et al., 
2004a, Gray et al., 1980). Some studies have shown that an understanding of the 
carriage state is vital for a better understanding of pneumococcal population biology 
(Brueggemann et al., 2003). This is because the population of pneumococci in the 
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nasopharynx more accurately represents the natural population of pneumococci 
circulating in that community. As such, it is thought that pneumococcal disease 
isolates are best considered within the context of the carriage population circulating 
in that community over the same time period. In addition, some authors have 
suggested that this approach helps avoid the risk of over- or under- estimating the 
invasive potential of pneumococcal isolates seen in invasive disease because it takes 
into account the level of exposure of the population to that serotype or strain. Also, it 
would provide better clarity on how pneumococcal disease relates to carriage 
(Brueggemann et al., 2003). Therefore, an effective approach to the study of 
pneumococcal population biology would include an understanding of the 
pneumococcal carriage population, the mechanisms of transmission and how this 
could potentially inform on the likely patterns of pneumococcal invasive disease 
within that local community.  
1.7.3. Tools for understanding pneumococcal population biology 
Streptococcus pneumoniae strains have been characterized by serotyping, a method 
that distinguishes specific pneumococcal types based on their capsular 
polysaccharides, which also serve as an important factor in determining the virulence 
potential of the pneumococcal strain (Briles et al., 1992). About 100 different 
pneumococcal serotypes have been identified, even though only a handful of these 
are known to cause disease. However, the advent of molecular typing methods have 
shown that within each pneumococcal serotype exists clearly distinct genotypes and 
also allowed for identification of pneumococcal strains with closely related genetic 
profiles as clones or clonal complexes (Enright and Spratt, 1998). Of these molecular 
typing methods, the use of MLST and affordability of WGS that gives access to the 
entire genome of S. pneumoniae, have allowed for a more informative description 
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and a clearer understanding of the evolving population biology of Streptococcus 
pneumoniae and mechanisms for expansion. These and other pneumococcal typing 
methods are described later in this chapter 
1.7.4. Evolution of pneumococci:  Molecular mechanisms of change in the 
pneumococcal population biology 
Since its’ discovery in the 1900, Streptococcus pneumoniae, a highly transforming 
pathogen, has evolved over time, often times as a response to the selective pressure 
of interventions such as antibiotic usage and the introduction of conjugate vaccines 
(Albrich et al., 2004, Chiba et al., 2014, Gladstone et al., 2015b, Croucher et al., 
2011). Additionally, it is thought that evolution of the pneumococcus could also be 
due to secular changes, changes that are not attributable to any specific interventions 
in the community (Jefferies et al., 2010). A good understanding of the population 
biology of Streptococcus pneumoniae in different geographical regions and across 
different age groups will provide clearer insights into the mechanisms of evolution 
and could inform on more effective strategies for control of pneumococcal carriage 
and disease. Studies into the mechanisms by which the pneumococcus has evolved 
have shown that this has included recombination of genomic material and point 
mutation, with recombination events occurring far more commonly (Croucher et al., 
2011). 
High rates of recombination occurring within the genomes of S. pneumonaie have 
been shown to be one of the main drivers of the changing population structure of S. 
pneumoniae. In addition to exchange of genetic material between pneumococcal 
strains, recombination exchanges are also known to occur between pneumococci and 
other streptococci which colonize the human upper respiratory tract, such as 
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Streptococcus mitis, Streptococcus infantis and Streptococcus oralis (Donati et al., 
2010, Sanguinetti et al., 2012). Some of these exchanges across species have 
involved virulence genes such as those encoding for pneumolysin, mitilysin and 
neuraminidase A (Johnston et al., 2010). It would seem obvious therefore, 
recombination events within pneumococcal strains and between the pneumococcus 
and other species have contributed to the evolution and structural diversity of the 
pneumococcus (Kilian et al., 2014).  
Studies using whole genome sequencing have also shown that rates of recombination 
are higher in non-typeable pneumococci which do not express a capsule than in 
encapsulated (typeable) pneumococci (Chewapreecha et al., 2014b, Croucher et al., 
2011). Non encapsulated pneumococci have been described frequently in carriage 
population and only rarely seen in invasive disease (Chewapreecha et al., 2014a, 
Marsh et al., 2010). Nevertheless, these non-encapsulated pneumococci are believed 
to play an important part in the pneumococcal population dynamics through 
switching between encapsulated and non-encapsulated states and thereby facilitate 
increases in antibiotic resistance. The importance of genetic recombination in 
promoting development of antibiotic resistant pneumococcal strains and facilitating 
pneumococcal virulence has been well-documented (Slager et al., 2014, Griffith, 
1928, Dowson et al., 1993). In addition, studies have demonstrated that 
pneumococcal serotype changes can be explained by recombination events occurring 
at the capsular locus (Salter et al., 2012, Mostowy et al., 2017). Serotype changes 
have been reported commonly in the context of concurrent nasopharyngeal carriage 
of multiple pneumococcal serotypes and frequently occur between vaccine serotypes 
(Kamng'ona et al., 2015). 
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1.7.5. Factors driving pneumococcal evolutionary changes  
1.7.5.1. Pneumococcal conjugate vaccination  
The use of PCVs, from as early as the year 2000 in the United States, has been 
effective in reducing the incidence of invasive disease and carriage of vaccine 
serotypes. Prevalence of PCV7 serotypes was seen to decrease from 64% of invasive 
and 50% of non-invasive isolates in 1999–2000 to 3.8% and 4.2%, respectively, 
across all age groups, in 2010–2011 (Richter et al., 2013). This decrease in 
prevalence of vaccine type serotypes following introduction of PCV-7, was also 
observed in other parts of the world (Gladstone et al., 2015b, Roca et al., 2011, 
Feikin et al., 2013, Nzenze et al., 2013) However use of PCVs have also resulted in 
an increase in non-vaccine serotypes, known as serotype replacement (Gladstone et 
al., 2015b). Another is the phenomenon referred to as capsular switching which 
occurs when a vaccine serotype is observed to acquire the capsule of a non-vaccine 
serotype (Wyres et al., 2013). Following introduction of PCV-7 in the USA, a shift 
in the pneumococcal population structure was observed as a result of the emergence 
of serotype 19A, a non PVC-7 vaccine serotype, due to capsular switching events 
with the PCV-7 vaccine serotype 19F, occurring in the PMEN1 lineage of 
pneumococcus (Croucher et al., 2011). Similarly, capsular switching events have 
been demonstrated in the switch from serotype 4, a PCV7 vaccine serotype, to 
serotype 19A (Golubchik et al., 2012). More recently, expansion of the serotype 
35B, ST156 lineage was reported in The USA, following the introduction of PCV-
13, which excludes serotype 35B. This expansion was due to a capsule switching 
event occurring between the serotype 35B, ST558 lineage and serotype 9V, ST156 
lineage giving rise to the serotype 35B, ST156 lineage (Chochua et al., 2017). The 
prevalence of serotype 35B appears to have increased in both invasive and non-
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invasive disease (Richter et al., 2014, Richter et al., 2013). Furthermore, through 
capsular switching, vaccine type pneumococcal strains have been able to evade the 
effects of conjugate vaccines, and sometimes become more virulent in the process. 
ST 320, originally seen as serotype 19F, a PCV-7 serotype, has since been seen in 
the post PCV-7 era to exhibit the capsule of serotype 19A, a non PCV-7 serotype. 
This serotype 19A variant was found to have spread across many parts of the United 
States and to other parts of the world (Ansaldi et al., 2011, Golubchik et al., 2012). 
The ST 320 has been shown to be highly antibiotic resistant, possessing the mefE 
and ermB genes which confer resistance to macrolide antibiotics (Bowers et al., 
2012, Croucher et al., 2013).     
Another way in which vaccination has influenced evolution of the pneumococcus is 
how selective vaccine-induced pressure has contributed towards increases in levels 
of antibiotic resistance amongst circulating pneumococci. With introduction of 
conjugate vaccines, the prevalence of penicillin non-susceptible pneumococci among 
non-vaccine type pneumococci has been noted to increase and become even more 
diverse (Gertz et al., 2010, Gherardi et al., 2012). 
Therefore, introduction of conjugate vaccines has triggered adaptive responses by 
the pneumococcus that have resulted in increasing levels of evolution of this highly 
transforming pathogen. Further effects on the pneumococcal population structure of 
long term use of conjugate vaccines remains unclear. The absence of more effective 
preventative strategies, such as use of protein antigen based vaccines may lead to 
further rounds of serotype replacement (Devine et al., 2017, Gladstone et al., 2015b). 
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1.7.5.2. Antibiotic Usage 
The use of antibiotics has been known to induce changes that have contributed to 
evolution of the pneumococcus, with emergence and spread of multi-drug resistant 
clones (McGee et al., 2001). The Pneumococcal Molecular Epidemiology Network 
clone 1 (PMEN1), an S. pneumoniae lineage, one of the first described 
pneumococcal antibiotic resistant clones, has been shown to be resistant to penicillin, 
chloramphenicol and tetracycline (Croucher et al., 2009). This clone, first identified 
in Barcelona in 1984, has subsequently been found in parts of Africa, Asia and 
America (Munoz et al., 1991, Parry et al., 2002, McGee et al., 2001). These 
evolutionary changes that have occurred in response to antibiotic-induced stress in 
the pneumococcus, have been mediated through different mechanisms including 
mutation, horizontal gene transfer and genetic recombination with the pneumococcus 
acquiring genes that confer resistance to known antibiotics (Slager et al., 2014, 
Hakenbeck et al., 1999, Dowson et al., 1989, Hanage et al., 2009). Previous studies 
have described mutations in penicillin binding protein (PBP) genes that conferred 
resistance to beta lactam antibiotics such as penicillin, amoxicillin and cefotaxime. 
Additionally, recombination events have been shown to occur between 
pneumococcal serotypes, such as between serotypes 9V and 23F, 9N and 14, 35C 
and 17F and 12F and 7F, and have included PBP genes. These recombination events 
have been associated with the emergence of pneumococcal strains with resistance to 
other classes of antibiotics (Hanage et al., 2009, Wyres et al., 2013). Recombination 
events have facilitated the transfer of transposon and integrative conjugative 
elements (ICEs) that have conferred antibiotic resistant properties across 
pneumococcal populations. The transposon Tn2010 is known to carry the mefE and 
ermB genes within the macrolide-resistant pneumococcal strain, ST 320 (Bowers et 
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al., 2012, Croucher et al., 2013). Other transposons such as Tn916, Tn5251, Tn5252, 
Tn5253 and Tn1545 are known to carry genes which confer resistance to 
chloramphenicol and tetracycline (Rice, 1998, Ayoubi et al., 1991).  
The pattern of antibiotic resistance amongst pneumococcal isolates is also known to 
be influenced by changes in prevalence of specific serotypes following the 
introduction of pneumococcal conjugate vaccination. In the USA, introduction of 
PCV7 was seen to precede changes in the sequences of resistance genes against 
macrolides and β-lactams (Bowers et al., 2012, Pelton et al., 2007). 
1.7.5.3.  Secular changes 
Regardless of the influence of vaccination or other major interventions in a 
community, temporal fluctuations in the prevalence of circulating serotypes or 
genotypes of pneumococci have been reported in different geographical settings 
(Finland and Barnes, 1977, Jefferies et al., 2010). In a study that employed MLST 
and eBURST analysis of invasive pneumococcal isolates collected over a period of 5 
years preceding the introduction of PCV-7 in Scotland, considerable changes in 
serogroup and clonal distributions were observed throughout the study period. Only 
9.8% of the 338 different STs identified were seen to be stable and associated with 
invasive disease every year of the study period. Many new STs were observed each 
year and persisted only transiently. The exception to this was the significant increase 
in serotype 1 ST 306 clone which was noted to persist throughout the 5 year period. 
Similar to the findings in Scotland, another study that performed large scale MLST 
characterization of both invasive and carriage pneumococcal isolates collected over a 
15 year period prior to introduction of PCV in an African country, fluctuations in the 
distributions of circulating STs were observed (Brueggemann et al., 2013). The 
authors noted that there were no major changes in the study area, such as changes in 
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antimicrobial use, laboratory practice or vaccine uptake that would have accounted 
for the fluctuations observed during the study period.  
It seems plausible therefore that, regardless of the response of the pneumococcus to 
selective pressure from interventions such as vaccination and antibiotic usage, 
secular changes in the distribution of circulating genotypes and serotypes would 
occur as part of the natural evolution of this pathogen.   
1.7.6. Regional Differences in Population Biology of S. pneumoniae  
Studies carried out in different regions of the world have demonstrated some 
similarities in the population biology of S. pneumoniae such as the global spread of 
some antibiotic resistant strains and the effects of vaccination on prevalence of 
vaccine type pneumococci. However, these studies have also highlighted important 
differences between regions in the population of circulating pneumococci, such as 
differences in the predominant serotypes and sequence types seen in invasive disease 
and in nasopharyngeal carriage.  
Following the introduction of PCV in many European countries, there were 
significant declines in IPD caused by vaccine serotypes (Tin Tin Htar et al., 2015). 
Some of the more prevalent serotypes seen in the post-PCV13 era included 24 F, 
22 F, 8 and 15A, with serotypes 19A and 3 the more prevalent serotypes seen in 
PCV10-using countries. Significant reductions in prevalence of serotypes 19A, 7 F, 
1 and 6A were observed in countries using PCV13. Similar reductions in prevalence 
of vaccine serotypes following PCV introduction has been observed in the USA 
(Richter et al., 2013). Non-PCV13 vaccine types were reported to emerge in the 
post-PCV13 period, even though most were seen to be less invasive in comparison to 
the pre-existing vaccine serotypes. Some of the serotypes with higher invasive 
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potential reported from the UK include serotypes 7F, 19A, 3, 8, and 33F (van Hoek 
et al., 2014).  
In contrast to observations in Western countries, the serotypes with highest 
prevalence in invasive disease in West Africa were predominantly serotypes 1 and 5 
(Adegbola et al., 2006). Serotype 3 was rarely seen in invasive disease but more 
common in carriage among West African isolates, contrasting with the pattern of 
serotype 3 epidemiology in some Western countries (Donkor et al., 2013, Martin and 
Brett, 1996). In addition, a few studies that evaluated the genetic population structure 
of African pneumococcal isolates revealed high levels of serotype and clonal 
diversity (Donkor et al., 2013, Chaguza et al., 2017). Serotypes 1 and 5, the leading 
causes of IPD in sub-Saharan Africa, were seen to be more clonal than other 
serotypes that were seen more commonly in carriage. Also, the PMEN clones, 
commonly seen in European and other Western countries, were rarely seen among 
African pneumococcal isolates (Donkor et al., 2013, Chaguza et al., 2017).  
 
1.8. S. pneumoniae serotype 1 disease 
S. pneumoniae serotype 1 is one the leading causes of IPD in different parts of the 
world (Adegbola et al., 2006, Holliman et al., 2007, Hausdorff et al., 2000, Chiou et 
al., 2008). It has been associated with pneumonia, meningitis, sepsis, empyema and 
rarer diseases such as peritonitis and salpingitis (Sirotnak et al., 1996, Westh et al., 
1990, Byington et al., 2002, Eltringham et al., 2003). In The Gambia, prior to the 
introduction of pneumococcal vaccines, it was the leading cause of IPD responsible 
for 20% of all cases (Adegbola et al., 2006). Other African countries have reported 
similar trends including Kenya (Brueggemann et al., 2013), Mozambique (Vallès et 
al., 2006), Togo, Burkina Faso (Traore et al., 2009) and Niger (Collard et al., 2013). 
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In developed countries including Spain, Denmark, Portugal, France, Switzerland and 
the UK, serotype 1 also plays a significant role in IPD (McChlery et al., 2005, 
Kronenberg et al., 2006, Konradsen and Kaltoft, 2002, Henriques Normark et al., 
2001, Hanquet et al., 2010, Aguiar et al., 2010). Some studies have attributed the 
increase in serotype 1 IPD to use of PCV-7 and tagged it a replacement non-vaccine 
serotype whilst other studies have attributed this to secular trends as many countries 
monitoring serotype 1 IPD over several years have seen annual fluctuations without 
the influence of vaccines (Hanquet et al., 2010). Interestingly, serotype 1 is one of 
few pneumococcal serotypes associated with outbreaks and has been responsible for 
several epidemics in different regions of the world (Leimkugel et al., 2005, Dagan et 
al., 2000, Staples et al., 2015). Across the meningitis belt, it has been responsible for 
highly lethal meningitis outbreaks in as seen recently in Ghana (Kwambana-Adams 
et al., 2016) and previously in Ghana and Togo with features similar to outbreaks 
caused by Neisseria meningitidis (Yaro et al., 2006, Leimkugel et al., 2005). A 
review of cases in the African meningitis belt revealed that serotype 1 was 
responsible for 59-79% of cases (Gessner et al., 2010). Outbreaks of serotype 1 have 
also been reported in men’s shelters in Boston (DeMaria et al., 1980) and Paris 
(Mercat et al., 1991); in closed communities in Israel (Dagan et al., 2000) and in 
Australia (Lai et al., 2013, Gratten et al., 1993, Staples et al., 2015). In contrast to the 
pattern of a high potential for causing severe disease with fatal outcomes in 
developing country settings, pneumococcal serotype 1 has been reported in some 
developed countries to cause non-severe disease with non-fatal outcomes (Sjostrom 
et al., 2006).  
 
Other interesting characteristics of pneumococcal serotype 1 include a high 
susceptibility to many antibiotics (Henriques Normark et al., 2001, Antonio et al., 
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2008) and in some studies affecting mostly older children and young adults (Collard 
et al., 2013, Traore et al., 2009).  
 
It has also been shown to have distinct geographical differences which may be due to 
its rarity in nasopharyngeal carriage (Brueggemann and Spratt, 2003). In a 
phylogenetic analysis conducted on 166 invasive serotype 1 isolates obtained from 
14 countries, three lineages were observed. Lineage A isolates were exclusively from 
Europe and North America with ST306 mainly from Europe and ST227 from North 
America, England and Canada. Lineage B was predominantly from Africa, majorly 
ST217 and lineage C from Chile, mostly ST615 (Brueggemann and Spratt, 2003). 
This geographic distinction has been supported by various studies, for example, the 
ST217 clonal complex is the predominant clone across many countries in the African 
meningitis belt such as The Gambia, Ghana, Burkina Faso, Togo and Niger (Antonio 
et al., 2008, Leimkugel et al., 2005, Yaro et al., 2006). Three of the licensed 
pneumococcal vaccines include protection against serotype 1 and are discussed in 
detail in section 1.9.  
 
 
1.9. S. pneumoniae serotype 1 carriage 
Although pneumococcal serotype 1 is one of the leading serotypes causing invasive 
pneumococcal disease (IPD) in many regions of the world, particularly in sub-
Saharan Africa, it is rarely found in carriage studies. In The Gambia, serotype 1 was 
found in 0.5% of 2478 isolates in a pneumococcal carriage study (Hill et al., 2006). 
This finding was similar to a report from Mozambique, where serotype 1 was the 
leading serotypes among invasive isolates (40%), with only one (0.5%) serotype 1 
isolate found among 192 carriage isolates (Vallès et al., 2006). In Kenya, no serotype 
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1 isolate was recovered from carriage despite being the leading cause of invasive 
disease (Brueggemann et al., 2013). Pneumococcal serotype 1 carriage rates reported 
in developed countries are largely similar to rates reported in developing country 
settings. In Switzerland, serotype 1 was found in 26 (1.7%) out of 1540 carriage 
isolates (Kronenberg et al., 2006) while in a study conducted in the UK comparing 
invasive and carriage isolates collected in the same region over the same time period, 
no serotype 1 isolate was found in carriage despite been found in invasive disease 
(Sleeman et al., 2006). It is unclear why the carriage rates of serotype 1 are so rare. 
One possible reason could be that commonly used culture methods are not sensitive 
enough to detect it in carriage. A study showed improved detection of S. pneumoniae 
in saliva samples compared to the nasopharynx using molecular methods (Krone et 
al., 2015). Another explanation could be due to a presumably short duration of 
carriage. In a longitudinal study carried out in Australia with 2-4 weeks sampling, 
only one child carried serotype 1 at 2 consecutive examinations. Serotype 1 was also 
found in low and high densities and co-carried with other serotypes in 34% of 
samples tested (Smith-Vaughan et al., 2009). The authors suggested that serotype 1 
carriage may be underestimated due to masking by other serotypes in co-
colonization (Smith-Vaughan et al., 2009). Prevalence of serotype 1 carriage has 
been reported to be high during outbreaks caused by this serotype. In an outbreak of 
serotype 1 pneumococcal pneumonia in a men’s shelter in Boston in 1978, 10 of 104 
(10%) residents of the shelter were carriers of pneumococcal serotype 1 (DeMaria et 
al., 1980) compared to 1 – 2% or less in the absence of an outbreak. Similarly, in 
1938 in Worcester Mass, the pneumonia outbreak that occurred was largely due to 
serotype 1 and the carriage rate was as high as 10% compared to being found only 
once or twice in 500 cultures in a normal population (Smillie et al., 1938). However, 
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this was not the case in another pneumococcal pneumonia outbreak in two men’s 
shelters in Paris from 1988 - 1989 with only one of the 57 serotypes isolated from 
carriers being serotype 1 (1.8%) (Mercat et al., 1991). The authors suggested that the 
low carriage rate could have been due to the timing of sampling as the 
nasopharyngeal carriage study was conducted at the end of the outbreak period. 
 
1.10. Pathogenesis and virulence factors  
Pathogenicity is defined as the ability of an organism or microbe to cause harm or 
disease in a host (Pirofski and Casadevall, 2012). Pathogenicity is thought to depend 
on possession by the microbe of certain virulence factors that mediate the disease 
outcome in the host. Virulence, on the other hand, is defined as the relative capacity 
of the microbe to cause disease or harm in the host. Whilst pathogenicity is often 
considered in terms of the presence or absence of this ability in the microbe, i.e. 
whether or not the microbe is pathogenic or not, virulence often refers to the extent 
or degree of damage or pathology caused by the microbe to the host. It has been 
suggested that both pathogenicity and virulence are inherent microbial properties that 
are usually expressed in the context of a susceptible host, thus highlighting the 
importance of the host-pathogen interaction in the expression of these properties by 
the microbe (Casadevall and Pirofski, 2001). This section discusses some important 
aspects of the pathogenicity and virulence factors of S. pneumoniae.     
 
S. pneumoniae is spread from person to person by air-borne droplets and often 
resides asymptomatically in the upper respiratory tract of humans. From the 
nasopharynx, the pneumococcus may spread to contiguous organs such as the ears, 
sinuses or it may get carried down the trachea and bronchi to the lungs (Bogaert et 
al., 2004a). It is also capable of penetrating the mucosal barrier of the respiratory 
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tract to gain access to the bloodstream and thereby spreading to other more distant 
parts of the body such as the lining of the abdominal cavity, bones and their joint 
spaces or the cerebrospinal fluid by penetrating the blood brain barrier (Figure 1.4). 
When it gains access to these parts of the body that are normally sterile, it can result 
in invasive disease such as pneumonia, septicaemia, arthritis, osteomyelitis and 
meningitis.  
 
 
Figure 1.4 Pathogenic route for S. pneumoniae infections. Adapted from 
(Bogaert et al., 2004a). 
 
In order to achieve this access, it possesses various attributes encoded by virulence 
factors that aid its establishment in host cells and facilitate its ability to cause 
disease. S. pneumoniae has several virulence factors described, the numbers of which 
appear to have increased in recent years with the aid of new technologies such as 
signature tagged mutagenesis (STM), transposon sequencing (Tn-seq), gene 
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expression assays such as microarray and deep RNA sequencing (Hava and Camilli, 
2002, van Opijnen et al., 2009, Orihuela et al., 2004, van Opijnen and Camilli, 2012, 
Mann et al., 2012). The advent of whole genome sequencing and functional 
characterisation of these genes in animal models have also facilitated the discovery 
of further virulence genes. Some virulence genes are present in almost all 
pneumococcal isolates while others vary from one pneumococcus to the other 
suggesting that different strains of S. pneumoniae may vary in their virulence 
properties. This variation across pneumococcal strains is consistent with the fact that 
S. pneumoniae is highly transformable and can readily uptake exogenous DNA from 
closely related species. Several virulence genes are found on the pneumococcal cell 
surface and others in the cytoplasm, (Fig 1.5). 
 
 
Figure 1.5 S. pneumoniae cell showing important virulence factors.  
LytA, autolysin; Eno, enolase; PavA, pneumococcal adhesion and virulence A; Hyl, hyaluronate 
lyase; PspA and PspC, pneumococcal surface protein A and C; PiuA, pneumococcal iron uptake A; 
PiaA, pneumococcal iron acquisition A; PsaA, pneumococcal surface antigen. Adapted from 
(Kadioglu et al., 2008). 
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1.10.1. Capsule 
Demonstration of the virulence properties of the pneumococcal polysaccharide 
capsule, a major virulence factor of S. pneumoniae, dates back to early experiments 
conducted by Fred Griffith, who observed that a non-encapsulated avirulent strain 
became virulent following co infection with a heat killed virulent encapsulated strain 
in mice (Griffith, 1928). The capsule contributes towards pathogenicity by disrupting 
several aspects of complement system and interferes with neutrophil mediated 
immunity leading to reduced opsonophagocytic capacity. Additionally, it is able to 
gain access to epithelial surfaces by avoiding entrapment in the nasal mucus (Hyams 
et al., 2010, Giebink et al., 1977). It has been reported that the capsule of different 
pneumococcal serotypes differs substantially in their ability to cause disease 
(Sandgren et al., 2004, Kelly et al., 1994) due to differences in their ability to evade 
host defence mechanisms. Melin et al. observed that serotypes 1 and 5, serotypes 
commonly associated with invasive disease, were particularly resistant to 
complement deposition and opsonophagocytic killing, whilst other serotypes such as 
6B and 23F, associated with carriage, were more sensitive to deposition of C3 and 
opsonophagocytosis (Melin et al., 2010). Also, animal experiments have provided 
evidence of a strong association between capsular type and ability to kill mice 
(Briles et al., 1992). 
 
S. pneumoniae has over 95 different capsular polysaccharides, all of which 
demonstrate a capsule locus showing similar organization with genes encoding 
specific capsular types flanked by genes common to all types and this locus has been 
published for 90 pneumococcal serotypes (Bentley et al., 2006). Amongst closely 
related serotypes based on cps genes, pneumococcal serotype 1 appears unique in its’ 
lack of the rhamnose biosynthesis gene, the result of frame shift mutations within the 
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gene (Mavroidi et al., 2007). The peculiarity of the cps locus of pneumococcal 
serotype 1 is further demonstrated by the presence of an unusual sugar AAT-Galp, a 
component of its’ pneumococcal teichoic and lipoteichoic acids. The only other 
organism reported to have this sugar within its capsule is Bacteroides fragilis 
(Aanensen et al., 2007). Most pneumococcal serotypes possess negatively charged 
polysaccharides but serotype 1 has both positive and negatively charged 
polysaccharides in a repeating unit structure referred to as a zwitterionic motif, 
which allows serotype 1 to function as a T-cell dependent antigen. In mice, this has 
been implicated in the formation of abscesses (Tzianabos et al., 1993, Velez et al., 
2009). 
 
1.10.2. Cell wall 
The cell wall is known for its ability to induce an inflammatory response and the 
presence of teichoic acid facilitates this process (Tomasz and Saukkonen, 1989). It 
activates the alternative complement pathway (Winkelstein and Tomasz, 1978) and 
stimulates the production of platelet activating factor (Cabellos et al., 1992). It also 
facilitates attachment to the host endothelial cells resulting in loss of barrier 
integrity, effects that are mediated through the production of cytokines (Geelen et al., 
1993). Experimental animals injected with purified cell wall or its products have 
been shown to exhibit signs that are similar to several pneumococcal diseases 
(Carlsen et al., 1992, Tuomanen et al., 1985).  
 
1.10.3. Pneumolysin 
Pneumolysin, one of the most studied pneumococcal proteins, is a highly conserved 
pneumococcal protein on account of which it has been proposed for use in the 
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formulation of protein vaccines (Briles et al., 2003, Kuo et al., 1995). It is a 53 kDa 
cytoplasmic protein and forms part of a larger group of proteins of pathogenic Gram 
positive bacteria known as cholesterol-dependent cytolysins. First cloned in 1983, 
the importance of this gene in virulence has been demonstrated in several animal 
infection models (Ogunniyi et al., 2007, Berry et al., 1989b). It has been shown to be 
cytotoxic and inhibits ciliary movements on respiratory epithelium (Feldman et al., 
1990). It also activates the classical complement pathway (Mitchell et al., 1990). 
Different alleles have been observed amongst different pneumococcal serotypes due 
to mutations occurring within the gene. Clonal expansion of specific clones carrying 
ply alleles expressing reduced or no haemolytic activity has been observed 
particularly with serotype 1 ST306 (Kirkham et al., 2006). In addition to serotype 1, 
serotypes 7F and 8 both predominantly invasive disease-causing serotypes have been 
found to have these alleles and have been associated with disease outbreaks 
(Jefferies et al., 2007, Staples et al., 2015). Interestingly, it has been observed that 
the allelic variation of ply responsible for reduced haemolytic activity has no effect 
in reducing the susceptibility of S. pneumoniae to pneumolysin based vaccines 
(Harvey et al., 2011). 
 
1.10.4. Pili 
Pili, filamentous structures found on the surface of many Gram-positive bacteria, are 
encoded within pathogenicity islands which are a group of mobile genetic elements 
acquired by bacteria through horizontal gene transfer. Pili were first observed on the 
surface of pneumococci in 2006 (Barocchi et al., 2006). PI-1 is encoded by the RlrA 
accessory region and has been shown to influence colonization, virulence and the 
inflammatory response in mouse models. Strains containing PI-1 were more virulent, 
Chapter one Introduction 
 
56 | P a g e  
 
exhibited enhanced adherence to lung epithelial cells and had a competitive 
advantage over strains mutant strains lacking this factor (Barocchi et al., 2006). A 
second type identified, PI-2, was also involved in adherence (Bagnoli et al., 2008). It 
was observed that PI-2 was associated with pneumococcal multilocus sequence type 
(MLST) belonging serotypes 1, 2, 7F, 19A and 19F. It was noted that strains 
belonging to clonal complex (CC) 271 were found to contain both PI-1 and P1-2 
(Bagnoli et al., 2008). 
 
1.10.5. S. pneumoniae surface proteins 
The pneumococcal cell surface is made up of several proteins which contribute 
significantly to the virulence of the organism. They are marked by one of three 
motifs; a choline binding domain, a lipoprotein domain or the LPXTG cell wall 
anchor, (Bergmann and Hammerschmidt, 2006) (Figure 1.6). Some of the well-
studied pneumococcal surface proteins thought to be potential pneumococcal vaccine 
candidates are discussed briefly below. 
 
 
Figure 1.6 Different classes of S. pneumoniae surface-exposed proteins. 
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The cell wall is made up of lipoteichoic acid (LTA), a phospholipid membrane (LM), peptidoglycan 
(PG), teichoic acid (TA) and phosphoryl choline (PCho) which anchors choline binding proteins to 
the cell wall (CBP). Adapted from (Bergmann and Hammerschmidt, 2006).  
 
1.10.5.1. Choline binding proteins (Cbps) 
Choline binding proteins are anchored by phophorylcholine on teichoic and 
lipoteichoic acids on the cell wall (Hakenbeck et al., 2009). S. pneumoniae produces 
different Cbps including CbpA, PspA (pneumococcal surface protein A), PcpA 
(pneumococcal choline-binding protein A), cell wall lytic enzyme; N-
acetylmuramoyl-L-alanine amidase (LytA; autolysin) and these are described briefly 
below. Other Cbps including CbpD, CbpE, CbpG, a b-N-acetylglucosamidase 
(LytB) and a b-N-acetylmuramidase (LytC; lysozyme) have been shown to play a 
role in nasopharyngeal colonization. CbpG has also been shown to play a role in 
sepsis (Gosink et al., 2000).  
 
Choline binding protein A (CpbA), also known as PspC (pneumococcal surface 
protein C) plays a role in adherence by binding to cytokine activated pneumocytes 
and endothelial cells. This is thought to be an important process for pneumococci 
transiting from colonization to invasive disease (Rosenow et al., 1997). It has also 
been shown to contribute to sepsis. Mice infected with PspC mutants showed a 
significant increase in survival than the wild type (Iannelli et al., 2004). Its locus is 
highly polymorphic due to the high variability observed in the proline rich region. 
However, the DNA encoding for signal peptides is conserved across strains (Brooks-
Walter et al., 1999).  
 
Pneumococcal surface protein (PspA) is an important pneumococcal surface protein 
shown to be required for full virulence of pneumococci (Ren et al., 2003). It is a 
lactoferrin binding protein that varies in molecular size ranging from 67 kDa to 99 
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kDa. It inhibits complement deposition and activation and interferes with uptake into 
phagocytes. Variations within the gene sequence have given rise to different PspA 
types (Crain et al., 1990); even though conserved epitopes remain that allow 
vaccination within a single type to confer cross protection to other types (Ren et al., 
2003). 
Pneumococcal choline-binding protein A (PcpA) was identified as a virulence factor 
in a large scale signature tagged mutagenesis experiment (Hava and Camilli, 2002). 
The gene pcpA encodes a 79 kDa protein containing a C terminal choline binding 
domain (Sanchez-Beato et al., 1998). It is involved in adherence of S. pneumoniae to 
human nasopharyngeal and lung epithelial cells (Khan et al., 2012). 
 
Autolysin (LytA) is a cell wall degrading enzyme that causes autolysis of the 
bacterial cell. Though normally inactive, it can be activated under conditions such as 
nutrient starvation or penicillin starvation. It releases degradation products such as 
peptidoglycan and teichoic acid, which can cause inflammation and release of 
bacterial proteins such as pneumolysin (Berry and Paton, 2000, Berry et al., 1989a). 
 
1.10.5.2. Liporoteins 
PsaA (pneumococcal surface adhesion A) is part of an ABC transporter operon in 
which PsaA is a substrate binding lipoprotein, PsaB, the ATP-binding protein and 
PsaC the permease likely involved in transporting manganese and zinc into the 
cytoplasm of pneumococcus. It is thought to function as an adhesin. Strains of the 
pneumococcus lacking this gene have been found to be avirulent in animal model 
tests (Sampson et al., 1994, Tseng et al., 2002).  
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PiuA (pneumococcal iron uptake A) and PiaA (pneumococcal iron acquisition A) are 
lipoprotein components of two iron ABC transporters (Brown et al., 2001). They 
have been found in all pneumococcal isolates tested and are required for virulence as 
demonstrated in murine infection models (Brown et al., 2001). 
Putative proteinase maturation protein A (PpmA) and streptococcal lipoprotein 
rotamase A (SlrA) are members of the family of peptidyl-propyl isomerases and are 
thought to be involved in secretion and activation of cell surface molecules. PpmA 
has been shown to be important in pneumococcal virulence (Overweg et al., 2000) 
and SlrA in nasopharyngeal colonization (Hermans et al., 2006).  
1.10.5.3. LPXTG-anchored surface proteins 
These are proteins covalently anchored to the cell wall through a carboxyl-terminal 
motif, LPXTG and are recognized by a sortase enzyme. They include 
neuraminidases (NanA and NanB), hyaluronate lyase and serine protease.  
  
NanA and NanB, two enzymes implicated in neuraminidase activity have been 
shown to be essential for colonization and infection of the upper and lower 
respiratory tract. Neuraminidase facilitates the survival of S. pneumoniae in the 
respiratory tract and blood by enabling attachment to epithelial cells. (Manco et al., 
2006). 
 
Hyaluronate lyase (Hyl), a 107 kDa protein attached to the cell wall breaks down 
hyaluronic acid, an important component of the mammalian connective tissue (Berry 
et al., 1994). It has been thought to facilitate bacterial penetration through the host 
tissue (Berry et al., 1994) Mutations in hyl did not have an impact on virulence in a 
mouse intraperitioneal challenge model using a serotype 2 strain (D39). However a 
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double mutation of hyl and ply showed significant reduced virulence (Berry and 
Paton, 2000). 
 
Serine protease (PrtA) was discovered during an immunological screening of 
convalescent patient sera (Zysk et al., 2000). The role of PrtA in pneumococcal 
virulence has been demonstrated in animal models, where survival in mice was 
significantly longer when infected with a PrtA negative mutant strain compared to 
the wild type (Bethe et al., 2001). Although the exact function of this protein is yet to 
be fully determined, it is known to be co-regulated with a number of virulence genes 
including ply (Bethe et al., 2001). 
 
1.10.5.4. Other S. pneumoniae surface proteins 
Surface proteins not having any of the three anchor motifs described above include 
pneumococcal histidine triad (Pht) proteins, pneumococcal adherence and virulence 
factor A, enolase and pneumococcal adhesion and virulence A (PavA).  
 
The Pht family proteins, characteristic of a conserved motif HxxHHxH, were 
discovered while utilizing whole genome sequences of pneumococci to identify 
proteins which protect against pneumococcal infections (Wizemann et al., 2001). 
This family consists of four proteins (PhtA, PhtB, PhtD, PhtE) and function by 
inhibiting complement deposition via the complement regulator, factor H (Ogunniyi 
et al., 2009). PhtD is one of the pneumococcal proteins currently included in protein 
vaccines undergoing clinical trials (Leroux-Roels et al., 2014).  
 
Enolase is a plasminogen receptor which mediates pneumococcal attachment to 
human epithelial and endothelial cell (Bergmann et al., 2013). PavA is an important 
pneumococcal surface protein involved in virulence and adhesion (Holmes et al., 
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2001, Pracht et al., 2005). Knock out mutants of this gene were less attenuated in 
mouse sepsis and meningitis models (Holmes et al., 2001, Pracht et al., 2005). 
 
1.11. Models utilized in studying the pathogenesis of S. 
pneumoniae 
1.11.1.  Experimental human pneumococcal carriage 
Humans are the natural host of S. pneumoniae and thus the development of an 
experimental human pneumococcal carriage model offers the potential for more 
accurate descriptions of mechanisms of protection against pneumococcal carriage. 
This human model experiment involves intranasal inoculation of a known quantity of 
S. pneumoniae to healthy adult volunteers (Gritzfeld et al., 2013). This model has 
been used in evaluating the suitability of candidate proteins for pneumococcal 
protein vaccines (McCool et al., 2002). It has also been used in determining 
appropriate methods for pneumococcal carriage detection, which will be useful in 
epidemiological and vaccine efficacy studies (Gritzfeld et al., 2013, Gladstone et al., 
2015a). Limitations of this model include ethical issues related to safety and 
logistical challenges with selection of volunteers, inoculums preparation and 
completeness of follow up.  
 
1.11.2. Animal models 
Due to the limitations associated with experimental human models, the use of animal 
models in studying the role of S. pneumoniae in nasopharyngeal carriage and 
invasive disease. These models are discussed briefly below. 
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1.11.2.1. Mammalian models 
Some mammalian models that have been used in pneumococcal research include 
rats, mice, rabbits, chinchilla, gerbil and guinea pigs with the latter three animal 
models used mostly in the study of middle ear infections (Chiavolini et al., 2008). 
However, for most other studies of bacterial pathogens, mice and rat models tend to 
be used more frequently, possibly due to their advantage of having tightly controlled 
immune system. Compared to rat models, mice are cheaper, easier to handle and 
better suited for screening of drugs and vaccines, and are therefore used more 
frequently than rat models. Additionally, the availability of the mouse whole genome 
sequence and technologies to induce mutations in the mouse genome makes it a 
more attractive model to study host pathogen interactions. Outbred mice are used to 
mimic the natural variation in response to infection seen in humans. Routes of 
administration may vary based on the intended experiments and may include, 
intranasal, intravenous, intraperitoneal and intra cerebral routes. Also, animal models 
have been developed for different invasive disease conditions including pneumonia, 
meningitis, sepsis, otitis media as well as carriage models (Chiavolini et al., 2008). 
Variations between mice in their susceptibility or resistance to pneumococcal 
infection have been shown highlighting the role of the genetic background of hosts 
in pneumococcal infections (Preston et al., 2004, Gingles et al., 2001). 
 
Animal models have been widely applied in pneumococcal research. Some of these 
applications include virulence testing of phenotypic pneumococcal strains (Williams 
et al., 2012), testing novel drugs and efficacy of antimicrobials (Sullivan et al., 
1993), pneumococcal vaccine assessments (Khan and Pichichero, 2013) and 
evaluating mechanisms of invasive pneumococcal disease pathogenesis (Ibrahim et 
al., 2004). Despite the usefulness of mammalian models, their use is associated with 
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a number of limitations including ethical challenges associated with use of mammals 
in research, the huge costs involved and the specialized training required to conduct 
animal experiments. 
1.11.2.2. Galleria mellonella infection model 
An alternative to mammalian models of infection is the use of invertebrate hosts, 
such as nematodes or insects. Nematodes or insects that could be used include 
Caenorhabditis elegans, Drosophila melanogaster and the larvae of the Greater wax 
moth, Galleria mellonella (Tan et al., 1999, Jander et al., 2000). Insects, like 
mammals, possess a complex innate immune system. Cells within the hemolymph 
are able to phagocytose or encapsulate invading microbes. They are also able to 
produce lysozyme and small antibacterial peptides.  
 
G. mellonella has been used extensively as an infection model in the study of 
bacterial infections including S. pneumoniae Proteus, Pseudomonas aeruginosa, 
Burkholderia cepacia, Acinetobacter, Group A Streptococcus, Staphylococcus 
aureus, Campylobacter, as well as fungal infections such as Cryptococcus, 
Aspergillus and Candida (Evans and Rozen, 2012, Jander et al., 2000, Gao et al., 
2010, Seed and Dennis, 2008). Use of a G. mellonella model offers some advantages 
over other insect models. The G. mellonella is relatively large, about 2 cm long 
weighing approximately 250 mg and thus they are easier to handle and for injecting 
clearly defined doses of bacteria. The G. mellonella model also allows for infection 
studies to be conducted at temperatures between 15C and 37C, hence thereby 
mimicking a mammalian environment unlike other insects such as the drosophila 
whose maximum temperature only allows for experimentation at 25C (Rejasse et 
al., 2012). In comparison to mammalian models, G. mellonella models are cheaper, 
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do not require specialized facilities for maintenance, are easier to use, do not require 
licences and are more ethically acceptable. They can be used as an initial tool in the 
screening of large numbers of strains thus reducing the number of strains needed for 
subsequent use in mouse models. Additionally, studies have shown good correlation 
between mice and G. mellonella virulence studies (Jander et al., 2000). Cells are 
injected via the first right pro-leg into the haemocoel and recent studies are exploring 
the mouth route. Evans et al showed for the first time that the G. mellonella model is 
a good tool for S. pneumoniae research. They demonstrated, for example, that a 
pneumolysin mutant was less virulent in the G. mellonella model than the wild type 
as demonstrated in several mice experiments (Evans and Rozen, 2012). 
1.12. Laboratory tools for pneumococcal characterization. 
1.12.1. Culture based identification of S. pneumoniae 
A range of specimen types is collected for identification of S. pneumoniae. These 
include nasopharyngeal swabs (NPS), sputum and specimens collected from 
normally sterile sites of the body such as blood, cerebrospinal fluid, joint fluid, 
pleural and lung aspirate.   
 
Laboratory processing of these specimens includes microscopy, standard culture, and 
testing for antibiotic sensitivity. Microscopic examination of specimens requires 
carrying out Gram stain. A Gram-positive result reveals lancet-shaped diplococcic 
and is indicative of S. pneumoniae. Specimens are cultured on selective defibrinated 
blood agar, mostly sheep or horse blood, supplemented with 5 µg/ml of gentamycin 
to prevent the growth of non-pneumococcal isolates. Alpha haemolytic colonies are 
confirmed as S. pneumoniae using optochin and bile solubility tests.  
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The optochin test is used in the presumptive identification of alpha-haemolytic 
streptococci. S. pneumoniae cells are sensitive to optochin (ethylhydrocupreine 
hydrochloride) though some strains are optochin resistant. Optochin sensitive S. 
pneumoniae surrounding a disk impregnated with optochin are lysed due to changes 
in surface tension, thus creating a clear zone of inhibition.  
 
The bile solubility test is used to differentiating S. pneumoniae from other alpha 
haemolytic Streptococci. Bile salts lower the tension between the bacterial cell and 
the medium thus enhancing the pneumococcus’ autolytic process resulting in the 
lysis of the cell wall. This effect is observed by clearing of the initially turbid bile 
solution. 
 
Pneumococcal antimicrobial susceptibility testing is often interpreted using standard 
interpretation guidelines such as the Clinical and Laboratory Institute (CLSI) 
guidelines.  
 
Limitations of culture based laboratory diagnosis of pneumococcus, particularly in 
resource- constrained settings such as in sub Saharan Africa, include non-availability 
of the test at the point of care, lack of appropriate specimen collection equipment, 
attendant challenges with specimen contamination and storage, lengthy waiting time 
for culture results and prior antibiotics use which reduces pneumococcal detection 
rates in samples collected. This has led to the development of molecular based 
methods to complement standard culture techniques.  
 
1.12.2. S. pneumoniae serotyping 
S. pneumoniae has a polysaccharide capsule, the basis for which it has been 
classified into more than 95 different types, also known as serotypes (Henrichsen, 
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1995, Oliver et al., 2013). These serotypes all play different roles with some 
serotypes more frequently associated with causing invasive disease and others more 
often seen in carriage (Sandgren et al., 2004). Given the significant contribution of 
this pathogen to serious diseases worldwide and with the advent of serotype-specific 
pneumococcal vaccines, pneumococcal serotyping is therefore required for effective 
monitoring of vaccine impact in communities and thus informs policy makers on 
priorities for the development of appropriate new vaccine formulations. It is also 
helpful for determining current and emerging pneumococcal serotypes thus 
facilitating our understanding of any regional or global changes in pneumococcal 
epidemiology. Additionally, pneumococcal serotyping is useful in the detection of 
multiple serotypes (Turner et al., 2011), shown to be common in nasopharyngeal 
carriage, even though the ability and extent to which multiple serotypes are detected 
will depend on the methods employed. Pneumococcal serotyping is performed either 
by phenotypic or genotypic methods. Phenotypic methods are based on biochemical 
assays and a few are described briefly below. 
 
1.12.2.1. Quellung Reaction  
This is the gold standard technique for pneumococcal serotyping and is widely used 
by different reference laboratories. New methods of pneumococcal serotyping that 
are developed need to be standardized against the Quellung reaction, which has both 
high sensitivity and specificity. The Quellung reaction was first described in 1902 by 
German bacteriologist, Ferdinand Neufeld (Austrian, 1981). The test is a 
biochemical reaction that involves binding of 
polysaccharide antigens of the pneumococcal capsule to antibodies in the serotype 
specific antisera. This results in the formation of a complex molecule with the 
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pneumococcal capsule appearing swollen when viewed under a microscope as a 
result of increased surface tension (Habib et al., 2014). Limitations of this method 
include the high cost of antiserum and the need for trained personnel for accurate 
interpretation of results, in comparison to the latex agglutination method. The test is 
also time consuming. 
 
1.12.2.2. Latex agglutination 
Agglutination tests were first discovered by Herbert Edward Durham and Max Von 
Gruber in 1896, whilst working with the pneumococcus, with the reaction called the 
Gruber- Durham reaction at the time. This principle has subsequently been applied to 
the detection of numerous other organisms. 
In this method, specific antibodies are attached to latex particles, which when in 
contact with a specific pneumococcal capsular antigen results in a visible 
agglutination reaction and a clearing of the background suspension. Latex 
agglutination serotyping has been shown to have good agreement with Quellung 
reaction (Lalitha et al., 1996). Also, it is fast and relatively easy to perform, does not 
require specialized equipment and is an inexpensive test. It is therefore a suitable 
method of choice for resource poor countries, and high throughput laboratories. 
Commercially prepared latex agglutination kits are available but often expensive. On 
the other hand, in-house preparations of latex reagents have also been used but often 
require extensive laboratory quality control procedures to prevent misinterpretation 
of results. In The Gambia, a locally prepared antibody coated latex agglutination test 
is used on colonies from primary culture plates suspended in saline (Adegbola et al., 
2006). The WHO recommended method for latex agglutination involves selecting 
unique or morphologically different strains of S. pneumoniae and serotyping these 
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strains (Satzke et al., 2013). However, to increase detection of multiple serotypes, 
the latex sweep agglutination method is used. This method involves serotyping a 
plate sweep of pneumococcal colonies. Various studies have demonstrated the 
suitability of this method particularly in large studies for improved detection of 
multiple serotypes and it was recently supported by the PneuCarriage study which is 
the largest study evaluating different pneumococcal serotyping methods (Turner et 
al., 2011, Satzke et al., 2015).  
 
1.12.2.3. Other phenotypic assays 
Other phenotypic assays for pneumococcal serotyping that have been developed 
include enzyme-linked immunosorbent assays (ELISA) and an enzyme linked 
immunoassay (EIA) (Lankinen et al., 2004); immune blot assays including dot blot 
and colony blot (Bogaert et al., 2004b) and bead based assays on flow cytometry or 
luminex platforms (Sheppard et al., 2011). However, these methods are generally 
expensive, time-consuming, limited in the number of serotypes detected or 
lacking specificity through cross reactions or have a combination of these factors.  
 
1.12.3. Molecular typing of S. pneumoniae 
The use of molecular tools in the study of S. pneumoniae has significantly improved 
our understanding of the behaviour of this pathogen. Numerous molecular methods 
have been employed in typing S. pneumoniae; a few are briefly described below. 
 
1.12.3.1. PCR based serotyping 
Production of the pneumococcal capsule is controlled by capsular polysaccharide 
genes located at the cps locus flanked by conserved dexB and aliA genes and 
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sequence data for the region is available for over 90 serotypes of S. pneumoniae 
(Bentley et al., 2006). The differences within the cps locus form the basis for 
differentiation of pneumococcal serotypes by most of the genotypic methods. 
The first multiplex PCR (mPCR) assay used in molecular serotyping was a seven 
step sequential assay capable of detecting 33 serotypes/ serogroups was developed in 
2006 from invasive pneumococcal disease (Pai et al., 2006). This assay was tested in 
The Gambia and its utility amongst carriage isolates and in the detection of multiple 
serotypes was well demonstrated (Antonio et al., 2009). This method utilizes PCR 
primer pools in a sequential manner and visualized by agarose gel electrophoresis 
based on amplicon sizes. It has since been modified to suit different geographical 
areas including Latin America (Dias et al., 2007), Europe (Iraurgui et al., 2010) and 
Africa (Morais et al., 2007). It has also been modified to use on a range of clinical 
specimens (Njanpop Lafourcade et al., 2010). One of the limitations of this method 
is cross reactivity within some serotypes as documented by Pai et al. For example, 
between serotype 6A and 6B which is because they share identical sequences within 
the cpsA loci differing in only one single nucleotide polymorphism in the wciP gene 
hence making it difficult to develop type specific primers. Other examples include 
serotypes 7F and 7C cross reacting with serotypes 7A and 7B as well as 9V, 38, 
11A, 12F, 22F, 33A, 33F, 35F and 18C (Pai et al., 2006). Identifying these 
individual serotypes would require further testing by serological methods of 
serotyping.  
 
Real time PCR (RT-PCR) was developed following the advent of mPCR. RT-PCR is 
relatively faster and more sensitive than mPCR and offers more specificity as it 
requires hybridization to a probe in addition to amplification primers (Azzari et al., 
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2010, Pimenta et al., 2013). Its limitation is that it is more expensive compared to 
mPCR and also has limited scope in multiplexing. 
 
Other methods include a PCR-Restriction Fragment Length Polymorphism (PCR-
RFLP) assay in which digested PCR amplicon fragments are analysed using gel 
electrophoresis and serotype is assigned a unique RFLP pattern (Batt et al., 
2005),combining PCR and electrospray ionization mass spectrometry (PCR/ESI-
MS) (Massire et al., 2012), PCR fragment analysis and automated fluorescent 
capillary electrophoresis (FAF-mPCR) (Selva et al., 2012), PCR and reverse line 
blot hybridization (mPCR/RLB) (O'Sullivan et al., 2011), a high throughput method 
using nanofluidic real time PCR (Dhoubhadel et al., 2014) and sequence-typing 
which utilizes a single primer pair to serotype pneumococcal isolates (Leung et al., 
2012). 
 
1.12.3.2. Molecular serotyping by microarray 
Microarrays are ordered sets of DNA molecules of known sequence fixed on a 
physical support. This technology allows for the simultaneous detection of thousands 
of genes in a small sample through specific binding to an array of high density 
probes. A microarray for molecular serotyping of S. pneumoniae with the ability to 
detect over 90 serotypes has been developed by the Bacterial Microarray Group 
(BµGS) at St George's University of London. The BμGS SP-CPSv1.1.0 microarray 
is a custom designed microarray on the Agilent SurePrint platform and 
comprised primarily of 60mer oligonucleotides probes (Newton et al., 2011). It was 
designed with multiple reporters representing all 432 known capsular polysaccharide 
synthesis genes (Bentley et al., 2006). It also has additional probes incorporated to 
distinguish between serotypes with similar sets of cps genes for example 6A vs 6B; 
Chapter one Introduction 
 
71 | P a g e  
 
7A vs 7F; 9A vs 9V; 11A vs 11D; 12F vs 44 etc. In addition, it has incorporated 
probes for the entire genome of two fully sequenced pneumococcal strains, TiGr4 
and R6. It has probes for antibiotic resistant genes alpA3, cat, ermB, ermC, mefA, 
sat4, tetK, tetL, tetM and tetO. It also has reporter elements for detecting other 
pathogens often found co-colonizing the nasopharynx namely Streptococcus 
agalactiae, Streptococcus equi, Streptococcus pyogenes, Staphylococcus aureus, 
Haemophilus influenza, Neisseria meningitides, Moraxella catarrhalis, Bordetella 
pertussis and Corynebacterium diphtheriae. This technique involves several steps of 
sample processing and labelling, hybridization, washing, image acquisition and data 
analysis (Newton et al., 2011). Data analysis is automated using empirical Bayesian 
statistical models (Newton et al., 2011).  
 
In addition to comprehensive molecular serotyping for 93 known pneumococcal 
serotypes, this method is able to detect multiple serotype carriage and the ability to 
determine the relative abundance of each serotype to as little as 1% (Turner et al., 
2011). This makes it a very attractive method when compared to all other methods of 
serotyping. It also has the potential to detect novel serotypes, co-carriage of S. 
pneumoniae with other pathogens and antibiotic-resistance genes. The microarray 
method has been utilized in several studies (Turner et al., 2011, Kandasamy et al., 
2015). Limitations of the microarray method include the need for technical expertise 
particularly for interpretation of any unusual findings, the relatively high cost of 
equipment and reagents thus limiting its availability to a small number of research 
laboratories.  
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1.12.3.3. Pulsed-field gel electrophoresis (PFGE) 
PFGE has been used extensively for investigating outbreaks and on-going disease 
surveillance due to its high epidemiological concordance and high discriminatory 
power. It is also relatively inexpensive and readily reproducible. This process 
involves cleaving genomic DNA with restriction endonucleases resulting in 
restriction fragments, which are separated on an agarose gel by 'pulsed-field' 
electrophoresis. This is visualised on the gel as bands to give a PFGE pattern 
(Lefevre et al., 1993). However, this method is not without limitations as it is time 
consuming, labour intensive and technically demanding. It could also be prone to 
significant subjectivity in interpretation of findings thus requiring continuous quality 
control to minimize this risk.  
 
1.12.3.4. Multiple-locus variable-number tandem repeat analysis (MLVA) 
MLVA is a method which targets short tandem repeats across the bacterial genome, 
has a scheme developed for S. pneumoniae targeting 17 distinct loci with a dedicated 
web-based database (Koeck et al., 2005). It has been applied in several 
epidemiological studies (Koeck et al., 2005, Yaro et al., 2006) but is not widely used 
as it is expensive and time consuming. 
 
1.12.3.5. Multilocus enzyme electrophoresis (MLEE) 
MLEE, another method used in epidemiological typing of different organisms, is 
based on the relative mobility under electrophoresis of large numbers of intracellular 
enzymes with unique mobility patterns associated with each strain (Selander et al., 
1986). It has a lower resolution than multilocus sequence typing (MLST), described 
below, and is therefore not as widely used. Despite the usefulness of these tools, 
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significant gaps remain in their ability to provide global epidemiological 
understanding of bacteria due in part to non-standardized approaches as results 
obtained were frequently not comparable between laboratories (Maiden, 2006, 
Maiden et al., 1998).  
 
1.12.3.6. Multilocus sequence typing (MLST) 
Multilocus sequence typing, proposed in 1998 (Maiden et al., 1998) as a genetic-
based method that could improve typing, was also applied in the study of population 
biology and in evolution studies. It involves sequencing of approximately 450-500 
bp internal fragments of several housekeeping genes typically using capillary Sanger 
sequencing. Each of the sequences is trimmed, assembled and submitted to the 
MLST database and assigned an allele number. A combination of seven allele 
numbers gives rise to an allelic profile called a sequence type (ST). The MLST 
database contains reference allele sequences, sequence types as well as 
epidemiological data for all strains submitted. The MLST scheme for S. pneumoniae 
uses internal fragments of seven housekeeping genes namely, aroE (shikimate 
dehydrogenase), gdh (glucose-6-phosphate dehydrogenase), gki (glucose kinase), 
recP (transketolase), spi (signal peptidase I), xpt (xanthine 
phosphoribosyltransferase), ddl (D-alanine-D-alanine ligase).  
The advantage of MLST over other genotyping methods lies in its reproducibility 
and portability. Materials can be exchanged between laboratories and it is accessible 
electronically, making it appropriate for use in evolutionary and epidemiological 
studies (Enright and Spratt, 1998, Maiden, 2006). The application of MLST has 
significantly improved our understanding of S. pneumoniae, as it has been used to 
characterize invasive and carriage strains (Antonio et al., 2008, Enright and Spratt, 
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1998, Brueggemann et al., 2003), track epidemic outbreaks (Antonio et al., 2008, 
Leimkugel et al., 2005), antimicrobial resistant strains (Pletz et al., 2004, Siira et al., 
2009) and to understand transmission dynamics (Hill et al., 2010).  
Despite its usefulness, MLST lacks the ability to adequately differentiate between 
bacterial strains since it is limited to variations in housekeeping genes. A more 
complete understanding of the role of S. pneumoniae in causing diseases would 
require an evaluation of other components of the bacterium such as virulence genes. 
With the advent of second-generation sequencing technologies, MLST can now be 
assigned from whole-genome sequence information, rather than sequencing each 
locus separately. This provides a more cost effective approach and MLST data can 
be used to correlate with other genomic features. 
  
1.12.3.7. Whole genome sequencing 
Whole genome sequencing (WGS) makes available the complete DNA sequence of 
bacterial cells.  
Sanger sequencing, also known as the chain termination or dideoxy method 
developed by Fredrick Sanger in the 1970s (Sanger et al., 1977) was one of the 
earlier methods of WGS. Improvements on the Sanger sequencing method led to the 
automated Sanger sequencing technique on the ABI platform by applied Biosystems. 
Sanger sequencing is performed with components required for DNA replication, a 
single stranded DNA template, a primer, polymerase deoxynucleoside triphosphates 
(dNTPs) and in addition, special dideoxynucleoside triphosphates (ddNTPs). DNA 
elongation which occurs by the incorporation of regular dNTPs by the DNA 
polymerase is terminated once ddNTPs is incorporated. This is due to the lack of a 
3′-OH group needed for the formation of phosphodiester bonds between two 
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nucleotides (figure 1.7). The ddNTPs are labelled with dyes that allow for their 
detection following capillary gel electrophoresis. 
 
 
 
Figure 1.7 Automated Sanger sequencing workflow 
 
The advantages of Sanger sequencing techniques over the new methods of 
sequencing are the production of high quality sequence data and long reads of about 
900bp. 
Since the inception of Sanger sequencing, several other sequencing technologies 
have been developed. These newer methods have a higher throughput and eliminate 
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electrophoresis as well as bacterial cloning. The disadvantage for these newer 
methods is that relatively short reads are produced. Some of these newer 
technologies include pyrosequencing (454) by Roche Inc., Branford, CT, USA; 
Sequencing by Oligo Ligation Detection (SOLiD) by Life technologies Corporation, 
Grand Island, NY, USA); MySeq and HiSeq by Illumina Inc., San Diego, CA, USA, 
The Ion Torrent Personal Genome Machine (PGMTM) by Life Technologies 
Corporation, Grand Island, NY, USA; the PacBio RS II Single Molecule Real-time 
Sequencing (SMRT) by Pacific Biosciences Inc., Menlo Park, CA 94025 (Metzker, 
2010) and MinION by Oxford Nanopore Technologies Ltd, Oxford, UK. 
Characteristics of these methods are summarized in table 1.1. 
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Table 1.1 Summary of sequencing technologies 
 
 Automated 
Sanger 
Sequencing 
454 Illumina SoLiD Ion Torrent PacBio Nanopore 
Company Applied 
Biosystems 
Inc. 
Roche diagnostics Illumina Inc Life technologies Life technologies Pacific 
biosciences 
Oxford nanopore 
technologies 
Year  2005 2006 2007 2010 2011  
Library 
preparation 
Yes Yes Yes Yes No No Minimal 
Amplification 
method 
 Emulsion PCR Bridge 
amplification 
Emulsion PCR Emulsion PCR No amplification No amplification 
Sequencing 
technology 
Chain 
termination 
Sequencing by 
synthesis - 
pyrosequencing 
Sequencing by 
synthesis - 
reversible dye 
termination 
Sequencing by 
ligation – 
oligonucleotide 
probe ligation 
Sequencing by 
synthesis – ion 
semi-conductor 
sequencing 
Sequencing by 
synthesis - single 
molecule real 
time sequencing  
Sequencing by 
synthesis - single 
molecule 
sequencing  
Detection 
method 
Fluorescent 
emission 
from dye 
terminator 
nucleotides 
Light emission 
from secondary 
reactions initiated 
by pyrophosphate 
release 
Fluorescent 
emission from 
incorporated dye-
labelled 
nucleotides 
Fluorescent 
emission from 
ligated dye-
labelled 
oligonucleotides 
Proton detection  Nanopore-based 
detection of 
single molecules 
Read lengths/run ~ 900 bases ~700 bases ~250 bases on 
Miseq and ~125 
bases on Hiseq 
50 – 75 bases  ~200 bases   
Maximum 
output/run 
 0.7 gb 15gb on Miseq 
and 1500 gb on 
Hiseq 
120gb 100gb 1gb 1gb 
Number of 
reads/run 
1 1 x 106 3 x 108 on Miseq 
and 5 x 109 on 
Hiseq 
1 x 109 6 x 107 1 x 106 6 x 104 
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Time/run 2h 24-48h 27h on Miseq 
and 240h on 
Hiseq 
14 days 2 – 5h 1-2h 48-72h 
Raw error rate 0.3 1 0.8 0.01 1 12.9 34 
Advantages Long reads 
and high 
quality 
sequencing  
Longest reads, 
greater accuracy 
and precision 
compared to other  
NGS methods 
 
Widest range of 
platforms 
ranging from 
Miseq to Hiseq 
X ten useful for 
population based 
studies. Very 
high throughput 
High throughput 
and accuracy 
Reduced 
turnaround time, 
flexible 
workflow and 
cheaper price 
compared to 
other NGS 
methods 
Longer reads and 
faster run times 
compared to 
most NGS 
methods. 
Portable devices. 
Easy sample 
preparation, no 
amplification 
step required 
prior to 
sequencing. 
Limitations Expensive, 
time 
consuming 
for large 
project and 
lower 
throughput 
compared to 
NGS 
methods 
High cost of 
reagents, complex 
sample 
preparation and 
high error rates in 
homopolymers 
repeats. 
Discontinuation of 
support from 
Roche in 2016. 
 Complex sample 
preparation, very 
long run times and 
short read lengths. 
Requires huge 
computational 
infrastructure and 
expert support to 
analyse raw data. 
Difficulty in 
reading 
homopolymer 
repeats 
High error rates, 
lower throughput 
compared to 
NGS methods 
and high cost per 
base 
High error rate. 
Requirement to 
optimize the 
speed of DNA 
translocation 
through the 
nanopore to 
ensure 
measurement of 
the ionic current 
change. 
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Of these methods, Illumina sequencing is currently the most widely used sequencing 
platform with a wide variety of sequencing instruments ranging from the lower 
throughput equipment such as the Miseq to ultra-high throughput equipment such as 
the Hiseq X10 suitable for population wide studies. The different Illumina 
sequencing equipment provide more options for cost, runtime and read length.  
Illumina sequencing workflow involves library preparation in which DNA is 
fragmented and ligated to adaptors at the 5’ and 3’ end of the DNA fragment.  
The ligated DNA fragments are loaded into a flow cell surface which has 
complementary oligonucleotides to the adaptors ligated to the DNA fragments. Each 
fragment undergoes bridge amplification to form distinct clonal clusters. This 
process is known as cluster generation. Sequencing by synthesis technology is 
utilized making use of a reversible dye termination method. In this method, four 
reversible terminator bound and fluorescently labelled dNTPs are present during 
each cycle of sequencing. Once incorporated, the DNA elongation is terminated and 
fluorescence captured (Figure 1.8)  
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Figure 1.8 Illumina sequencing work flow 
 
These methods produce large data sets, which need to be assembled into continuous 
DNA sequences (contigs), with several genome assemblers being put use. In 
addition, several computer programs are now readily available for processing 
sequence data. 
 
This availability of whole genome sequence of different strains of S. pneumoniae in 
addition to mutagenesis and functional characterization of knock out mutants using 
various animal models and assays is fast revolutionizing the understanding of 
pathogens and their interactions with host cells.  
 
For pneumococcal serotyping, it is hoped that next generation sequencing will fill 
the gaps experienced in the application of existing serotyping methods such as 
challenges with long turnaround time and limitations with multiplexing for multiple 
serotype detection. Whole genome sequencing offers an advantage over existing 
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serotyping methods as serotypes of pneumococcal isolates have been deduced by 
mapping raw sequence reads against reference capsular locus sequencing (Everett et 
al., 2012) and in-silico methods have been used to differentiate non-typeable S. 
pneumoniae (Chewapreecha et al., 2014a). Another advantage of this method is the 
potential it holds for discovering novel pneumococcal serotypes and detecting 
capsular switching. However, a limitation of this method is its’ requirement for 
computational capacities, complex bioinformatics pipelines and expertise and longer 
preparation times. A modification of this method, based on target enrichment 
coupled with tagged sample pooling for the identification and serotyping of S. 
pneumoniae by using next generation sequencing (Liyanapathirana et al., 2014) 
offers some improvement in terms of cost. Nevertheless, this modification still 
requires significant bioinformatics expertise and has reduced specificity of primers in 
identifying closely related serotypes. 
 
Other applications of WGS include characterizing multiple antibiotic resistant 
pandemic strains (Fani et al., 2011, Croucher et al., 2009), understanding the role of 
virulence factors (Paton and Giammarinaro, 2001) and in reverse vaccinology to 
identify vaccine candidates (Wizemann et al., 2001, Paton and Giammarinaro, 2001, 
Di Guilmi and Dessen, 2002). However, up to 30% of predicted coding sequences 
encode proteins of unknown function and are often referred to as hypothetical 
proteins. Also, little is known regarding the genetic attributes of invasive strains such 
as pneumococcal serotype 1 in causing disease. Continued whole genome 
sequencing and functional characterization of genes across strains from different 
global locations will be required to fully understand the genetic basis of S. 
pneumoniae pathogenesis, which will inform development of appropriate and 
improved preventative and therapeutic strategies.  
Chapter one Introduction 
 
82 | P a g e  
 
1.13. Treatment and Control of S. pneumoniae infection 
1.13.1. Antibiotics 
Antibiotic therapy forms the mainstay of treatment of pneumococcal disease. Even 
though variations in antibiotic treatment offered across different clinical settings 
exist, the WHO recommends the use of penicillin as first line antibiotic treatment 
(WHO, 2013). Recommendations for antibiotic treatment options in areas with high 
levels of proven penicillin resistance include the use of 3rd generation cephalosporins 
such as ceftriaxone and cefotaxime (Bradley et al., 2011). 
A major concern with the use of antibiotics is the development of antimicrobial 
resistance. This is particularly worrisome with the pneumococcus, a naturally 
transforming organism, which has the ability to transfer and spread resistant genes 
between pneumococcal strains (Croucher et al., 2011). The pneumococcus becomes 
resistant to antibiotics by altering itself to block the action of the antibiotic. 
Antibiotics work against bacteria by either interfering with cell wall synthesis, 
nucleic acid synthesis or with protein synthesis. Beta lactam antibiotics, such as 
penicillins known for their characteristics beta lactam ring in their chemical structure 
interferes with cross linking of peptidoglycan of the pneumococcal cell wall by 
binding to transpeptidase enzyme thus blocking its action and inhibiting cell wall 
synthesis. The pneumococcus develops resistance to penicillin by alterations to 
penicillin binding proteins through transformation thereby inhibiting the action of 
penicillin. Macrolides, tetracyclines and chloramphenicol interfere with microbial 
protein synthesis by binding to either the 50s or 30s ribosomal subunits thereby 
inhibiting the synthesis of the polypeptide chain. Pneumococcus develops resistance 
to these drugs by methylating the ribosomal subunits via genes usually found on 
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plasmids such as the erm genes. By doing this, the pneumococcus is able to prevent 
the antibiotic from binding to the ribosomal subunit. In addition, pneumococci 
develop resistance to antibiotics via efflux pumps encoded for by transposable 
elements. This way, the pneumococcus is able to pump out antibiotics once it has 
gained entry into the cell. 
Factors contributing to increases in antibiotic resistance include widespread abuse of 
antibiotics and clonal spread of antimicrobial resistant strains. In Iceland for 
example, increase in antibiotics resistance was observed over several years. Initially, 
expansion of an international multidrug resistant clone Spain6B-2 was observed and 
this declined after a public health intervention. However, in subsequent years, an 
expansion of a different international multidrug resistant clone Taiwan19F-14 was 
observed to cause higher antibiotic resistance rates than had been described 
previously (Hjalmarsdottir and Kristinsson, 2014). A study conducted in four 
African countries, namely Senegal, Ivory Coast, Tunisia and Morocco reported high 
resistance to penicillin (mostly intermediate), erythromycin, tetracycline and 
cotrimoxazole (Benbachir et al., 2001). In Nigeria, Iroezindu et al showed that there 
was high prevalence of resistance to commonly prescribed drugs including 
penicillin, cotrimoxazole and ceftriaxone (Iroezindu et al., 2014) while in Ghana, 
intermediate resistance to penicillin was reported (Dayie et al., 2013). In The 
Gambia, resistance to tetracycline, cotrimoxazole chloramphenicol and penicillin 
have been documented (Adegbola et al., 2006). 
 
Implications of antimicrobial resistance among pneumococci, particularly for 
developing countries where the burden of disease is highest, include higher costs of 
treatment, as the alternative drugs to which the pneumococcus is sensitive are 
frequently more expensive, and non–availability of such drugs, both factors of which 
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contribute to increase poor treatment outcomes and deaths from IPD in these 
settings. In addition, with very high pneumococcal carriage rates in developing 
countries, the likelihood of spread of these antimicrobial resistant genes is high and 
would further worsen the existing challenges with effective control of pneumococcal 
disease. 
Interestingly, pneumococcal serotype 1 has been shown to be susceptible to most of 
the antibiotics tested with the exception of cotrimoxazole (Konradsen and Kaltoft, 
2002, Porat et al., 2001). The Pneumococcal Molecular Epidemiology Network 
(PMEN), established in 1997 to enhance global surveillance of antibiotics resistant 
strains (McGee et al., 2001) currently has 43 clones in the network, four of which are 
serotype 1 strains. All four serotype1 strains have been reported to be penicillin 
susceptible (Porat et al., 2001, Brandileone et al., 1998, Henriques Normark et al., 
2001). This high susceptibility to antibiotics of serotype 1 relative to lower antibiotic 
susceptibility patterns for other pneumococcal serotypes may be attributed to its 
rarity in nasopharyngeal carriage, which reduces the probability for recombination 
events to occur. In a study comparing antibiotic susceptibility patterns between 
serotypes mostly found in invasive disease (serotype 1 and 5) and those found 
mostly in nasopharyngeal carriage (serotype 6B and 23F), it was observed that 
serotypes 1 and 5 were susceptible to all antibiotics tested including penicillin, 
erythromycin and tetracycline but not to trimethoprim-sulfamethoxazole (SXT). In 
contrast, a significant proportion of the strains belonging to serotype 6B (56%) and 
23F (21%) were resistant to penicillin and were associated with multidrug resistance 
(Porat et al., 2001).  
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1.13.2. Vaccines  
1.13.2.1. History of S. pneumoniae vaccines 
The first pneumococcal vaccine trial was conducted by Sir Almroth E. Wright, a 
British physician in 1911. He tested a killed whole cell pneumococcal vaccine on 
South African miners who had a high incidence of pneumococcal infections at the 
time. His intervention resulted in a significant reduction in pneumonia incidence 
amongst the miners (Wright et al., 1914). That trial paved the way for many other 
trials that led to the licensure of two hexavalent polysaccharide vaccines in the 
United States which were later withdrawn in 1954. The advent of antibiotics proved 
to be very effective against pneumococcal infections during this time. The interest in 
pneumococcal vaccines was rekindled in the 1970s because of the emergence of 
pneumococcal strains with reduced susceptibility to available antibiotics at the time 
(Kazanjian, 2004). This led to the development of the pneumococcal polysaccharide 
vaccine and its use were championed by Robert Austrian and others. Firstly, a 14-
valent vaccine was licensed in The United States in 1977 and later replaced by a 23-
valent vaccine in 1983 (Grabenstein and Klugman, 2012). Conjugate vaccines, with 
increased immunogenicity, were later developed and licensed in the United States in 
2000 and have since been introduced to national childhood vaccination programs in 
many other countries around the world. 
 
1.13.2.2. Current licensed S. pneumoniae vaccines 
Two different types of pneumococcal vaccine are currently licensed, namely, the 
polysaccharide vaccines (PPSV) and the conjugate vaccines (PCV) (Table 1.1). 
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These vaccines are licensed for use in different parts of the world today with 
different dosing schedules and across different age groups. 
Table 1.2 Current licensed pneumococcal vaccines and serotypes included 
 
Vaccines Pneumococcal serotypes included 
PCV-7 4 6B 9V 14 18C 19F 23F       
PCV-10 4 6B 9V 14 18C 19F 23F 1 5 7F    
PCV-13 4 6B 9V 14 18C 19F 23F 1 5 7F 3 6A 19A 
PPSV-
23 
4 6B 9V 14 18C 19F 23F 1 5 7F 3 33F 19A 
 2 8 9N 10A 11A 12F 15B 17F 20 22F    
PCV, pneumococcal conjugate vaccine; PPSV, pneumococcal polysaccharide vaccine 
 
1.13.2.3. Pneumococcal polysaccharide vaccines 
Pneumovax23, produced by Merck, Whitehouse Station, NJ, USA is a 
pneumococcal conjugate vaccine containing purified capsular polysaccharides from 
23 different serotypes of S. pneumoniae, including serotype 1. It is recommended for 
use in adults over 65 years of age and for younger adults with increased risk of an 
IPD. This vaccine has been shown to be very useful in immune competent 
individuals (Butler et al., 1993). The vaccine is currently used in many developed 
countries but is yet to be widely used in many developing countries, including any 
African country, probably due to the relatively high costs. 
Pneumococcal polysaccharide vaccines induce a B-cell response with the production 
of anticapsular opsonising immunoglobulin but no T-cell response and hence no 
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memory, limiting its usefulness in children less than 2 years of old (Douglas et al., 
1983). Due to the fact that this vaccine is not usually immunogenic in children less 
than 2 years, it is not recommended for use in this age group. Given the significantly 
high risk of pneumococcal invasive disease in this age group, the need for an 
effective vaccine led to the development of pneumococcal conjugate vaccines. 
 
1.13.2.4. Pneumococcal conjugate vaccines. 
Several pneumococcal conjugate vaccines have undergone clinical trials around the 
world but the first licensed PCV vaccine, available in 2000, was a 7-valent 
pneumococcal conjugate vaccine, Prevenar 7 developed Wyeth, New York, NY, 
USA. It contains capsular polysaccharides from seven serotypes (Table 1.1) 
conjugated with an alum-bound adjuvant to a non-toxic mutant of diphtheria toxin 
(CRM197) acting as a protein carrier. Selection of the seven serotypes included in 
PCV-7 was based on the serotypes with the highest prevalence in invasive disease in 
developed countries particularly in the United States of America. PCV-7 did not 
include serotype 1.as it was not one of the leading serotypes in invasive disease in 
The USA, even though it was one of the two predominant serotypes in IPD in 
several African countries. Improving on the performance of the PCV-7, a 13-valent 
conjugate vaccine, PCV-13, containing all seven serotypes included in PCV-7 and 
six additional serotypes including serotype 1, was licensed and has been in use in 
many countries since 2010 (Centers for Disease and Prevention, 2010). Also 
available is a 10-valent conjugate vaccine, PCV- 10 Synflorix, developed by 
GlaxoSmithKline, London, UK containing all the serotypes contained in PCV7 and 
serotypes 1, 5 and 7F. The conjugate vaccines are able to induce both B-cell and T-
cell responses, which make them suitable for children less than 2 years old. 
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Currently, several African countries have introduced PCV-10 or PCV-13 into their 
national immunization programs.  
The introduction of pneumococcal conjugate vaccines has led to a significant 
decrease in rates of pneumococcal disease caused by vaccine serotypes (Kaplan et 
al., 2004, Roca et al., 2013, Roca et al., 2011). The administration of these vaccines 
also had indirect effects or “herd effects”, with reductions in invasive pneumococcal 
disease incidence amongst the non-vaccinated population, mostly attributed to the 
reduction of transmission of vaccine serotypes in communities as a result of 
decreased carriage (Roca et al., 2011). In addition to reducing rates of invasive 
disease and carriage, use of the conjugate vaccines have led to reductions in 
antimicrobial resistance is some settings as many drug resistant clones identified 
prior to the advent of conjugate vaccines are serotypes covered by these vaccines 
(Dagan, 2009).  
 
The effectiveness of PCVs amongst Africans has been demonstrated by various 
studies. In The Gambia, a trial of the PCV-9 vaccine involving 17437 children age 6-
51 weeks old showed a 15% reduction in hospitalisation and a 16% reduction in all-
cause mortality as well as a 7% and 37% vaccine efficacy against both clinical and 
radiological pneumonia (Cutts et al., 2005). In another trial in The Gambia, use of 
the PCV-7 showed a significant reduction in the carriage prevalence of vaccine type 
pneumococci amongst healthy participants (Roca et al., 2011, Roca et al., 2013). The 
PCV-7 was introduced in the Gambian Expanded Program on Immunization (EPI) in 
2009, however this vaccine lacked pneumococcal serotype 1 and 5, which were the 
leading cause of IPD in the Gambia (Adegbola et al., 2006). The serotype 1 and 5-
containing PCV13 was subsequently introduced to the national immunization 
programme in 2011.  
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The effect of PCVs on serotype 1 is still being monitored. Some countries have 
reported an increase in pneumococcal serotype 1 following the use of PCV-7 (Nunes 
et al., 2008). Trials in The Gambia and in South Africa, of the 9-valent PCV-9, 
which contains serotype 1, showed limited vaccine efficacy against disease caused 
by serotype 1, even though the size of these studies were small (Cutts et al., 2005).  
 
In spite of the proven effectiveness of currently available pneumococcal conjugate 
vaccines, there are a few limitations associated with their use. One of the more 
serious concerns is due to the fact that protection is limited to vaccine serotypes with 
the risk of replacement in the population with non-vaccine serotypes in carriage and 
disease (Byington et al., 2005, Park et al., 2008). In England and Wales, an increase 
in non-PCV13 invasive pneumococcal disease was observed in children younger 
than 5 and adults over 45 years old (Waight et al., 2015). In the same region, an 
increase in non-PCV 13 serotypes was also observed in nasopharyngeal carriage 
with significant differences observed in serotypes 21, 23B, 33F and 35F (Gladstone 
et al., 2015b). In the USA, replacement in non-PCV13 vaccine types has been 
documented in invasive disease and carriage mostly due to serotypes 21 and 15B/C 
(Lee et al., 2014). In Africa, serotype replacement in pneumococcal nasopharyngeal 
carriage has been documented in Kenya after introduction of PCV-10 (Hammitt et 
al., 2014) but not in Gambia in a village randomized trial of PCV-7 (Roca et al., 
2011, Roca et al., 2013). Other limitations include the high cost of production which 
translates to high vaccine costs and the complexities of conjugation with over 90 
pneumococcal serotypes involved. There are also concerns with possible increases in 
incidence of disease caused by other respiratory pathogens such as Staphylococcus 
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aureus. These limitations have indicated the need for further research into alternative 
pneumococcal vaccines. 
 
1.13.2.5. Future pneumococcal vaccines 
One of the options for alternative pneumococcal vaccines that have been widely 
explored is the use of proteins that are highly conserved in the pneumococcus in 
producing pneumococcal protein vaccines. This is expected to address concerns 
related to limited serotype coverage seen with the use of PCVs. Five pneumococcal 
proteins leading in the development of pneumococcal protein vaccines either 
individually or in combination are pneumolysin (Ply), pneumococcal histidine triad 
protein D (PhtD), pneumococcal surface protein (PspA), pneumococcal, 
pneumococcal surface adhesion A (PsaA) and PcpA (Leroux-Roels et al., 2014, 
Prymula et al., 2014, Bologa et al., 2012, Berglund et al., 2014, Chen et al., 2015). 
The GlaxoSmithKline (GSK) Biologicals protein vaccine containing Ply and PhtD is 
currently undergoing a phase II clinical trial in The Gambia (Odutola et al., 2015). 
Other types of vaccines under investigation include the use of inactivated 
unencapsulated whole cell pneumococci. The whole cell pneumococcal vaccines 
would offer some cost advantage over conjugate vaccines due to their lower cost of 
production (Goncalves et al., 2014). Other considerations alternative pneumococcal 
vaccines include use of DNA vaccines, which are simpler to manufacture, offer 
lower production costs and are better stability during transportation, conditions 
which are favourable to developing countries (Miyaji et al., 2002, Vadesilho et al., 
2012). 
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1.13.3. Other control measures 
Other control measures against pneumococcal infections include reductions in air 
pollution from cigarette smoking and use of biomass fuels such as wood burning 
stoves, and overcrowding all of which have been shown to be risk factors for 
pneumococcal infections (Reisman et al., 2014, Nuorti et al., 2000). Also, provision 
of adequate nutrition and improving public health awareness on pneumococcal 
infections would facilitate more effective control of pneumococcal infections.  
 
Active surveillance is also an important tool in the control of pneumococcal 
infections. It provides information on the burden of disease, prevailing serotypes, 
antimicrobial use and resistance patterns and information on vaccine usage and 
effectiveness. This improves local awareness and informs national and international 
policy makers on effective treatment and prevention strategies. 
 
1.14. Project aims and objectives 
The significant burden of S. pneumoniae, a leading cause of severe bacterial illness 
and deaths globally, on health systems at regional and country levels, underscores 
the need for continued efforts at effective control and prevention of this pathogen. 
Regional differences in the population structure and epidemiology of S. pneumoniae, 
as well as recent changes such as the introduction of pneumococcal conjugate 
vaccines and changing trends in antibiotic use, highlight the importance of on-going 
surveillance at regional and country levels. This thesis aimed to describe the 
population structure of S. pneumoniae in The Gambia in the context of PCV 
vaccination and the patterns of antibiotics resistance among pneumococcal isolates. 
Given the  importance of S. pneumoniae serotype 1 as a leading cause of IPD in the 
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West Africa sub-region, this thesis aimed to understand in particular, the 
characteristics of invasive and carriage serotype 1 strains in West Africa, particularly 
the clonal complex consisting of sequence type 217 (ST217) and the locus variants  
 
The specific objectives were to: 
 
 Determine the population structure of pneumococci in The Gambia in both 
invasive pneumococcal disease and nasopharyngeal carriage over the last two 
decades, including the pre- and post-PCV era. This aim would be used to test 
the hypothesis that sustained vaccination is associated with changes in the 
predominant serotypes and sequence types circulating in The Gambia. 
 
 Determine the antibiotic resistant patterns and assess the impact of 
vaccination on the prevalence of antibiotic-resistant S. pneumoniae in 
nasopharyngeal carriage and invasive disease isolates in rural and urban 
Gambia. This aim would be used to test the hypothesis that the introduction 
of PCVs would result in reductions in levels of antibiotic resistance among 
pneumococcal isolates circulating in The Gambia as the known antibiotic 
resistant strains are included in the vaccine. 
 
 To describe the evolution of pneumococcal serotype 1 strains in West Africa. 
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2. Materials and methods  
2.1. Bacterial strains 
S. pneumoniae isolates obtained from patients and healthy volunteers in the West 
African sub-region were included in this study. A detailed description of the 
countries from which these pneumococcal isolates were obtained, the rationale for 
selection, age groups and associated metadata has been provided in sections 3.2, 4.2 
and 5.2.  
 
2.2. Primers used in this study 
A list of the primers used for molecular serotyping and multilocus sequence typing 
(MLST) is provided below (Table 2.1). All primers were obtained from Metabion 
International, Germany. 
Table 2.1 List of primers used in this study 
*Primer Sequence (5′ to 3′) Size 
(bp) 
Purpose Reference  
cpsA F GCA GTA CAG CAG TTT GTT GGA CTG ACC 190 S. pneumoniae 
detection 
(Pai et al., 2006)  
cpsA R GAA TAT TTT CAT TAT CAG TCC CAG TC 190 S. pneumoniae 
detection 
  
wzy F CTC TAT AGA ATG GAG TAT ATA AAC TAT 
GGT TA 
280 S. pneumoniae 
serotype 1detection 
  
wzy R CCA AAG AAA ATA CTA ACA TTA TCA CAA 
TAT TGG C 
280 S. pneumoniae 
serotype 1detection 
  
aroE F GCC TTT GAG GCG ACA GC  405 MLST  (Enright and Spratt, 
1998) 
 
aroE R TGC AGT TCA (G/A)AA ACA T(A/T)T TCT AA  405 MLST   
gdh F ATG GAC AAA CCA GC(G/A/T/C) AG(C/T) TT 460 MLST   
gdh R GCT TGA GGT CCC AT(G/A) CT(G/A/T/C) CC  460 MLST    
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gki F GGC ATT GGA ATG GGA TCA CC 483 MLST    
gki R TCT CCC GCA GCT GAC AC  483 MLST    
recP F GCC AAC TCA GGT CAT CCA GG 450 MLST    
recP R TGC AAC CGT AGC ATT GTA AC  450 MLST    
spi F TTA TTC CTC CTG ATT CTG TC 474 MLST    
spi R GTG ATT GGC CAG AAG CGG AA  474 MLST    
xpt F TTA TTA GAA GAG CGC ATC CT 486 MLST    
xpt R AGA TCT GCC TCC TTA AAT AC   MLST    
ddl F TGC (C/T)CA AGT TCC TTA TGT GG 441 MLST    
ddl R CAC TGG GT(G/A) AAA CC(A/T) GGC AT 441 MLST    
*The primers are named after the gene; cpsA, capsular biosynthesis gene A; wzy, O-antigen polysaccharide 
polymerase; aroE, shikimate dehydrogenase; gdh, glucose-6-phosphate dehydrogenase; gki, glucose kinase; 
recP, transketolase; spi, signal peptidase I; xpt, xanthine phosphoribosyltransferase); ddl, D-alanine-D-alanine 
ligase. 
 
2.3. Culture and storage conditions for S. pneumoniae isolates 
All carriage isolates of S. pneumoniae were obtained by culturing nasopharyngeal 
swabs (NPS) stored in Skim Milk Tryptone Glucose Glycerol (STGG) directly, or 
from frozen glycerol stocks of pneumococci. Invasive isolates were obtained from 
frozen glycerol stocks of pneumococci. Gentamicin sheep blood agar (GBA) plates 
consisting of 39 g/L Columbia base agar (Oxoid, Basingstoke, UK), 5% (v/v) 
defribinated sheep blood (TCS, Biosciences Ltd, Botolph Claydon, UK) and 5 µg/ml 
gentamicin (Oxoid, Basingstoke, UK) were used for both direct culture and reviving 
of stored isolates. All cultured plates were incubated for 18-24 hours at 37ºC in 5% 
CO2.  
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2.3.1. Optochin sensitivity 
Pneumococci were confirmed by morphological characteristics and optochin 
sensitivity. Presumptive pneumococcal colonies were picked from the primary plate 
and streaked onto 5% sheep blood Columbia agar (BA) plates. A 5 µg optochin disc 
(Oxoid, Basingstoke, UK) was placed in the centre of each streak and incubated 
overnight at 37ºC in 5% CO2. Zones of inhibition greater than 14 mm indicated 
susceptibility. S. pneumoniae ATCC 49619 and Streptococcus pyogenes ATCC 
49399 strains were used as positive and negative controls respectively.  
 
2.3.2. Storage of S. pneumoniae cells 
All confirmed S. pneumoniae cells were stored in 15% glycerol broth at -70ºC in line 
with standard protocols (Satzke et al., 2013), until retrieved for further processing.  
 
2.3.3. Antimicrobial susceptibility testing 
2.3.3.1. Disk diffusion method 
Antimicrobial susceptibility testing was performed using the Kirby-Bauer disc 
diffusion method for pneumococcal isolates following the Clinical and Laboratory 
Standards Institute (CLSI) guidelines (CLSI, 2011). S. pneumoniae ATCC 49619 
was included as a control strain in each batch of susceptibility testing. Inocula were 
prepared from fresh cultures (18-24 hour) of confirmed pneumococcal isolates from 
BA plates. Pneumococcal colonies were emulsified in 2 ml normal saline of turbidity 
equivalent to 0.5 McFarland standard, and spread evenly onto Mueller Hinton agar 
plates supplemented with 5% sheep blood using sterile cotton tipped swabs (Fisher 
Scientific UK Ltd, Loughborough, UK). Using sterile forceps, antibiotic discs of 
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prescribed concentrations were placed onto the inoculated plate. Antibiotics tested 
included oxacillin (1 µg), chloramphenicol (30 µg), erythromycin (5 µg), 
cotrimoxazole (1.25 µg/23.75 µg), tetracycline (30 µg) and cefotaxime (30 µg) 
purchased from Oxoid, Basingstoke, UK. Inoculated plates were incubated for 16-18 
hours at 37°C in 5% C02. Zone of inhibition sizes were measured and interpreted 
using the CLSI interpretative chart (CLSI, 2017) (Table 2.2).  
2.3.3.2. Epsilometer (E-test) agar diffusion method 
To determine minimum inhibitory concentration (MIC), E-test strips were used. The 
strips were applied using sterile forceps onto inoculated agar plates (described 
section 2.3.4.1) facing upwards towards the opening of the plate. The MIC value was 
read following overnight incubation where the edge of the inhibition ellipse 
intersected the strip. MICs were determined for penicillin and cefotaxime and results 
interpreted using the CLSI interpretative chart (CLSI, 2017) (Table 2.2). 
 
Table 2.2 Clinical and Laboratory Standards Institute interpretative charts of 
pneumococcal disk diffusion zone size 
 Sensitive Intermediate  Resistant  
Disk diffusion  Mm mm mm 
Chloramphenicol ≥ 21 - ≤ 20 
Erythromycin ≥ 21 16-20 ≤ 15 
Co-trimoxazole ≥ 19 16-18 ≤ 15 
Tetracycline ≥ 28 25-27 ≤ 24 
MIC  µg/ml µg/ml µg/ml 
Penicillin ≤0.06  0.12-1 ≥2 
Cefotaxime ≤ 1 2 ≥4 
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2.4. DNA extraction and analysis 
2.4.1. Extraction of genomic DNA  
One millilitre of sterile phosphate buffered saline (PBS) was added to an 18-24 hour 
pneumococcal cultured blood agar plate and the cells scrapped with a sterile L-shape 
plastic spreader to make a suspension of all the pneumococcal colonies. The 
suspension was collected and centrifuged at 7500 rpm for 10 min. The pellet was 
resuspended in 20 mg/ml lyzozyme in lysis buffer (20 mM Tris-Cl, pH8.0, 2 mM 
sodium EDTA, 1.2% Triton X-100). DNA was extracted using the DNeasy Blood & 
Tissue Kit, (Qiagen, Crawley, UK), following manufacturer’s Gram positive 
protocol. DNA was eluted in 200 μl of elution buffer and stored at -20°C. DNA was 
quantified using the nanodrop for microarray analysis. In preparation for whole 
genome sequencing, DNA was quantified using picogreen and DNA integrity 
assessed by agarose gel electrophoresis. 
 
2.4.2. Agarose gel electrophoresis 
Agarose gels were prepared by dissolving agarose (Sigma-Aldrich, Poole, UK) in 1 
× TAE buffer (40 mM Tris Acetate, 1 mM EDTA, pH 8) to a final concentration of 
1% (w/v). Ethidium bromide (Sigma-Aldrich, Poole, UK) was added to a 
concentration of 0.1 µg/ml. DNA samples mixed with DNA loading buffer at a 5:1 
ratio were loaded onto the gel in an electrophoresis tank containing 1 × TAE buffer. 
DNA fragments were separated at 120 V for 1 hour and visualised by UV 
illumination using a gel documentation system (Gel Doc 2000; Bio-Rad, UK). Band 
sizes were estimated by comparing with quantitative DNA markers, Quick-Load® 
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100 bp DNA Ladder and 50 ng NEB Lambda DNA-Hind III Digest (New England 
Biolabs (UK) Ltd). 
 
2.5. Pneumococcal serotyping  
2.5.1. Latex agglutination 
Latex agglutination was performed as described previously (Adegbola et al., 2006, 
Roca et al., 2011). Briefly, pneumococcal cell suspensions were made in 2 ml 
normal saline (1.0 McFarland) from an overnight blood agar plate. 20 µl of the 
suspension was dispensed into 10 separate wells of a serotyping tray and an equal 
amount of each of the main group (A, B, C, D, E, F, G, H, I and Omni) latex antisera 
(Statens Serum Institute, Copenhagen, Denmark) added to the wells. The mixture 
was rocked for a maximum of two minutes and agglutination observed in the wells. 
This procedure was then repeated with the subgroups under each main group and 
further typed with corresponding serum factor types. The pneumococcal serotype 
was determined with the aid of a chart provided by Staten Serum Institute, Denmark. 
 
2.5.2. Molecular serotyping by block PCR 
All serotype 1 isolates were confirmed by molecular serotyping as described 
previously (Pai et al., 2006). All reagents were purchased from Qiagen Ltd, UK 
except primers from Metabion International AG, Germany. Glycerol stocks of cells 
were used as template in a multiplex PCR reaction that comprised of: 
 
PCR cycling conditions were as follows: 
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95C hold for 15 min, followed by 35 cycles of  
94C for 30 sec  
54C for 90 sec 
72C for 60 sec 
72C final extension for 10 min.  
 
Products were visualized by agarose gel electrophoresis. 
 
2.6. Multilocus sequence typing  
MLST was performed on all S. pneumoniae serotype 1 carriage and invasive (2004 -
2014) isolates in this study. Isolates were recovered from glycerol stocks by plating 
out on 5% BA plates and incubated at 37C in 5% CO2 for 18 hours. A single colony 
from each isolate was picked, streaked and incubated at 37C for 18 hours. Glycerol 
stocks were prepared and these were used as templates for amplification of the seven 
housekeeping genes (aroE, gdh, gki, recP, spi, xpt, and ddl) targeted for MLST. The 
reaction mixture contained: 
  
10X Buffer with 1.5 mm MgCl2 2.5 µl  
10 mM dNTPs      0.5 µl  
12.5 mM primers      1 µl each  
5 U/µl Taq Polymerase     0.25 µl 
Template (glycerol stocks)     1 µl  
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Sterile DNA free water     To 25 µl 
 
PCR cycling conditions were as follows:  
5 min hold at 95C, followed by 30 cycles of  
95C for 30 sec,  
55C for 30 sec  
72C for 1 minute and a final extension of  
72C for 10 min.  
 
Products were visualized by agarose gel electrophoresis. PCR products were purified 
using Exonuclease I and Shrimp Alkaline Phosphatase (USB, Staufen, Germany). 
The reaction mixture contained: 
 
Exonuclease I      0.5 µl 
Shrimp Alkaline Phosphatase    0.5 µl 
PCR product      8 µl 
Sterile DNA free water     To 10 µl 
 
Cycling conditions were as follows: 
 
37C for 45 min 
80C for 20 min 
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Sequencing was done on both strands with BigDye Terminator Cycle Sequencing kit 
(Applied Biosystems, UK). The reaction mixture contained: 
 
 5X Buffer       2.075 µl  
BigDye    0.5 µl  
5 µM primer      0.32 µl  
Cleaned PCR products     2 µl 
Sterile DNA free water     To 10 µl 
 
PCR cycling conditions were as follows: 
 
 1 min hold at 96C, followed by 30 cycles of 
96C for 10 sec  
50C for 5 sec 
60C for 4 min 
 
The labelled fragments were separated by size using 3130xl Genetic Analyser 
(Applied Biosystems, UK). Sequences were edited, complementary sense and 
antisense fragments were aligned using the Lasergene software (version 7.1; 
DNASTRAR, US) and submitted to the MLST database website (www.mlst.net). 
Existing or novel allele type numbers were assigned and sequence type numbers 
defined by the MLST database.  
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2.7. Whole genome sequencing, assembly and annotation of S. 
pneumoniae serotype 1 genomes. 
Whole genome sequencing (WGS) of pneumococcal serotype 1 isolates used in this 
thesis was performed at the Wellcome Trust Sanger Institute (WTSI) Cambridge, 
UK. Sequencing was performed by staff of the WTSI as part of the Pneumococcal 
African Genome (PAGe) consortium and the Global Pneumococcal Sequencing 
(GPS) Project of which The MRC Gambia Unit is a collaborating institution.   
Multiple paired-end DNA sequencing using index tagged libraries was performed 
using the Illumina Genome Analyser GAII (Illumina, USA) as described previously 
(Cornick et al., 2015). Published sequence reads generated have been deposited in 
the European Nucleotide Archive (ENA) (http://www.ebi.ac.uk/ena/) under study 
number ERP000156 (Cornick et al., 2015).  
All sequence analysis was conducted on the Genomics Virtual Lab on the Cloud 
Infrastructure for Microbial Genomics (CLIMB) running on Ubuntu (Connor et al., 
2016). Paired end sequencing reads in fastq format were downloaded unto the server 
and subjected to the nullabor pipeline (Seemann T) which is one of the 
bioinformatics tools preloaded on the CLIMB server.  
 
With the nullabor pipeline, the following analysis were performed: 
- Sequencing reads were trimmed and low quality bases and reads removed 
using Trimmomatic (Bolger et al., 2014). 
- Species identification was performed per isolate by a k-mer analysis against a 
database of known genomes using Kraken version 0.10.5-beta (Wood and 
Salzberg, 2014). 
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- De novo assemblies were generated using MEGA-HIT version 1.0.3 (Li et 
al., 2015) and annotation performed using Prokka version 1.12-beta 
(Seemann, 2014). 
- MLST profiles were determined for each isolate from generated assemblies 
using the Seeman’s MLST program (Seemann T). 
- Antibiotic resistance genes were detected from generated assemblies using 
abricate version 0.3 (Seemann T) against a database of known antimicrobial 
resistance genes. 
- Single nucleotide variants (SNVs) were determined from the sequencing 
reads by mapping them to the reference genome- spn1041 (Genbank: 
CACE00000000) using Snippy version 3 (Seemann T) and multiple sequence 
alignment of SNVs in the core genome of all isolates generated using snippy-
core. A maximum likelihood and phylogenetic tree was generated using 
FastTree version 2.1.8 Double precision (No SSE3)~ OpenMP (8 threads) 
and the distance matrix based on pairwise SNV difference between the 
isolates was calculated. 
 
Using the multiple sequence alignment generated from the nullabor pipeline, 
recombination events was determined using Genealogies Unbiased By 
recomBinations In Nucleotide Sequences (Gubbins) algorithm (Croucher et al., 
2015). With Gubbins, a phylogenetic tree was constructed based on putative point 
mutations occurring outside regions having high densities of base substitutions. 
Recombination events were displayed in a heatmap. 
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A phylogenetic tree was constructed using RAxML v7.0.4 (Stamatakis, 2006) with 
the generalized time reversible (GTR) model with Gamma heterogeneity among 
nucleotide sites and 100 bootstrap replicates. Visualization and annotation with 
associated metadata of study isolates  was performed using FigTree version 1.4.2 and 
Interactive Tree of Life (iTOL) software (Letunic and Bork, 2016).  
 
Visualization of the evolutionary signals from the core and accessory regions of the 
genomes was performed using PANINI (Pangenome Neighbor Identification for 
Bacterial Populations), a web based tool that integrates with Microreact (Abudahab 
et al., 2017) 
 
2.8. Ethical approval 
Approval for the studies conducted in this thesis was obtained from the Joint 
Medical Research Council (MRC)/Gambia Government Ethics Committee and the 
Ethics Committee of the London School of Hygiene & Tropical Medicine, UK. 
Community and individual consent was obtained from study participants and the 
conduct of the trial was guided by a Data Safety and Monitoring Board. 
 
2.9. Data analysis 
All statistical analyses were carried out in STATA (version 11, Stata Corporation, 
College Station TX) and significance testing performed Chi-square test. A p-value of 
less than 0.05 was taken to indicate statistical significance. To determine the 
geographical relationship of serotype 1 and 5 clones to those found in other regions 
of the world, cluster analysis of allelic profiles of serotype 1 and 5 isolates from this 
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study and those from the MLST database was performed using geoBURST 
(http://goeBURST.phyloviz.net).  
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3. Population structure of Streptococcus pneumoniae in The Gambia 
from pre-and post-introduction of pneumococcal conjugate vaccines 
3.1. Introduction 
Streptococcus pneumoniae remains a leading cause of serious infections and deaths 
in young children and the elderly globally (O'Brien et al., 2009). As global efforts to 
prevent and control pneumococcal disease gain momentum, a good understanding of 
the population structure of Streptococcus pneumoniae, including the circulating 
pneumococcal serotypes and genotypes would be critical in guiding the development 
of appropriate interventions. Some studies have reported changes in circulating 
serotypes causing invasive disease and nasopharyngeal carriage in different parts of 
the world (Ubukata et al., 2015, Devine et al., 2017). However, most of these studies 
have been conducted in developed country settings with few in developing countries 
and there remain large gaps in our understanding of the pneumococcal population 
structure in developing countries where the burden of disease is disproportionately 
highest. In addition, changes in recent times, such as the increasingly widespread 
introduction of routine pneumococcal vaccination and changing patterns of HIV 
prevalence, could have an impact on the circulating pneumococcal serotypes and 
genotypes.   
The PCV- 7, the first licensed pneumococcal conjugate vaccine rolled out across 
many countries including countries in Sub-Saharan Africa, recorded huge successes 
in the reduction of IPD and nasopharyngeal carriage caused by vaccine serotypes 
(Waight et al., 2015, Mackenzie et al., 2016, Roca et al., 2013). Despite these 
successes, the introduction of PCV-7 has been associated with an increase in IPD 
caused by non-vaccine serotypes (Olarte et al., 2017, Del Amo et al., 2016). 
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Additionally, serotypes 1 and 5 were not included in PCV-7; these two serotypes 
have been known to be leading serotypes causing IPD in sub-Saharan Africa 
(Adegbola et al., 2006, Everett et al., 2012, Brueggemann et al., 2013). Reports from 
The Gambia indicated that approximately one in every five cases of IPD were 
attributable to serotype 1 in the pre-PCV era (Adegbola et al., 2006). There have also 
been reports of deadly epidemic outbreaks in the African meningitis belt caused by 
pneumococcal serotype 1 (Kwambana-Adams et al., 2016, Leimkugel et al., 2005, 
Yaro et al., 2006). Consequently, the use of increased valence vaccines that contain 
serotypes 1 and 5, such as PCV 10 (PCV7 serotypes plus serotypes 1, 5 and 7F) and 
PCV13 (PCV-7 plus serotypes 1, 5, 3, 6A, 19A, 7F) would seem appropriate for sub-
Saharan Africa. In The Gambia, PCV-7 was introduced into its national 
immunization programme in 2009, with a switch to PCV-13 in 2011. 
Given the importance of pneumococcal serotype 1 as a leading cause of IPD in The 
Gambia, monitoring the population structure of invasive disease-causing serotypes 
before and after the introduction of PCV-13 into routine immunization in The 
Gambia would be vital in any efforts to assess vaccine impact. Similarly, it would be 
both appropriate and critical to monitor any changes in the pneumococcal population 
in nasopharyngeal carriage, as nasopharyngeal carriage is known to precede invasive 
disease and pneumococcal vaccination could have an effect on serotypes seen in 
carriage.  
The aims of this chapter are to undertake a longitudinal study to determine the 
population structure of S. pneumoniae in The Gambia from January 1995 - 
December 2016, providing a description of the circulating serotypes and associated 
genotypes and in particular pneumococcal serotype 1. It also aims to assess any 
changes in the circulating pneumococcal serotypes following the introduction of the 
Chapter three Population structure of S. pneumoniae 
 
108 | P a g e  
 
pneumococcal conjugate vaccine in The Gambia. These aims will be used to explore 
the hypothesis that sustained vaccination can cause serotype replacement and that 
inclusion of further serotypes in formulation may not be as effective as expected. 
3.2. Methods 
Pneumococcal studies conducted in The Gambia from 1995- 2016 were sourced 
through a literature search as well as on-going unpublished studies (personal 
communication). Eight main datasets contributing to various studies conducted 
during the pre-defined period were identified. Of these, four studies were selected for 
the current analysis as they were conducted across different regions in The Gambia, 
covering a larger geographical spread (Figure 3.1), and also included study 
population of all age groups (Table 3.1). 
 
 
Figure 3.1 Map of The Gambia showing the administrative regions. 
Nasopharyngeal pneumococcal carriage isolates were obtained from Sibanor in the Western 
Region and Basse in the Upper River Region of The Gambia. Invasive isolates were obtained from 
the MRC clinic in the Greater Banjul area embedded in the Western Region and the health centres in 
the Central River Region and the Upper River Region. Map taken from Ezilon (www.exilon.com) 
 
Chapter three Population structure of S. pneumoniae 
 
109 | P a g e  
 
Table 3.1 Selected published pneumococcal studies conducted in The Gambia 
from 1996 – 2016 
  Study name 
Study$  PNI SVT PSP PCSU 
Characteristics         
Location 
MRC Ward, 
Fajara 
Sibanor, Foni Basse & Bansang Basse 
Region* WR WR URR URR 
Setting Urban & rural Rural Rural Rural 
Invasive/carriage Invasive Carriage Invasive Carriage 
Context 
Hospital 
surveillance  
PCV-7 vaccine 
trial - CSS 
Population based 
surveillance 
Population 
based CSS 
Period of 
collection 
Jan 1995-Dec 
2014 
Dec 2003 - Feb 
2009 
May 2008 -    
Dec 2016 
May - Aug 2009 
Age group All age groups All age groups ≥ 2 months 
All age groups, 
6-10 years in 
some 
Specimen# 
Blood, CSF, LA, 
PF, JFA 
NPS 
Blood, CSF, LA, 
PF, JFA 
NPS 
*WR; Western Region, CRR; Central River Region, URR; Upper River Region. 
#CSF, cerebrospinal fluid; LA, lung aspirate; PF, pleural fluid; JFA, joint fluid aspirates. 
$ PNI study; pneumococcal invasive disease study, SVT; pneumococcal carriage study conducted in 
the Western Region, PSP; pneumococcal surveillance project, PCSU study; pneumococcal carriage 
study conducted in The Upper River Region of The Gambia. 
 
The IPD studies selected included the pneumococcal invasive disease (PNI) study, a 
hospital-based pneumococcal surveillance at the Medical Research Council (MRC) 
hospital in the Western region of The Gambia (Figure 3.1) and the pneumococcal 
surveillance project (PSP), a population-based surveillance of IPD investigating 
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effectiveness of the introduction of PCV (Mackenzie et al., 2016). This population-
based surveillance was conducted in the Upper River Region (URR) and the Central 
River Region (CRR), both rural parts of The Gambia (Figure 3.1). For both studies, 
clinical specimens were collected from patients presenting at peripheral and referral 
health facilities or at the MRC ward with suspected pneumonia, septicaemia or 
meningitis. Specimens included blood, cerebrospinal fluid (CSF), lung aspirates, 
pleural aspirates or a combination of these. When more than one isolate was obtained 
during a single episode of illness, for example from blood and CSF, only one isolate 
was included in the analysis. Pneumococcal isolates obtained from these studies 
were serotyped as part of previous studies (Mackenzie et al., 2016, Adegbola et al., 
2006) or sent to the World Health Organization (WHO) Regional Reference Lab 
(RRL) for invasive bacterial disease for the West Africa region, located at the MRC 
Gambia Unit, for pneumococcal serotyping by latex agglutination and antimicrobial 
susceptibility testing. All isolates were genotyped by multi-locus sequence typing 
(MLST). 
Two nasopharyngeal carriage studies were included in this analysis. Firstly, large 
pneumococcal carriage studies (SVT studies) conducted in 21 selected rural villages 
in the Western region of The Gambia (Figure 3.1), which have been described 
previously (Hill et al., 2006, Roca et al., 2011). Briefly, a pre-vaccination cross 
sectional survey was conducted between December 2003 and May 2004 in which 
nasopharyngeal swab (NPS) samples were collected from subjects of all age groups 
(Hill et al., 2006). Following this, a single-blinded, cluster-randomised (by village) 
trial to evaluate the impact of PCV-7 on pneumococcal carriage was conducted in 
the study villages (Roca et al., 2011). In one group of 11 villages, all individuals 
over the age of 30 months received one dose of PCV-7 whilst subjects in this age 
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group resident in 10 control villages received one dose of Serogroup C 
meningococcal conjugate vaccine. All children less than 30 months of age in both 
study groups and infants born during the course of the trial received PCV-7. NPS 
were collected in three different cross-sectional surveys (from 4-6 months, 12-14 
months and up to 30 months) (Roca et al., 2011).  
Secondly, a cross-sectional population-based nasopharyngeal carriage study 
conducted in the Upper River Region of The Gambia between May and August 2009 
(Usuf et al., 2015). All ages were sampled but in some households, only those ages 
6-10 were sampled as this was the age group that participated in an earlier PCV- 9 
trial (Cutts et al., 2005) conducted in The Gambia from 2000 – 2004. 
3.3. Results 
3.3.1. Epidemiology background of isolates 
3.3.1.1. Western region 
A total of 6371 NPS samples were collected from the Western Region, of which 
52.19% (3325/6371) were positive for S. pneumoniae. Of the 3325 NPS positive for 
S. pneumoniae, a total of 3807 S. pneumoniae carriage isolates obtained and were 
analysed in this study (Roca et al., 2011). The percentage of males and females 
carrying S. pneumoniae were 50.37% (1675/3325) and 49.53% (1648/3325) 
respectively. The age distribution of individuals carrying S. pneumoniae was 26.80% 
(891/3325), 35.58% (1183/3325) and 37.56% (1249/3325) for ages < 5 years, 5 
<15years and ≥ 15years respectively. 
A total of 890 invasive pneumococcal isolates collected from 1995 – 2015 in the 
Western Region. However, 11 isolates were non-viable after culture and were 
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dropped from further analysis. Hence, a total of 879 pneumococcal isolates were 
analysed in this study. A summary of the specimen types and brief description of 
patient characteristics is provided in Table 3.2. 
Table 3.2 Summary of patient characteristics of all invasive isolates analysed 
from the Western Region, The Gambia (N=879) 
Characteristic Category Isolates  
N (%) 
Age group (years) <5 years 392 (44.60) 
 
5 - <15 years 107 (12.17) 
 
≥15 years 248 (28.21) 
 
Unknown 132 (15.02) 
Gender Female 325 (36.97) 
 
Male 463 (52.67) 
 
Unknown 91 (10.35) 
Specimen Blood 647 (73.61) 
 
CSF 121 (13.77) 
 
LA 56 (6.37) 
  Others 55 (6.25) 
Total  879 
CSF, cerebrospinal fluid; LA, lung aspirate. Other specimen include pleural fluid and joint fluid 
aspirates. 
 
3.3.1.2. Upper River region 
A total of 1228 S. pneumoniae carriage isolates obtained from 1117/2933 NPS 
samples collected from the Upper River Region were analysed in this study (Usuf et 
al., 2015). Of the 1117 individuals carrying S. pneumoniae, 50.58% were males and 
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49.42% females. The age distribution of individuals carrying S. pneumoniae was 
33.21% (371/1117), 53.80% (601/1117) and 12.98% (145/1117) for ages < 5 years, 5 
<15years and ≥ 15years respectively. 
A total of 400 pneumococcal isolates were collected from 2008 – 2016 in the Upper 
River Region but only 394 viable isolates were analysed in this study. Patient 
characteristics are shown in Table 3.3. 
Table 3.3 Summary of patient characteristics of all invasive isolates analysed 
from the Upper River Region, The Gambia 
Characteristics Category  Isolates  
N (%) 
Age group (years) <5 years 326 (82.74) 
 
5 - <15 years 33 (8.38) 
 
≥15 years 39 (7.36) 
 
Unknown 6 (1.52) 
Gender Female 161 (40.86) 
 
Male 230 (58.38) 
 
Unknown 3 (0.76) 
Specimen Blood 286 (72.59) 
 
CSF 27 (6.85) 
 
LA 69 (17.51) 
  Others 12 (3.05) 
Total  394 
CSF, cerebrospinal fluid; LA, lung aspirate. Other specimen include pleural fluid and joint fluid 
aspirates 
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3.3.2. Overall serotype distribution of pneumococcal study isolates 
3.3.2.1. Western Region 
In the Western region of The Gambia, 53 pneumococcal serotypes/groups were 
found causing IPD. Of these 53 serotypes, the leading ten serotypes were 1, 5, 14, 
6A, 23F, 19A, 12F, 6B, 19F and 7F accounting for 73.17% (643/879) of all 
pneumococcal isolates (Table 5.4). PCV-7, PCV-10 and PCV-13 serotypes 
accounted 25.6% (225/879), 61.56% (541/879) and 76.12% (669/879) of all 
pneumococcal isolates causing IPD.  
Among children <5 years old, the leading serotypes causing IPD in the Western 
region were serotypes 14 (15.56%, n=61/392), 5 (14.03%, n=55/392) and 1 (13.52%, 
n=53/392). Among children 5 - <15 years, serotypes 1 (36.45%, 39/107), 5 (14.95%, 
n=16/107) and 14 (6.54%, n=7/107) were the leading causes of IPD and among 
patients ≥15 years, serotypes 1 (23.39%, n=58/248), 5 (12.10%, n=30/248) and 7F 
(5.65%, 14/248) were the leading causes of IPD. 
Of 3807 pneumococcal carriage isolates obtained, the leading serotypes obtained 
were 3, 15B/C, 6A, 11, 35B/C, 23F, 19F, 6B, 16A/F and 34, all accounting for 
49.76% (1895/3807). PCV7, PCV-10 and PCV-13 serotypes accounted for 22.25% 
(847/3807), 24.4% (929/3807) and 41.81% (1592/3807) of all pneumococcal 
carriage isolates obtained.  
Serotypes 1 and 5 were rarely found among nasopharyngeal carriage pneumococcal 
isolates (0.89% and 0.45% respectively; Figure 3.2) even though they were the 
leading serotypes amongst invasive isolates (19.23% and 14.11% respectively). In 
contrast, serotypes 11, 35B/C and 34 were predominant in carriage but rarely found 
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among invasive isolates (Figure 3.2), whilst serotypes 6B and 23F were commonly 
found among both invasive and carriage isolates. 
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Table 3.4 Age distribution of pneumococcal serotypes among invasive (1995-
2015) and carriage (2003-2009) isolates collected from the Western Region of 
The Gambia 
 
Invasive isolates   Carriage isolates 
Serotype <5 
years 
5-<15 
years 
≥15 
years 
Unknown All 
ages 
(n) 
All 
ages 
(%) 
  < 5 
years 
5-<15 
years 
≥ 15 
years 
Unknown All 
ages 
(n) 
All 
ages 
(%) 
1 53 39 58 19 169 19.23  12 11 11 0 34 0.89 
5 55 16 30 23 124 14.11  4 10 3 0 17 0.45 
14 61 7 12 4 84 9.56  40 22 18 0 80 2.1 
6A 51 5 4 12 72 8.19  109 47 49 0 205 5.38 
23F 24 6 8 7 45 5.12  87 42 37 0 166 4.36 
19A 21 2 10 6 39 4.44  52 37 30 0 119 3.13 
12F 10 1 12 8 31 3.53  5 8 11 0 24 0.63 
6B 16 3 5 7 31 3.53  74 47 40 0 161 4.23 
19F 12 5 6 2 25 2.84  83 33 47 0 163 4.28 
7F 7 1 14 1 23 2.62  4 18 9 0 31 0.81 
3 2 1 8 6 17 1.93  60 152 126 1 339 8.9 
9V 7 3 4 3 17 1.93  41 38 29 0 108 2.84 
25 1 0 13 1 15 1.71  0 3 0 0 3 0.08 
46 7 1 5 1 14 1.59  0 4 8 0 12 0.32 
4 3 4 6 0 13 1.48  18 37 38 0 93 2.44 
9L 6 0 4 2 12 1.37  12 6 14 0 32 0.84 
10A/C 4 1 3 2 10 1.14  29 40 56 0 125 3.28 
18C 7 1 0 2 10 1.14  9 35 32 0 76 2 
9A 8 0 2 0 10 1.14  17 13 8 0 38 1 
2 6 0 1 2 9 1.02  0 6 4 0 10 0.26 
15B/C 2 0 5 2 9 1.02  78 69 61 0 208 5.46 
16A/F 1 1 7 0 9 1.02  30 61 54 0 145 3.81 
11 1 1 7 0 9 1.02  45 78 67 0 190 4.99 
35B/C 0 1 1 2 4 0.46  40 67 75 0 182 4.78 
34 1 0 2 1 4 0.45  39 59 38 0 136 3.57 
NT 0 0 0 0 0 0  19 46 67 0 132 3.47 
Others 26 8 21 19 74 8.41  167 391 422 0 980 25.77 
Total 392 107 248 132 879 100   1,074 1,379 1,353 1 3,807 100 
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3.3.2.2. Upper River Region 
Of 45 different serotypes found causing IPD in the Upper River Region (URR), the 
leading serotypes were 1, 5, 12F, 23F, 14, 35B, 9V, 6A, 6B and 24A/B, accounting 
for 72.85% (287/394) of all pneumococcal isolates (Table 3.5). PCV-7, PCV-10 and 
PCV-13 serotypes accounted for 15.48% (61/394), 52.79% (208/394) and 58.63% 
(231/394) respectively of all invasive pneumococcal isolates.  
Among children > 5 years old, the leading serotypes causing invasive disease in the 
URR were serotypes 1 (19.63%, n=64/326); 12F (15.03%, n=49/326) and 5 (12.88%, 
n=42/326). Among children 5 - <15 years, serotypes 1 (42.42%, n=14/33), 5 
(30.30%, n=10/33) and 35B (9.09%, n=3/33) were predominant. Whilst in the age 
group ≥15 years, serotypes 1 (31.03%, n=9/29), 12F (17.24%, n=5/29) and 5 
(17.24%, n=5/29) were the leading causes of IPD. 
Seventy-five different pneumococcal serotypes were found among the 1228 
pneumococcal carriage isolates collected. Serotypes 6A, 23F, 3, 19F, 34, 15B, 14, 
11A, 19A and NT were the leading serotypes found among all pneumococcal 
nasopharyngeal carriage isolates in the URR (Table 3.5). PCV-7, PCV-10 and PCV-
13 serotypes accounted for 23.04% (283/1228), 25.33% (311/1228) and 48.7% 
(598/1228) respectively of all pneumococcal carriage isolates.  
Similar to the Western region, serotypes 1 and 5 were rarely found in 
nasopharyngeal carriage (0.98% and 0.90% respectively- Figure 3.3) despite being 
the leading causes of IPD (21.7% and 14.46% respectively).  
Chapter three Population structure of S. pneumoniae 
 
118 | P a g e  
 
Table 3.5 Age distribution of pneumococcal serotypes among invasive (2008-
2016) and carriage (2009) isolates collected from the Upper River Region of The 
Gambia. 
  
Invasive isolates   Carriage isolates 
Serotype 
<5 
years 
5-<15 
years 
≥15 
years 
Unknown 
All ages 
(n) 
All ages 
(%) 
  
< 5 
years 
5-<15 
years 
≥ 15 
years 
All ages 
(n) 
All ages 
(%) 
1 64 14 9 0 87 22.08 
 
7 1 4 12 0.98 
5 42 10 5 0 57 14.47 
 
2 4 5 11 0.9 
12F 49 0 5 1 55 13.96 
 
5 0 4 9 0.73 
23F 16 0 0 0 16 4.06 
 
45 11 37 93 7.57 
14 13 1 0 1 15 3.81 
 
21 4 15 40 3.26 
35B 12 3 0 0 15 3.81 
 
13 6 9 28 2.28 
9V 9 2 2 0 13 3.3 
 
5 1 5 11 0.9 
6A 8 2 0 0 10 2.54 
 
87 8 66 161 13.11 
6B 9 1 0 0 10 2.54 
 
6 2 5 13 1.06 
24B/F 8 0 1 0 9 2.28 
 
1 1 9 11 0.89 
46 7 0 0 1 8 2.03 
 
1 1 1 3 0.24 
3 7 0 0 0 7 1.78 
 
17 14 59 90 7.33 
15B/C 6 0 0 0 6 1.52 
 
25 4 23 52 4.23 
19A 3 0 3 0 6 1.52 
 
13 3 20 36 2.93 
2 4 0 0 2 6 1.52 
 
2 0 4 6 0.49 
38 5 0 1 0 6 1.52 
 
1 1 7 9 0.73 
40 5 0 0 0 5 1.27 
 
0 2 8 10 0.81 
7B 5 0 0 0 5 1.27 
 
0 1 1 2 0.16 
11B 4 0 0 0 4 1.01 
 
1 1 3 5 0.41 
13 4 0 0 0 4 1.01 
 
7 8 17 32 2.61 
25F 4 0 0 0 4 1.01 
 
0 1 1 2 0.16 
9L 3 0 1 0 4 1.01 
      
19F 3 0 0 0 3 0.76 
 
43 8 36 87 7.08 
34 1 0 0 0 1 0.25 
 
17 6 33 56 4.56 
11A 1 0 0 0 1 0.25 
 
7 3 27 37 3.01 
NT 0 0 0 0 0 0 
 
8 5 22 35 2.85 
Others 34 0 2 1 37 9.42 
 
73 56 248 377 30.71 
Total 326 33 29 6 394 100  407 152 669 1228 100 
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Figure 3.2 Pneumococcal serotype distribution of invasive and carriage isolates 
from the Western Region of The Gambia from (1995-2015). 
The red arrow shows the leading invasive serotypes while the other serotypes are the leading 
serotypes in nasopharyngeal carriage.  
 
 
Figure 3.3 Pneumococcal serotype distribution of invasive and carriage isolates 
from the Upper River Region of The Gambia from (1995-2016). 
The red arrow shows the leading invasive serotypes while the other serotypes are the leading 
serotypes in nasopharyngeal carriage.  
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3.3.3. Yearly and monthly distribution of invasive pneumococcal 
serotypes 
Distribution of pneumococcal serotypes varied from year to year, most notable were 
the yearly fluctuations of serotypes 1 and 5. Prior to the introduction of PCV-7 in 
The Gambia, pneumococcal serotypes 1 and 5 were the leading causes of IPD and 
remained consistently the leading serotypes post introduction of PCV-7 and PCV-13. 
The slight exception to this pattern was in the post PCV-13 era when serotype 12F 
was the second leading cause of IPD after serotype 1, with serotype 5 was the third 
leading serotype.  
The prevalence of serotype 1 varied from as high as 40% and 32% in 2007 and 1997 
to as low as 3% to 8% in 2006 and 2015 respectively. The prevalence of serotype 
12F increased from zero in 2006 and 2007 pre PCV-7 to 26% and 21% in 2011 and 
2015 post PCV-7. The reverse of this distribution pattern was observed for serotypes 
4, 6B, 18C and 19F which decreased from the pre-PCV introduction to the post 
PCV-7 introduction. The prevalence of serotype 14 decrease post PCV-7 vaccination 
but has re-emerged post PCV-13 introduction. Other non-vaccine types causing IPD 
in 2015 and 2016 were serotypes 9V and 23F (Figure 3.4). 
Pneumococcal non-vaccine serotypes 12F and 35B were rarely detected in the PCV-
7 era, but were subsequently observed in the post PCV-13 era, possibly as 
replacement serotypes (Figure 3.4). 
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Figure 3.4 Yearly distribution of invasive isolates from The Gambia. 
Each serotype is represented as a percentage of all invasive pneumococcal isolates obtained in each 
year as indicated on the primary Y-axis. PCV-7 vaccine serotypes, the additional six serotypes 
making up PCV-13 serotypes and the non-vaccine serotypes (NVT) are presented on the secondary Y-
axis as a percentage of all invasive isolates yearly. PCV-7 was introduced in The Gambia national 
immunisation scheme in 2009 and PCV-13 in 2011. 
 
The majority of pneumococcal isolates were obtained between December and May 
each year. Peaks in the numbers of isolates occurred from March to May (hot dry 
season) mostly as serotypes 1 and 5 (Figure 3.5).  
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Figure 3.5 Monthly distribution of top 10 invasive isolates from The Gambia. 
Each serotype is represented as a percentage of all invasive pneumococcal isolates obtained in each 
year as indicated on the X-axis.  
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In the WR, MLST was conducted on 32 of 34 serotype 1 carriage isolates obtained. 
ST3081 (17/32) was the leading ST followed by ST618 (12/32). Only one ST217 
isolate was found. All ST618 isolates were found in 2004 and 2007 while all ST3081 
isolates were found in 2007 and 2008.  
3.3.4.2. Invasive pneumococcal disease 
MLST analysis was performed on 877 of 1273 randomly selected pneumococcal 
invasive isolates collected. Overall, 201 STs were found causing IPD with the 
leading STs ST3081_serotype 1 (11.40%, n=99/877), ST618_serotype 1 (10.72%, 
n=94/877), ST3404_serotype 5 (7.75%, n=68/877), ST989_serotype 12F (7.30%, 
n=64/877), ST289_serotype 5 (3.88%, n=34/877), ST802_serotype 23F (2.05%, 
n=18/877), ST847_serotype 19A (2.05%, n=18/877), ST63_serotype 14 (1.60%, 
n=14/877), ST217_serotype 1 (1.48%, n=13/877), ST3339_serotype 5 (1.37%, 
n=12/877) all accounting for 51% of all cases of IPD over the period 1995 to 2016 
(Figure 3.6).  
The distribution of ST3081, ST618 and ST217; the three predominant serotype 1 
STs varied over the study period. ST618 was the predominant and stable ST 
associated with serotype 1 IPD from 1995- 2006 and was last observed in The 
Gambia in 2007. In contrast, ST3081 was first observed in The Gambia in 2007 and 
thereafter became the predominant ST of serotype 1. ST217, although observed in 
lower numbers was seen along with ST618 in the earlier years and with ST3018 in 
the more recent years (Figure 3.6). Distribution of the three leading pneumococcal 
serotype 5 STs, ST3404, ST289 and ST3339 varied from year to year. However, 
unlike serotype 1, all three STs occurred simultaneously for most of the time. Also, 
the prevalence of ST289 increased in the post PCV-13 era and ST3404 started to 
decline post PCV-7 (Table 3.6). 
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Figure 3.6 Yearly distribution of sequence types from The Gambia over two 
decades. 
Each ST is represented as a percentage of all genotyped invasive pneumococcal isolates obtained in 
each year as indicated on the Y-axis. PCV-7 was introduced in The Gambia national immunization 
scheme in 2009 and PCV-13 in 2011. 
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The ST989, belonging to serotype 12F, was observed to increase in the post PCV-13 
era, whilst ST847, ST63 and ST802, belonging to serotypes 19A, 14 and 23F 
respectively, were not observed post PCV-13 introduction. However, serotype 14 
and 23F isolates observed in the post PCV-13 period were mostly due to ST2447 and 
ST1526 respectively (Table 3.6).  
Table 3.6 Sequence types of pneumococcal serotypes in the pre and post 
introduction of PCV-7 and PCV-13 in The Gambia 
Serotype ST Pre-PCV7 Post PCV7 Post-PCV13 
1 217 10 1 2 
 618 94 0 0 
 3081 29 17 54 
5 289 5 1 28 
 
3404 37 16 13 
14 63 12 0 1 
 
3321 11 0 0 
 
2447 2 0 8 
19A 847 17 0 1 
 
9769 0 0 1 
23F 802 16 1 1 
 
1526 1 0 8 
9V 280 5 2 3 
  5719 0 0 3 
Pre-PCV7, 1995 – August 2009; Post PCV-7, September 2009 – May, 2011; Post PCV-13, June 2011 
– 2016. 
 
Use of the minimum spanning tree showed a clear geographical clustering of the 
Gambian serotype 1 STs compared with serotype 1 STs from other parts of Africa 
and Asia obtained from the MLST database (http://pubmlst.org/spneumoniae/). In 
addition, these STs were different from STs obtained from the other parts of the 
world where the clonal complex 306 predominates (Figure 3.4). In contrast to the 
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pattern seen for serotype 1 STs, Gambian serotype 5 STs were seen to cluster 
together with STs from Africa and other parts of the world. 
 
Figure 3.7 geoBURST analysis comparing Gambian pneumococcal serotype 1 
(A) and serotype 5 (B) isolates to the rest of Africa, Asia and globally. 
Each circle represents a single sequence type (ST). The area of each circle is proportional to the number 
of isolates included in the analysis.  
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3.4. Discussion 
This study provides data on the prevailing serotypes and sequence types of S. 
pneumoniae in The Gambia over a 20 year period. Importantly, these isolates were 
collected during the pre, and for a few years, in the post-PCV-13 vaccination era, 
and as such provides valuable background data that will be relevant for a robust 
interpretation of any changes in the circulating pneumococcal serotypes observed 
following the introduction of routine vaccination with the pneumococcal conjugate 
vaccines in The Gambia.   
Results from this study indicate that there was a reduction in IPD caused by vaccine 
type serotypes following the introduction of PCV, with the exception of serotypes 1 
and 5. The reduction of vaccine serotypes after the introduction of PCVs has been 
reported elsewhere, including in other parts of Africa (Mackenzie et al., 2016, Cohen 
et al., 2016). Pneumococcal serotype 1 has been known to be one of the leading 
causes of IPD in The Gambia and other parts of West Africa. Given the introduction 
of PCV-13; a serotype 1 containing conjugate vaccine, in The Gambia it was 
unexpected that this strain persisted after vaccination. This might be related to the 
fact that serotype 1 has been reported to cause IPD mostly amongst older children 
and young adults than it does in children less than 5 years old (Kwambana-Adams et 
al., 2016, Brueggemann et al., 2013). Since PCV is given to infants at 2, 3 and 4 
months of age, it is plausible that a longer post-PCV period of observation than has 
been covered by this study might be required to observe any appreciable effects of 
the vaccine in the older population who do not receive this vaccine but remain the 
age group that are most at risk for pneumococcal serotype 1 IPD. This finding may 
also point to the need for a review of current target age groups for pneumococcal 
vaccination, as has been reported in a few studies previously (Klugman et al., 2011). 
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In Ghana, despite the introduction of PCV-13 in the national immunization program 
in 2012, a deadly outbreak caused by serotype 1 was reported in 2016 with most of 
the cases seen among older children and young adults (Kwambana-Adams et al., 
2016). Earlier trials of the 9-valent conjugate vaccine (PCV-9), a serotype 1-
containing pneumococcal vaccine, in South Africa and in The Gambia both reported 
findings that were inconclusive on the vaccine’s protection against serotype 1 
disease (Klugman et al., 2011, Cutts et al., 2005). 
All serotype 1 isolates in this study belonged to the ST217 clonal complex, the same 
clonal complex to which serotype 1 strains were isolated in other parts of Africa 
(Brueggemann and Spratt, 2003). Reports have shown that most serotype 1 isolates 
obtained from South and East Africa mostly comprise of ST217 (Brueggemann et 
al., 2013, du Plessis et al., 2016), with West African isolates mostly comprising of 
ST303 isolates (Leimkugel et al., 2005, Kwambana-Adams et al., 2016). In The 
Gambia, however, two major STs were observed to be circulating, ST618 which has 
been reported in other parts of West Africa and ST3081 reported only in 
neighbouring Senegal within Africa and in Oman in the MLST database. Our 
findings indicate that ST3081 emerged as a new dominant clone in 2007 prior to the 
introduction of PCVs in The Gambia and subsequently spread across the entire 
country, causing IPD. In addition, ST3081 was seen to have replaced ST618, which 
had been the dominant lineage among serotype 1 isolates circulating in The Gambia 
for over a decade prior. This change in dominant genotypes was also observed 
among serotype 1 isolates obtained from the nasopharynx of healthy individuals in 
The Gambia with the time period of the switch also seen to be similar (Ebruke et al., 
2015), an indication that this change had occurred both in invasive disease and 
carriage states as well as across both rural and urban settings in The Gambia. It may 
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be that the observed change in dominant circulating genotypes is reflecting adaptive 
changes by the pneumococcus in response to changes in the human population and 
human activity, which yet remain unclear.  
The clonal replacement observed in The Gambia has also been reported in Brazil 
where temporal switching between two lineages of serotype 1 and wide dispersion of 
a Swedish clone was observed (Chiou et al., 2008). A possible explanation for this 
replacement in dominant clones could be genetic recombination or point mutations 
as occurs in the evolution of certain microbes, with recombination the more likely 
scenario in the case of S. pneumoniae (Henriques-Normark et al., 2008, Feil et al., 
2000, Spratt et al., 2001). This could be attributed to particular characteristics of the 
host community, such as antibiotics usage, vaccine selective pressure or a virulence 
advantage of the pneumococcal lineage (Spratt and Greenwood, 2000). A study 
conducted in Portugal among healthy carriers revealed an emergence and expansion 
of a serotype 1 lineage soon after the introduction of PCV-7 (Nunes et al., 2008). 
However, a carriage study of serotype 1 in the context of a PCV-7 vaccine trial in 
The Gambia did not show substantial evidence that the observed changes in 
genotype were as a result of selective pressure through vaccination (Ebruke et al., 
2015). The effect of vaccination as a contributing factor to the observed changes in 
genotypes of serotype 1 remains to be proven. It becomes critically important, 
therefore to exploit the use of more informative techniques such as whole genome 
sequencing to determine the absolute genetic differences between these two STs and 
thus improve our understanding of the key mechanisms involved in clonal 
replacement. 
Results from this study show that pneumococcal serotype 1 has a geographical 
structure with strains from Africa and Asia clustering together and that these strains 
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cluster differently from pneumococcal serotype 1 strains from other parts of the 
world, as has been reported in some other studies (Brueggemann and Spratt, 2003). 
A short duration of nasopharyngeal carriage of pneumococcal serotype 1 strains, 
resulting in reduced spread of the organism during travel across geographical 
regions, may be a possible explanation for the observed geographic clustering. It 
would appear that among S. pneumoniae serotype 1 strains in West Africa, there is 
an expansion of the ST217 clonal complex, as has been reported not only in The 
Gambia, but also in Ghana, Niger and Burkina Faso. This spread seems to be 
responsible for the deadly epidemics observed in these geographical areas (Antonio 
et al., 2008, Leimkugel et al., 2005, Yaro et al., 2006), including a recent outbreak of 
pneumococcal serotype 1 meningitis in 2016 in Ghana (Kwambana-Adams et al., 
2016). This study provides critical background data that will be useful in interpreting 
any subsequent observed changes in the circulating pneumococcal serotype 1 strains 
and thus help improve our knowledge of the patterns of spread and the phylogenetic 
structure of this serotype. 
Findings from this study show that pneumococcal serotype 5, like serotype 1, is a 
major cause of IPD in The Gambia and rarely found in nasopharyngeal carriage is 
consistent with reports from other studies (Brueggemann et al., 2013). All serotype 5 
isolates included in this study belonged to the ST289 clonal complex dominated by 
ST289 and ST3404. In contrast to serotype 1, serotype 5 STs fluctuated throughout 
the study period and at 2016 both STs were found co-occurring. Additionally, unlike 
the predominant serotype 1 STs that showed a clear geographical clustering, the 
same dominant serotype 5 ST289 has been reported in various regions of the world 
and across different continents. Further studies of serotype 5 will be useful in 
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understanding the reasons behind these differences in distribution between these two 
important pneumococcal serotypes and the public health relevance.  
Another noteworthy finding from this study is that different genotypes of vaccine 
serotypes emerged post vaccination. This may suggest that within a given serotype 
there is significant genetic and immunogenic variation. Among serotype 14 isolates, 
ST63 dominated pre-vaccination but ST2447, a SLV of ST63, now dominates post 
vaccination. Similarly, among serotype 23F, ST802 was occurring mostly pre PCV-7 
vaccination, however post-vaccination, ST1526 was the predominant ST. Given the 
fact that current PCVs in use has been shown to be effective against serotypes 
included in the vaccine, it is not known to what extent the changes in the circulating 
STs might impact on the effectiveness of currently used pneumococcal conjugate 
vaccines. 
Replacement of vaccine serotypes with non-vaccine serotypes following introduction 
of pneumococcal conjugate vaccines has been noted as one of the outcomes of PCV 
use and this effect has been reported in several countries (Janoir et al., 2016, Del 
Amo et al., 2016). In the USA, serotype 19A became a major replacement serotype 
in the Post PCV-7 era (Pilishvili et al., 2010). In this study, we report that 
pneumococcal serotype 12F emerged as an important replacement serotype. In 
particular, this serotype was hardly seen in the pre-vaccination period but 
subsequently became one of the leading causes of IPD amongst study isolates in the 
post-PCV period. Similar to pneumococcal serotype 1, serotype 12F was rarely 
detected in nasopharyngeal carriage and all isolates belonged to a single dominant 
clonal complex, ST989. Reports from other parts of the world have shown that 
serotype 12F is able to cause epidemic outbreaks similar to serotype 1 (Deng et al., 
2016). This is of particular importance given the fact that serotype 12F is not 
Chapter three Population structure of S. pneumoniae 
 
132 | P a g e  
 
included in PCV13 currently in routine use in The Gambia. In addition, this study 
shows the emergence of non-vaccine type serotype 35B which has also been reported 
in other parts of the world (Olarte et al., 2017). These findings on emergence of non-
vaccine pneumococcal serotypes that have epidemic potential may suggest that the 
impact of currently used PCV may be far from optimal.  
Findings from this study highlight the need for the continuous population-based 
post-vaccine surveillance of the circulating pneumococcal serotypes to provide a 
robust evidence base for the timely review of existing policies on the prevention and 
control of pneumococcal disease. New vaccines that contain coverage against the 
predominant circulating serotypes are needed. In addition, given the importance of 
serotypes 1, 5 and 12F, emphasis on the closer monitoring of any changes in the 
molecular epidemiology of these strains would be helpful for refinements to be made 
in appropriate intervention guidelines that will aid better preparedness for epidemic 
outbreaks. 
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4. Antibiotic susceptibility patterns of Streptococcus pneumoniae in 
The Gambia from pre-and post-introduction of pneumococcal 
conjugate vaccines 
4.1. Introduction 
Antibiotic resistance is a global problem and is now gaining more attention 
worldwide (Laxminarayan et al., 2013, Laxminarayan et al., 2016). The increasing 
global attention this problem has attracted is due in part to a growing recognition of 
its potential for severe adverse effects on health systems including reductions in the 
effectiveness of existing treatments for severe illnesses with associated increasing 
deaths. In resource poor countries, the challenge with antibiotic resistance is 
particularly worrying as unavailability of alternative drugs are often unaffordable by 
majority of those affected. This frequently leads to delays in treatment that further 
worsen treatment outcomes. For S. pneumoniae, the problem of antibiotic resistance 
is of particular concern due to the disproportionately heavy burden of pneumococcal 
disease and associated higher mortality rates in developing countries in comparison 
to developed countries (O'Brien et al., 2009). 
Antibiotic resistance in S. pneumoniae isolates is mediated through mechanisms 
employed by the bacteria to evade the effects of antibiotic treatment; some of these 
mechanisms have been discussed briefly in section 1.13.1. Antibiotic resistance in S. 
pneumoniae was first described in the 1960s and has since evolved over time 
(Hansman, 1967). The PMEN network was set up to monitor global patterns of 
antibiotic resistance among S. pneumoniae isolates (McGee et al., 2001). 
The introduction of pneumococcal vaccines has been shown to reduce resistance 
among pneumococcal isolates (Kyaw et al., 2006). Serotypes included in the 1st 
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licenced conjugate vaccine PCV-7 were largely responsible for multidrug resistance 
(Whitney et al., 2000). The reduction in carriage and transmission of these vaccine 
serotypes that followed introduction of PCV-7, along with reductions in antibiotic 
usage, led to a corresponding decrease in the prevalence of antibiotic resistance 
among circulating pneumococcal isolates(Kyaw et al., 2006). However, with 
serotype replacement, non-vaccine serotypes subsequently emerged, some of which 
were antibiotic resistant, such as the post PCV-7 emergence of serotype 19A in the 
USA (Pelton et al., 2007). The introduction of PCV-13, with its wider valency 
including additional six serotypes, would appear to have stemmed this problem 
(Tomczyk et al., 2016, Dagan et al., 2015). However, as the possibility that emerging 
non-vaccine serotypes could develop resistance to antibiotics remains, the problem 
of antibiotic resistance continues to pose a challenge for healthcare systems. 
It is therefore important to continue to monitor the effect of vaccination and 
antimicrobial resistance globally and at country levels to help inform effective 
strategies for prevention and control of antibiotic resistance. PCV-7 was introduced 
in The Gambia in 2009, with a switch to PCV-13 in 2011. In the previous chapter,  
described the serotypes and genotypes among invasive and carriage isolates in The 
Gambia collected over two decades over the pre- and post- PCV era.  
The aim of this chapter is to describe the antibiotic resistant patterns and assess the 
impact of vaccination on the prevalence of antibiotic-resistant S. pneumoniae in 
nasopharyngeal carriage and invasive disease isolates in rural and urban Gambia. In 
addition, to determine if the emerging non-vaccine serotypes are susceptible or 
resistant to antibiotics used commonly in The Gambia. This aim would be used to 
test the hypothesis that the introduction of PCVs would result in reductions in levels 
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of antibiotic resistance among pneumococcal isolates circulating in The Gambia as 
the known antibiotic resistant strains are included in the vaccine. 
4.2. Methods 
Parent studies and sources of pneumococcal isolates used and analysed in this 
chapter have been described in section 3.2 of this thesis. These studies were 
conducted in The Gambia over the period 1995- 2015. 
Briefly, invasive pneumococcal isolates were obtained from a hospital-based 
pneumococcal surveillance at the MRC hospital in the Western region of The 
Gambia and from a population-based surveillance of IPD in the Upper and Central 
River Regions investigating effectiveness of the introduction of PCV in The Gambia. 
Nasopharyngeal carriage isolates included in this chapter were obtained from large 
pneumococcal carriage studies conducted on healthy participants residing in 21 
villages in the Western region of The Gambia.  
As part of these studies, antibiotic susceptibility testing was conducted on these 
isolates by the MRC Unit, The Gambia, of which I contributed to. Antibiotic 
susceptibility testing was not performed on carriage isolates collected from the 
Upper River Region and so these isolates were excluded from analyses done in this 
chapter. 
Study isolates were tested by the Kirby-Bauer disk diffusion and Epsilometer (E-
test) agar diffusion methods for pneumococcal isolates following the Clinical and 
Laboratory Standards Institute (CLSI) guidelines (CLSI, 2017) as described in 
section 2.3.3. Antibiotics tested by disk diffusion included, chloramphenicol (30 µg), 
erythromycin (5 µg), cotrimoxazole (1.25 µg/23.75 µg) and tetracycline (30 µg). E-
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test to determine MICs was performed for penicillin and cefotaxime. All results were 
interpreted using the CLSI guidelines as summarized in the table 4.1 (CLSI, 2017). 
Table 4.1 Clinical and Laboratory Standards Institute interpretative charts of 
pneumococcal disk diffusion zone size and minimum inhibitory concentration 
 Sensitive Intermediate  Resistant  
Disk diffusion  mm Mm mm 
Chloramphenicol ≥ 21 - ≤ 20 
Erythromycin ≥ 21 16-20 ≤ 15 
Co-trimoxazole ≥ 19 16-18 ≤ 15 
Tetracycline ≥ 28 25-27 ≤ 24 
MIC  µg/ml µg/ml µg/ml 
Penicillin ≤0.06  0.12-1 ≥2 
Cefotaxime ≤ 1 2 ≥4 
 
4.3. Results 
4.3.1. Epidemiological background of study isolates 
Of 1,290 invasive pneumococcal isolates collected from the Western and Upper 
River Regions of The Gambia over the study period, antibiotic susceptibility testing 
was performed on 1055 (82%) isolates and analysed in this study. Characteristics of 
the patients from whom these isolates were collected are shown in Table 4.2.  
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Table 4.2 Summary of patient characteristics from whom invasive isolates were 
collected from 1995 – 2015 and included in this study 
Characteristics Category  Isolates  
N (%) 
Age group (years) <5 years 540 (51.2) 
 
5 - <15 years 128 (12.1) 
 
≥15 years 257 (24.4) 
 
Unknown 130 (12.3) 
Gender Female 393 (37.3) 
 
Male 572 (54.2) 
 
Unknown 90 (8.5) 
Specimen Blood 769 (72.9) 
 
CSF 132 (12.5) 
 
LA 94 (8.9) 
  Others 60 (5.7) 
Total  1055 
CSF, cerebrospinal fluid; LA, Lung aspirate 
Of 3,807 pneumococcal carriage isolates obtained from studies conducted in the 
Western Region of The Gambia, antibiotic susceptibility testing was available for 
2,884 isolates (76%) and analysed in this study. The percentage of males and 
females carrying S. pneumoniae were 49.7% (1434/2884) and 50.2% (1449/2884) 
respectively. 
4.3.2. Antibiotic susceptibility patterns among invasive pneumococcal 
isolates 
Pneumococcal invasive isolates collected from patients with IPD in The Gambia 
were highly susceptible to four of the six antibiotics tested; cefotaxime (100%), 
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penicillin (99.8%), erythromycin (96.4%) and chloramphenicol (81.9%). Reduced 
susceptibility was observed for tetracycline (40.8%) and co-trimoxazole (26.2%) 
(Table 4.3).  
Table 4.3 Overall distribution of antimicrobial susceptibility patterns of 
invasive pneumococcal isolates in The Gambia from 1995 – 2015 (n =1055 [for 
erythromycin, n=473]) 
Antibiotics Resistant Intermediate Susceptible 
  n (%) n (%) n (%) 
Co-trimoxazole 715 (67.77) 64 (6.07) 276 (26.16) 
Chloramphenicol 191 (18.1) - 864 (81.9) 
Tetracycline 493 (46.73) 132 (12.51) 430 (40.76) 
Erythromycin 7 (1.48) 10 (2.11) 456 (96.41) 
Penicillin 0 2 (0.19) 1053 (99.81) 
Cefotaxime 0 0 1055 (100) 
Disk diffusion test was performed for co-trimoxazole, chloramphenicol, tetracycline and 
erythromycin. E-test was done for Penicillin and cefotaxime 
 
Monitoring the resistance patterns of invasive isolates from The Gambia over the pre 
and post PCV era, resistance to co-trimoxazole appeared to increase over time from a 
prevalence of 60.77% in the pre-PCV era to 95.15% in the post-PCV13 era (Table 
4.4). Whereas for tetracycline, chloramphenicol and erythromycin, a fluctuating 
pattern with a slight decrease from the pre-PCV 7 era to post introduction of PCV-7 
and subsequently increasing in the post PCV-13 era (Table 4.4) was observed. The 
only two isolates with intermediate resistance to penicillin were found in the Pre-
PCV7 and Post-PCV 7 era.  
Table 4.4 Antimicrobial resistance of invasive pneumococcal isolates distributed 
by study periods (pre-PCV-7, post-PCV-7 and post PCV-13) in The Gambia 
  Number (%) of resistant invasive isolates 
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Antibiotics Pre-PCV7 (n=831) Post-PCV7 (n=59) Post-PCV13 (n=165) 
Co-trimoxazole 
   
Intermediate 62 (7.46) 2 (3.39) 0 
Resistant 505 (60.77) 53 (89.83) 157 (95.15) 
Chloramphenicol 
   
Resistant 145 (17.45) 9 (15.25) 37 (22.42) 
Tetracycline 
   
Intermediate 99 (11.91) 11 (18.64) 22 (13.33) 
Resistant 396 (47.65) 22 (37.29) 75 (45.45) 
Erythromycin Pre-PCV7 (n=249) Post-PCV7 (n=59) Post-PCV13 (n=165) 
Resistant 2 (0.80) 1 (1.69) 4 (2.42) 
Pre-PCV7, 1995 – August 2009; Post PCV-7, September 2009 – May, 2011; Post PCV-13, June 2011 
– 2015. 
 
Stratifying by vaccine types, no significant differences were found between PCV-7, 
PCV-13 and non-vaccine serotypes for resistance to co-trimoxazole and 
erythromycin (p=0.086 and 0.606 respectively). However, prevalence of resistance 
to chloramphenicol was significantly higher among NVT, and resistance to 
tetracycline significantly higher among PCV-7 serotypes, in comparison to other 
vaccine types (p = 0.002 and p<0.001, respectively) (Table 4.5). 
Table 4.5 Antimicrobial resistance of invasive isolates (n =1055 [for 
erythromycin, n=473]) stratified by PCV vaccine and non-vaccine types 
  Number (%) of resistant invasive isolates 
Antibiotics PCV-7 (n=255) PCV-13  (n=544) NVT (n=256) 
Co-trimoxazole 
   
Intermediate 20 (7.84) 24 (4.41) 20 (7.81) 
Resistant 170 (66.67) 384 (70.59) 161 (62.89) 
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Chloramphenicol 
   
Resistant 33 (12.94) 95 (17.46) 63 (24.61) 
Tetracycline 
   
Intermediate 19 (7.45) 88 (16.18) 25 (9.77) 
Resistant 156 (61.18) 214 (39.34) 123 (48.05) 
Erythromycin PCV-7 (n=227) PCV-13  (n=118) NVT (n=128) 
Resistant 2 (1.69) 2 (0.88) 3 (2.34) 
PCV-7 vaccine serotypes (PCV-7), the additional six serotypes making up PCV-13 serotypes (PCV-
13) and the non-vaccine serotypes (NVT) are all other serotypes not contained in PCV-13. 
 
4.3.3. Yearly antibiotics susceptibility patterns 
The year by year data for co-trimoxazole resistance showed a noticeable increase in 
2010 post introduction of PCV-7 and subsequently remained high over the rest of the 
period under review. A substantial increase in chloramphenicol resistance was 
observed in 2002 and 2003, prior to the introduction of PCVs in The Gambia which 
was followed by lower resistance levels over the subsequent years. Resistance to 
tetracycline appeared to fluctuate from year to year throughout the study period, 
mostly between 20% - 60% prevalence rates whilst resistance to erythromycin was 
generally very low (below 10%) all through the review period with no erythromycin- 
resistant isolates seen in 2014 and 2015 (Figure 4.1). 
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Figure 4.1 Yearly antimicrobial resistance patterns among 1055 invasive study 
isolates collected from 1995- 2015. 
For erythromycin, antibiotics data included was from 2004 -2015, n=473. 
PCV-7 was introduced in The Gambia national immunization scheme in 2009 and PCV-13 in 2011. 
The bar colours blue, orange and grey represent percentage of resistant, intermediate and resistant 
isolates respectively per year. 
 
4.3.4. Antibiotic resistance patterns by pneumococcal serotypes 
Antibiotic resistance patterns for the leading pneumococcal serotypes seen among 
invasive isolates in The Gambia as described in section 3.3.3, all of which are 
included in PCV-13 except serotype 12F, are shown in Figure 4.2. Pneumococcal 
serotype 7F showed high levels of resistance to all but one of the antibiotics tested. 
Of 25 serotype 7F isolates analysed, 96% were resistant to tetracycline and co-
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trimoxazole, while 72% were resistant to chloramphenicol. Of 147 serotype 5 
isolates tested, 90%, 26.4% and 12.2% were resistant to co-trimoxazole, tetracycline 
and chloramphenicol respectively. In addition, the two isolates that showed 
intermediate resistance to penicillin were both serotype 5 isolates (not shown in Fig 
4.2). Of 234 pneumococcal serotype 1 isolates tested, 61.1%, 34.6% and 12% were 
resistant to co-trimoxazole, tetracycline and chloramphenicol respectively. 
Resistance to erythromycin was low (<10%) among all the leading pneumococcal 
serotypes (Fig. 4.2). Of 110 study isolates tested for erythromycin, two serotype 1 
isolates were resistant. 
Among NVTs, resistance among serotype 12F isolates (n=50) were 92%, 88% and 
66% to co-trimoxazole, tetracycline and chloramphenicol respectively. Other non-
vaccine serotypes not shown in Figure 4.2 include serotype 46, with 70.6%, 70.6% 
and 41.8% of 17 isolates tested found to be resistant to co-trimoxazole, tetracycline 
and chloramphenicol respectively. 
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Figure 4.2 Antibiotics resistance patterns of the leading pneumococcal serotypes 
causing IPD in The Gambia. 
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4.3.5. Antibiotic resistance patterns by pneumococcal sequence types 
Antibiotic resistant patterns by sequence type is shown in figure 4.3 for the leading 
STs among invasive isolates in The Gambia.  
The two leading STs observed in this study were ST618 and ST3081, both of which 
are serotype 1 STs, with our report in the previous chapter indicating that ST3081 
had replaced ST618 as the leading serotype 1 ST circulating in The Gambia. In this 
study, resistance patterns to chloramphenicol and tetracycline were similar for both 
STs. However, 93.9% (77/82) of ST3081 isolates were resistant to co-trimoxazole in 
comparison to only 26.6% (25/94) of ST618 isolates (Figure 4.3). Yearly distribution 
of serotype 1 STs in The Gambia showed that from 1995 – 2005, most serotype 1 
isolates had high susceptibility to co-trimoxazole, mostly due to ST618. However, 
from 2006 co-trimoxazole resistance among serotype 1 isolates were mostly due to 
ST3081 (Figure 4.4). In addition, both serotype 1 isolates found to be resistant to 
erythromycin were ST3081 isolates (Figure 3). Among ST217 isolates, a serotype 1 
genotype observed to be occurring during periods of occurrence of both ST618 and 
ST3081, all isolates were resistant to tetracycline (100%). In addition, resistance to 
chloramphenicol among ST217 isolates was much higher than was observed among 
ST618 and ST3081 isolates (Figure 4.3). 
Among the serotype 5 predominant STs, ST289 and ST3404, resistance to co-
trimoxazole was high, but was low for chloramphenicol and tetracycline. In addition, 
one isolate each of these two STs showed intermediate resistance to erythromycin. 
Among ST847 isolates, the predominant serotype 19A ST in The Gambia, all 
isolates were resistant or showed intermediate resistance to co-trimoxazole, but all 
isolates belonging to this ST were sensitive to chloramphenicol. Among serotype 14 
STs, all ST63 were resistant to tetracycline while ST3321 isolates showed only 
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intermediate resistance. Both ST802 of serotype 23F and ST3324 of serotype 6A, 
showed high resistance to co-trimoxazole and tetracycline but lower for 
chloramphenicol. However, only one 23F ST1526 isolate showed intermediate 
resistance to erythromycin.  
All serotype 12F isolates included in this study belong to ST989 in The Gambia and 
so results by ST is similar to what was reported in section 4.3.4. 
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Figure 4.3 Antibiotics resistance patterns of the leading pneumococcal sequence 
types causing IPD in The Gambia. 
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Figure 4.4 Yearly antimicrobial resistance patterns among S. pneumoniae 
serotype 1 study isolates collected from 1995- 2015 
PCV-7 was introduced in The Gambia national immunization scheme in 2009 and PCV-13 in 2011. 
 
4.3.6. Antibiotic susceptibility patterns among pneumococcal carriage 
isolates 
As was observed among pneumococcal invasive isolates, nasopharyngeal carriage 
isolates were highly susceptible to erythromycin (91.2%) and chloramphenicol 
(88.3%). Reduced susceptibility was observed for tetracycline (41.5%) and co-
trimoxazole (33.4%) (Table 4.6). 
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Table 4.6 Antibiotic susceptibility patterns among pneumococcal carriage 
isolates (n=2,884) 
Antibiotics Resistant  
N (%) 
Intermediate 
N (%) 
Susceptible 
N (%) 
Co-trimoxazole 1,551 (53.78) 369 (12.79) 964 (33.43) 
Chloramphenicol 338 (11.72) - 2,546 (88.28) 
Tetracycline 1,282 (44.45) 404 (14.01) 1,198 (41.54) 
Erythromycin 40 (1.39) 215 (7.45) 2,629 (91.16) 
 
4.3.7. Antibiotic resistance patterns among carriage isolates stratified by 
pneumococcal serotypes  
Stratifying by pneumococcal serotypes (Table 4.7), resistance patterns among 
carriage isolates included in this study were similar to those for pneumococcal 
invasive isolates reported above. Across all 26 carriage serotypes represented, 
resistance to co-trimoxazole or tetracycline was consistently high or moderate. 
Among serotypes 1 and 5 carriage isolates included in this study, 79% and 64%, 
respectively, were resistant to co-trimoxazole, with little (4%) or no (0%) resistance 
to chloramphenicol and erythromycin respectively. In contrast, serotype 12F isolates 
demonstrated high levels of resistance to three of the four antibiotics tested 
(Tetracycline 100%, co-trimoxazole 83% and chloramphenicol 83%). Similarly, 
among serotype 7F isolates, high to moderate levels of resistance to these three 
antibiotics was observed, with 76%, 56% and 32% resistance prevalence to 
Tetracycline, co-trimoxazole and chloramphenicol respectively. (Table 4.7). 
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Table 4.7 Antibiotic Susceptibility of pneumococcal carriage isolates from The 
Gambia stratified by serotypes 
    
Chloramphenicol 
  
Erythromycin 
    
Co-trimoxazole 
    
Tetracycline 
  
Serotyp
e 
Total 
(n) R   (%) 
S 
(%)   
R 
(%) 
I 
(%) 
S 
(%)   
R 
(%) 
I 
(%) 
S 
(%)   
R 
(%) 
I 
(%) 
S 
(%) 
1 28 4 96  0 4 96  79 7 14  32 43 25 
2 7 29 71  0 14 86  29 14 57  57 0 43 
3 213 11 89  1 5 93  31 5 64  39 14 47 
4 75 15 85  1 13 85  35 17 48  31 29 40 
5 14 0 100  0 7 93  64 21 14  43 0 57 
11 134 11 89  3 9 88  60 12 28  31 22 46 
12 18 83 17  0 22 78  83 11 6  100 0 0 
14 52 8 92  0 12 88  69 17 13  73 8 19 
25 3 0 100  0 0 100  33 0 67  0 100 0 
34 113 6 94  1 6 93  48 29 23  17 23 60 
46 6 17 83  0 0 100  100 0 0  100 0 0 
6A 166 17 83  1 13 87  67 22 11  70 4 26 
6B 126 13 87  0 4 96  79 15 6  34 21 45 
7F 25 32 68  0 0 100  56 28 16  76 16 8 
9A 21 5 95  0 0 100  95 0 5  48 19 33 
9L 26 8 92  0 0 100  54 19 27  15 31 54 
9V 76 20 80  1 16 83  93 3 4  37 17 46 
NT 128 10 90  5 4 91  48 8 44  48 7 45 
10A/C 62 0 100  0 2 98  27 13 60  15 15 71 
15B/C 105 8 92  1 5 94  89 4 8  34 14 51 
16A/F 66 0 100  0 3 97  73 6 21  77 3 20 
18C 56 13 88  2 9 89  36 21 43  55 9 36 
19A 87 7 93  1 7 92  68 18 14  47 11 41 
19F 119 10 90  0 7 93  83 9 8  71 8 20 
23F 117 14 86  3 11 85  78 11 11  85 5 10 
35B/C 95 9 91   2 15 83   29 14 57   31 18 52 
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Table 4.8 Antimicrobial resistance of nasopharyngeal carriage isolates (n 
=2884) stratified by PCV vaccine and non-vaccine types 
 
PCV-7 vaccine serotypes (PCV-7), the additional six serotypes making up PCV-13 serotypes (PCV-
13) and the non-vaccine serotypes (NVT) are all other serotypes not contained in PCV-13. 
 
4.4. Discussion 
This study provides the patterns of antibiotic susceptibility among invasive and 
carriage pneumococcal isolates in The Gambia over a 20 year period including the 
pre-PCV and PCV era. Results from this study indicate that susceptibility of both 
invasive and nasopharyngeal carriage pneumococcal isolates in The Gambia to 
commonly used antibiotics was generally high, with 99.8% of invasive isolates 
susceptible to penicillin and over 80% of invasive and carriage isolates susceptible to 
chloramphenicol. The exceptions to this pattern of high susceptibility of study 
isolates to the commonly used antibiotics were the high levels of non-susceptibility 
  Number (%) of resistant carriage isolates 
Antibiotics PCV-7 (n=621    ) PCV-13  (n= 533 ) NVT (n= 1730) 
Co-trimoxazole  
  
Intermediate 79 (12.72) 76 (14.26) 214 (12.37) 
Resistant 442 (71.18) 281 (52.72) 828 (47.86) 
Chloramphenicol    
Resistant 81 (13.04) 66 (12.38) 191 (11.04) 
Tetracycline    
Intermediate 86 (13.85) 62 (11.63) 256 (14.80) 
Resistant 347 (55.88) 275 (51.59) 660 (38.15) 
Erythromycin    
Intermediate 59 (9.50) 40 (7.50) 116 (6.71) 
Resistant 7 (1.13) 5 (0.94) 
28 1.62) 
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to co-trimoxazole and tetracycline with as much as 68% of invasive isolates and 54% 
of carriage isolates resistant to co-trimoxazole. This study also showed that levels of 
co-trimoxazole resistance increased over time from the pre-PCV era into the PCV 
era, and the levels of antibiotic resistance differed by pneumococcal serotypes and 
sequence types. These results provide important background data for continued 
monitoring of antibiotic resistance patterns following the introduction of 
pneumococcal vaccines in The Gambia.   
Findings of high levels of susceptibility of pneumococcal isolates in The Gambia to 
commonly used antibiotics, and in particular a very low prevalence of intermediate 
resistance (0.2%) of invasive pneumococci to penicillin, is at variance with reports of 
high rates of penicillin resistance in other parts of Africa. In contrast to our findings, 
much higher rates of up to 28% and 55.3% respectively of full and intermediate 
resistance to penicillin have been reported from invasive isolates in North West 
Nigeria (Lliyasu et al., 2015) and similarly high rates (>20%) of penicillin non-
susceptible pneumococci have been reported previously in many other African 
countries (Benbachir et al., 2001, El Mdaghri et al., 2012, Wasfy et al., 2005, Vallès 
et al., 2006). Findings from this study, which included pneumococcal isolates 
collected from the Western, Upper and Central regions of The Gambia over time 
periods spanning the pre- and post- PCV era, indicate that the prevalence of 
penicillin resistant invasive pneumococci has remained very low in The Gambia post 
PCV introduction. In the USA, decreases in the prevalence of antibiotic resistant 
pneumococci was observed following introduction of PCV (Richter et al., 2014). 
The decrease in prevalence of penicillin-resistant pneumococci was thought to be 
due to decreases in antibiotic use in the USA that followed introduction of PCV. 
Reasons why the rates of penicillin-resistant pneumococci have remained low in The 
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Gambia are still unclear but could be due to differences in use of antibiotics between 
countries, as access to antibiotics may be generally poorer in The Gambia than it is 
in other countries. Difficulties in access to antibiotics in The Gambia might be 
related to a combination of factors such as higher drug costs, less availability and 
poorer disposable incomes in many families, as has been suggested previously 
(Adegbola et al., 2006, Adetifa et al., 2012). Some studies have shown that use of 
antibiotics could drive increases in rates of antibiotic resistance among pneumococci. 
Low rates of 1.4% for penicillin resistant and 10.9% for reduced sensitivity 
pneumococci among carriage isolates obtained from young children have also been 
reported from Niger during the pre-PCV era although little is known of the patterns 
of antibiotic use in that setting (Ousmane et al., 2017). 
In this study, prevalence of non-susceptibility to co-trimoxazole throughout the study 
period was 73.8% and 66.6%, among invasive and carriage pneumococci 
respectively. These high rates of non-susceptibility to co-trimoxazole are consistent 
with reports from other parts of Africa and elsewhere including from Kenya 98.6% 
(Kobayashi et al., 2017), Malawi 96% (Cornick et al., 2014) and India, 81.8% (Jain 
et al., 2005). Importantly, results from this study indicate that the high levels of 
resistance to co-trimoxazole cut across all the predominant serotypes and sequence 
types seen in The Gambia. Evidence of non-susceptibility to co-trimoxazole in many 
settings, along with reports of poor clinical response to co-trimoxazole treatment, 
formed the basis for current treatment guidelines for pneumonia, in particular that 
amoxicillin be used in place of co-trimoxazole as first line treatment (WHO, 2012). 
Our results show that the pattern of non-susceptibility to co-trimoxazole has 
persisted and increased in the post PCV era in The Gambia and provide evidence that 
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the drug may not be appropriate for treatment of pneumococcal diseases in The 
Gambia.   
Reports from other parts of the world have shown a decrease in resistant 
pneumococci following introduction of PCV, driven largely by decreases in 
antibiotic-resistant vaccine serotypes (Kyaw et al., 2006, Tomczyk et al., 2016). In 
the current study, other than a significant increase in resistance to co-trimoxazole 
from a prevalence of 60.8% in the pre-PCV-7 era to 95.2% in the post PCV-13 era, 
our results did not show any difference in prevalence of resistance to the commonly 
used antibiotics between the periods before and after introduction of PCV in The 
Gambia. These results contrast with reports from The USA and France which 
showed that overall rates of antibiotic resistance among pneumococci decreased 
following introduction of the PCV-13 (Richter et al., 2014, Janoir et al., 2016). 
Reductions in the proportions of pneumococcal isolates resistant to penicillin, 
erythromycin, cotrimoxazole and tetracycline were reported in France (Janoir et al., 
2016). Observed decreases in prevalence of antibiotic resistant pneumococci in these 
two countries were noted to be due, in large part, to declines in the PCV-13 vaccine 
serotype 19A, which had been shown previously to be multi-drug resistant. The 
absence of an appreciable reduction in levels of resistance to most of the antibiotics 
included in the current study, might be due to the relatively short period of 
observation (2011-2015) following introduction of PCV-13 in the current study. 
Continued surveillance for a longer period of time following PCV-13 introduction in 
The Gambia would allow for better appreciation of the true effect of PCV-13 on 
antibiotic resistance patterns.            
In addition, this study showed that among invasive pneumococci, the predominant 
non vaccine serotype in The Gambia, serotype 12F, demonstrated high levels of 
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resistance to three of the antibiotics tested, including co-trimoxazole and 
chloramphenicol. In contrast, isolates belonging to serotypes 1 and 5, two of the 
leading PCV-13 vaccine types in The Gambia, demonstrated high levels of resistance 
to only 2 of the antibiotics tested. Serotype 12F has been shown to be an important 
emerging non-vaccine serotype that could play a role in driving antibiotic resistance 
patterns. Reports from France showed that non-PCV-13 serotypes increased 
significantly following introduction of PCV-13, accounting for more than half of all 
IPD in the country and that serotype 12F was the leading non-PCV serotype 
consistently associated with resistance to multiple antibiotics, including co-
trimoxazole, tetracycline, erythromycin and chloramphenicol (Janoir et al., 2016). 
Results from the current study highlight the need for continued monitoring of 
emerging pneumococcal serotypes circulating in The Gambia and their antibiotic 
resistance patterns, to inform on more effective control measures against IPD in the 
post PCV-13 era.     
Most of the resistance to co-trimoxazole seen in serotype 1 was due to ST3081, 
whereas susceptibility of ST618 serotype 1 isolates was high. In the previous 
chapter, it was shown that ST3081 had replaced ST618 as the predominant serotype 
1 ST circulating in The Gambia. The finding in this chapter that the high levels of 
ST3081 resistant strains appeared to have emerged over a period of time would 
suggest that antibiotic pressure might have played a role in the replacement of ST618 
by ST3081 as the dominant serotype 1 clone.  
In conclusion, this study showed that levels of antibiotic non-susceptibility among 
invasive pneumococci in The Gambia have fluctuated over the years following 
nationwide introduction of PCV. Importantly, non-susceptibility to most of the 
commonly used antibiotics and in particular resistance to penicillin, has remained 
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low in comparison to rates observed in other parts of Africa and some other 
developing countries. This finding could have implications for continued use of 
penicillin in this region. Also, this study has highlighted the need for continued 
monitoring of emerging non-vaccine type pneumococci in the post PCV era, and that 
these NVT could play an important role in patterns of antibiotic resistance among 
pneumococci in The Gambia.   
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5. Comparative genomic analysis of S. pneumoniae serotype 1 
strains from West Africa 
5.1. Introduction 
Studies conducted and described in previous chapters of this thesis on the population 
structure of S. pneumoniae in The Gambia among invasive and carriage isolates 
highlight the importance of pneumococcal serotype 1 in The Gambia and provide a 
description of some important characteristics of S. pneumoniae serotype 1. These 
characteristics include a clonal replacement of dominant clones, i.e. ST3018 
replacing ST618 and specific differences in antimicrobial resistance patterns among 
circulating serotype 1 STs. A better understanding of the genomics characteristics of 
these STs will be useful in broadening our understanding on in the evolution of S. 
pneumoniae in The Gambia and West Africa. 
Evidence for geographical clustering of pneumococcal serotype 1 has been shown in 
studies performed on isolates obtained across different regions of the world 
(Brueggemann and Spratt, 2003, Cornick et al., 2015). A phylogenetic study 
utilizing MLST reported that of 166 pneumococcal serotype 1 isolates from 16 
locations around the world, three distinct lineages were observed, with lineage A 
strains from Europe and North America, lineage B mostly from Africa and Israel and 
lineage C predominantly from Chile (Brueggemann and Spratt, 2003). More 
recently, the Pneumococcal African Genomics (PAGe) Consortium reported similar 
findings of geographical clustering of pneumococcal serotype 1 from WGS of 448 
isolates from 27 countries across different parts of the world, including 11 in Africa 
(Cornick et al., 2015). The phylogenetic studies grouped these isolates into four 
lineages, three of which (A-C) had been previously described (Brueggemann and 
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Spratt, 2003) of which African serotype 1 isolates were found in lineage B. The 
newly described lineage D comprised of Asian isolates. In a further classification, 
the African lineage B phylogeny was grouped into six distinct clades (labelled i-vi) 
which clustered by geography. Pneumococcal serotype 1 strains from The Gambia 
collected over a five year period (2003- 2008) were grouped into 3 distinct clades (i, 
iii and v) and this was dependent on ST. ST3081 isolates were grouped in clade v 
along with STs from South Africa and Mozambique while ST618 isolates grouped 
into clade i. 
As demonstrated in the studies described above, whole genome sequencing (WGS) 
which is now more readily available and affordable than previously, offers the 
potential to evaluate bacterial genomes on a small scale as well as in large 
epidemiological studies (Chewapreecha et al., 2014c, Laabei et al., 2014, 
Chewapreecha et al., 2014a). S. pneumoniae, a naturally transforming organism, is 
known to have evolved over time, its’ evolution mediated by different genetic 
mechanisms including point mutation, recombination and horizontal gene transfer. 
These evolutionary changes could be due to selective pressures from various factors 
including antibiotics usage and vaccination with PCV (Croucher et al., 2011). WGS 
offers the opportunity to understand more clearly, the relative importance of these 
mechanisms in the evolution of S. pneumoniae in different geographical settings. 
PCV 7 was introduced in The Gambia in 2009, and this was later replaced by PCV 
13 in 2011. It remains unclear how this intervention may have affected evolution of 
S. pneumoniae, in particular the predominant pneumococcal serotypes and sequence 
types circulating in The Gambia. 
Given the importance of pneumococcal serotype 1 as a leading cause of IPD in The 
Gambia, this chapter aims to describe the phylogenetic structure of pneumococcal 
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serotype 1 strains collected over a 20 year-period, 1995 – 2015, including historical 
pneumococcal serotype 1 isolates and serotype 1 isolates collected in the post PCV 
era in The Gambia. Employing recombination and pan genome analysis, it also aims 
to understand the evolution of STs in West Africa. It is hoped that findings from this 
chapter will provide clearer insights into the pattern of replacement observed 
previously in The Gambia among the predominant pneumococcal serotype 1 strains. 
5.2. Methods 
Two hundred and fifty one S. pneumoniae serotype 1 isolates were randomly 
selected from pneumococcal serotype 1 isolates obtained from invasive disease and 
nasopharyngeal carriage studies. These isolates were predominantly recovered from 
The Gambia but other context isolates recovered from West African countries 
including Togo, Senegal, Niger and Benin were also included. 
 
All invasive isolates (188 isolates) were obtained from the World Health 
Organization Regional Reference Laboratory (WHO RRL) hosted at The MRC Unit 
The Gambia. Gambian isolates were sent in to the WHO RRL from a hospital-based 
pneumococcal surveillance at the MRC hospital in the Greater Banjul Area and from 
a population-based surveillance of PCV effectiveness in the Upper River Region of 
The Gambia (as described in section 3.2). Other invasive disease isolates were sent 
to the WHO RRL from major referral hospitals in Togo from Centre Hospitalier 
Universitaire - Tokoin of Lome, Senegal from Hopital d’Enfant Albert Royal, Dakar, 
Ghana from Kumasi Teaching Hospital, Kumasi, Niger from Centre Hospitalier 
Universitaire - Laboratoire Hopital National, NE Niamey and Benin from Service 
National de Laboratoire Sante Publique. All nasopharyngeal carriage isolates (63 
isolates) were obtained from carriage studies on healthy individuals from the 
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Western Region and Upper River Region of The Gambia (study description in 
section 3.2). A summary of the characteristics of patients from whom 251 S. 
pneumoniae serotype 1 isolates were collected and analysed in this chapter are 
described in Table 5. 1. 
Table 5.1 Summary of patient characteristics from whom isolates analysed in 
this study were collected (N=251) 
Characteristic Category Isolates  
N (%) 
Age group (years) <5 years  150 (59.76) 
 5 - <15 years  56 (22.31) 
 ≥15 years  27 (10.76) 
 Unknown  18 (7.17) 
*Context Hospital 57  (22.71) 
 Surveillance 131  (52.19) 
 Carriage 63  (25.10) 
Gender Female 83 (33.07) 
 Male 104 (41.43) 
 Unknown 64 (25.50) 
Specimen Blood 110 (43.82) 
 CSF 43 (17.13) 
 LA 26 (10.36) 
 NPS 63 (25.10) 
  Others 9 (3.39) 
Country The Gambia 219 (87.25) 
 Senegal 13 (5.18) 
 Togo 9 (3.59) 
 Niger 7 (2.79) 
 Ghana 2 (0.80) 
 Benin 1 (0.40) 
N, number of isolates; CSF, Cerebrospinal fluid; LA, Lung aspirate; NPS, nasopharyngeal swabs. Other 
specimen include pleural fluid and joint fluid aspirates.*Context: Hospital surveillance conducted from 1996-
2015 (MRC, Clinic, Western Region, The Gambia); 2007-2010 (Tokoin Teaching Hospital, Togo); 2010 (Hopital 
d’Enfant Albert Royal, Dakar, Senegal); 2009-2010 (Centre Hospitalier Universitaire - Laboratoire Hopital 
National, NE Niamey, Niger); population based surveillance into PCV effectiveness conducted in the Upper 
River region of The Gambia, 2008-2015, pneumococcal carriage studies conducted in the Western region of The 
Gambia from 2003-2009 and South West Nigeria in 2009. 
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Study isolates comprised of 13 sequence types all within the ST217 clonal complex, 
namely, ST3081, ST618, ST303, ST217, ST2084, ST612, ST3575, ST3581, 
ST10649, ST11779, ST12197, ST12310 and ST3579 (Table 5.2).  
 
Table 5.2 Multilocus sequence type profiles of S. pneumoniae serotype 1 isolates 
from West Africa 
  Sequence types  Specimen 
ST N (%) aroE gdh gki recP spi xpt ddl Invasive Carriage 
3081 142 (56.57) 10 18 4 1 7 232 9 98 44 
618 64 (25.50) 13 8 4 1 7 19 14 50 14 
303 10 (3.98) 10 5 4 1 7 19 9 8 2 
217 16 (6.37) 10 18 4 1 7 19 9 14 2 
2084 3 (1.20) 13 8 4 2 7 19 14 3 0 
612 3 (1.20) 10 18 4 1 7 19 31 3 0 
3575 3 (1.20) 10 191 4 1 7 19 9 3 0 
3581 2 (0.80) 13 8 4 115 7 19 14 2 0 
10649 2 (0.80) 10 338 4 1 7 19 9 2 0 
11779 2 (0.80) 338 18 4 1 7 232 9 2 0 
12197 2 (0.80) 338 18 4 1 7 232 9 2 0 
12310 2 (0.40) 10 18 4 1 2 232 9 0 1 
3579 1 (0.40) 13 8 4 5 7 250 14 1 0 
Total 251        188 63 
aroE, shikimate dehydrogenase; gdh, glucose-6-phosphate dehydrogenase; gki, glucose kinase; recP, 
transketolase; spi, signal peptidase I; xpt, xanthine phosphoribosyltransferase); ddl, D-alanine-D-alanine ligase. 
 
DNA was extracted and quantified as described in section 2.4 and sent to WTSI for 
whole genome sequencing as described in section 2.7. Paired end sequencing reads 
were analysed using the nullabor pipeline (section 2.7).  
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5.3. Results 
5.3.1. Genomic characterisation 
Of the 251 serotype 1 genomes analysed using the nullabor pipeline, the median 
depth of coverage was 220, ranging from 63 – 460. The average GC content was 
40% ranging from 37.8 to 42.7. Sequencing reads were mapped to reference genome, 
SPN1041 [Genbank: CACE00000000]. The size of draft assemblies ranged from 
2022554 – 2375186 bp and the number of contigs from 128 – 539.  
5.3.2. Phylogenetic analysis 
A maximum likelihood phylogenetic tree using RAxML was constructed from core 
genome alignments of 251 serotype 1 isolates utilizing the Gubbins algorithm. The 
tree was constructed based on putative point mutations occurring outside 
recombination regions for better evolutionary inference. The tree was rooted at 
midpoint and visualized using ITOL. S. pneumoniae serotype 1 isolates included in 
this study belonging to the same ST clustered on monophyletic branches on the 
phylogenetic tree. The serotype 1 strains grouped into four clades (figure 5.1). 
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Figure 5.1 Maximum-likelihood phylogenetic tree of CC 217 S. pneumoniae 
serotype 1 isolates.  
Branch lengths and labels are coloured by clades. The internal ring after the labels represent the STs 
and the outer ring represents indicate if invasive or carriage isolates as represented by the key on the 
left. 
  
The shortest branch lengths on the tree were observed in clade 1 indicative of a 
newly emerging clone. This clade comprised of 2 sub-clades, the first sub-clade 
consisting of all ST3081 and its’ single locus variants ST12917, ST12310 and 
ST11779 from both invasive disease and nasopharyngeal carriage. All isolates in this 
clade came from The Gambia and neighbouring country Senegal. Three ST217 
isolates, two from invasive disease and one from carriage, recovered from The 
Gambia formed a subclade within the ST3081 dominated clade 1. Within clade 1 
nasopharyngeal carriage isolates clustered more closely with each other compared to 
invasive disease isolates. 
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Clade 2 comprised of the remaining ST217 isolates from both invasive disease and 
nasopharyngeal carriage and its single locus variants, ST303, ST10649, and ST3575. 
Isolates from other West African countries were mostly found in clade 2. Within 
clade 2, all ST303 clustered together and as observed in clade 1 the carriage isolates 
clustered together on the phylogenetic tree. Clusters of ST217 isolates were 
separated by ST3575 isolates. 
Clade 3 comprised of all ST618 isolates and its’ single locus variants ST2084, 
ST3581 and double locus variant ST 3579 isolated from both invasive disease and 
nasopharyngeal carriage. West African isolates included in this study were also 
found in this clade. The branch lengths in clade 3 were longer and varied 
substantially than those from clade 1. This is a reflection of the epidemiological data 
showing that ST618 (Clade 3) were in existence several years before the emergence 
of ST3081 (Clade 1) in The Gambia. Within clade 3, all the different STs clustered 
together as well as nasopharyngeal carriage isolates.  
Clade 4 comprised of all three ST612 isolates from The Gambia and Senegal. ST612 
is a single locus variant of ST217.  
No clear clustering of isolates was observed with other associated patient 
characteristics such as age group, gender and specimen and hence these are not 
shown in figure 5.1.  
 
5.3.3. Recombination analysis 
To understand the evolutionary characteristics occurring within pneumococcal 
serotype 1 isolates from West Africa included in this study, regions of recombination 
were predicted from the core genome alignments of all study serotype 1 isolates 
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using Gubbins. Sequence reads were mapped against a serotype 1 reference 
sequence, Sp1041 with Genbank accession number CACE00000000. 
Unique patterns of recombination blocks were observed in each of the four clades 
within this study (Figure 5.2). Clade 1 consisting mostly of ST3081 isolates had 12 
recombination blocks and was placed on a branch that had accumulated 1142 SNPs 
with 1065 occurring inside recombination regions. Clade 2 consisting of ST217 and 
ST303 isolates had 26 combination blocks occurring and placed on a branch that had 
accumulated 1932 SNPs occurring of which 1819 occurred inside recombination 
regions. Clade 3 isolates consisting of mostly ST618 isolates had the highest number 
of recombination blocks (33) occurring suggesting that it has been the oldest ST and 
had more time for recombination to occur. Isolates within clade 3 were placed on a 
branch that had accumulated a total of 3464 SNPs of which 97% were found inside 
recombination regions (3370/3464). Clade 4 isolates consisting of ST612 isolates 
had 14 recombination blocks occurring and was placed on a branch that had 
accumulates a total of 760 SNPs with 645 occurring within recombination regions. 
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Figure 5.2 Presence and absence of recombination blocks within CC217 S. 
pneumoniae serotype 1. 
The heat map on displays the presence and absence recombination blocks next to the phylogenetic 
tree. Red segments represent present while white segments represent absent. The blue blocks 
represent recombination events occurring in a single isolate. 
 
 
Regions within the genomes where recombination events were occurring include 
genes within the capsular loci, genes coding for antibiotics resistance, phage, 
restriction modification systems, transport proteins, hypothetical proteins and well 
known pneumococcal virulence genes. Specific examples include the pneumococcal 
capsular region in which recombination events were occurring in all four clades. The 
recombination blocks overlapped with different genes within this region that were 
clade specific. For example, the recombination block overlapping wzx, gla and udg 
was specific to clade 1 isolates only, while recombination blocks overlapping wzy to 
wzg were unique to clade 2, 3 and 4 (Figure 5.3).  
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Figure 5.3 Recombination blocks occurring within the pneumococcal capsular 
region. 
The heat map on displays the presence and absence recombination blocks next to the phylogenetic 
tree. Red segments represent present while white segments represent absent. The blue blocks 
represent recombination events occurring in a single isolate. 
 
Recombination blocks overlapping with antibiotics resistance genes including pbp1b 
and  gyrA found in a clade 1 ST12310 isolate pbp2A in all four clades in clade 
specific recombination blocks, pbp2x in clade 2 ST303 isolates only, as well as ciaR, 
ciaH, pbX, mraW and mraY. The gene folP in clade 1 among 5 ST3081 isolates. 
Known virulence genes that play a role in nasopharyngeal carriage zmpB, nanA and 
nanB were seen in clade 2 and 3, but not in clade 1. The gene cbpA in all 4 clades, 
pepA and pepO in clade 3 only. Previous studies showed that an important difference 
between ST3081 and ST618 isolates was the presence of two different types of 
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fucose metabolism operons which is consistent with what has also been observed 
among the current study isolates that includes more serotype 1 isolates collected over 
a longer period than in previous reports. Recombination was observed occurring 
within this region among only clade 2 and 3 isolates, but not clade 1 isolates. In 
addition, the carriage cluster of ST618 isolates in clade 2 had a unique recombination 
block occurring within this region. 
5.3.4. Pan genome analysis 
Pangenome analysis was conducted using Roary software. Gene presence or absence 
table was inputted into Panini to explore the accessory genome of serotype 1 isolates 
included in this study. Output from Panini was sent to the webtool Microreact and 
visualised in the context of the phylogeny and associated metadata. The accessory 
genome content of isolates clustered isolates from the three main clades (clade 1, 2 
and 3) into three distinct clusters Clade 3 isolates made up of mostly ST618 isolates 
clustered farther away from clade 1 and 2 clusters, a reflection of MLST types and 
core genome content (figure 5.4).Genes contributing to the clustering of the 
accessory genomes are listed in Appendix 1.2 
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Figure 5.4 Pneumococcal accessory region of pneumococcal serotype 1 genomes 
Panel A: Pneumococcal serotype 1 phylogeny based on the core region. Panel B: Heat map showing 
the presence and absence of accessory genes within the dataset. Blue represents genes present and 
white represents genes absent. C. Output from PANINI on the pneumococcal serotype 1 accessory 
region. The outer circles are coloured by clade and the inner circles by invasive disease or carriage. 
 
Among clade 1 isolates two main clusters were observed, one made up of mostly 
invasive isolates and the other made up of mostly nasopharyngeal carriage isolates 
(figure 5.4). Differences observed among carriage and invasive isolates were due to 
large numbers of uncharacterized proteins which were unique to carriage isolates, 
but not found among invasive isolates within the clades. Characterized proteins 
found included some conserved proteins among the ST618 carriage isolates such as 
chloramphenicol acetyl transferase. Others were genes that are part of toxin-antitoxin 
systems including pezT-2 (toxin PezT) and xre (HTH-type transcriptional regulator 
Xre).  
Other accessory genes contributing to differences observed among serotype 1 
isolates in this study determined by ABRICATE software in the nullabor pipeline 
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include genes coding for antimicrobial resistance (Figure 5.5). Of interest, the tetM 
responsible for resistance to tetracycline was found among clades 2 and 3 isolates 
but not in clade 1. Two alleles of tetM were found; all clade 2 isolates harboured the 
tetM2 (Genbank accession number X90939) and clade 3 isolates harboured the 
tetM12 allele (Genbank accession number FR671418). Among clade 3 isolates, the 
tetM12 allele was found mostly among carriage isolates. 
 
Figure 5.5 antibiotics resistance genes 
The left panel is the pneumococcal serotype 1 phylogeny base on the core region. The heat map 
shows the presence and absence of resistance genes. Orange blocks represent genes present, while 
purple blocks represent genes absent. 
 
 
5.4. Discussion 
This study highlights some important characteristics that aid our understanding of 
the evolution of pneumococcal serotype 1 among pneumococcal isolates from across 
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the West Africa sub-region. It highlights the important role of recombination in 
evolution of serotype 1 STs in the sub-region as well as associated genes such as 
antimicrobial resistance genes, virulence genes and colonization factors associated 
with these processes. It also highlights important genomic differences between the 
major circulating serotype 1 STs (ST618 and ST3081) that could explain the clonal 
replacements observed in The Gambia. 
Phylogenetic analysis grouped study isolates into four clades with ST3081 belonging 
to Clade 1 and ST618 belonging to Clade 3, and separated on long branches. The 
ST3081 Clade had shorter branch lengths than the ST618 Clade, indicative of a more 
recently evolved clade and is consistent with the epidemiological data discussed in 
chapter 3. This finding is also consistent with findings from earlier studies conducted 
on African serotype 1 isolates which included a subset of isolates included in this 
dataset. In those earlier reports, ST3081 isolates grouped with Clade v and ST618 
isolates grouped with other Asian clones in Clade i  (Cornick et al., 2015). With the 
inclusion of more historical serotype 1 isolates and serotype 1 isolates in the post-
2011 period sampled during a global serotype 1 study, a greater degree of 
diversification in terms of branch lengths occurring among Clade 1 isolates are seen 
in comparison to what had been reported earlier. In addition, this study revealed 
clusters of carriage isolates on the phylogenetic tree in different clades, providing an 
opportunity to explore differences between invasive and carriage strains, which had 
not been possible in the previous study due to its smaller sample size and shorter 
period of coverage. Other important findings from the phylogenetic analysis 
included the separation of ST217 isolates into 2 different clades in this study, Clades 
1 and 2. Three isolates found in Clade 1, were observed to share the most common 
recent ancestor with ST3081 isolates and in Clade 2, shared the most common recent 
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ancestor with ST303 isolates. Studies conducted on a large collection of 226 ST217 
isolates from nine African and four Asian countries grouped these STs into 5 clusters 
(Chaguza et al., 2016). In that study, Gambian ST217 isolates were found in two 
clusters, SC3-SEA along with samples from Mozambique and Malawi, where Clade 
1 isolates in the current study belong and the SC2-WA with isolates from West 
Africa and some parts of Asia where Clade 2 isolates in the current study belonged 
(Chaguza et al., 2016). This may indicate some inter-country transmission of clones. 
This possibility should be considered given the increase in international travel across 
countries with increasing human activity in recent years and also since The Gambia 
is a known tourist destination, thereby attracting more frequent international travels. 
These factors may have contributed to the observed diversity of pneumococcal 
serotype 1 strains in the West Africa sub-region. 
The pneumococcus is a highly transforming pathogen and it has been shown that 
recombination events play a major role in its evolution (Croucher et al., 2011, 
Chewapreecha et al., 2014b).  This study showed that recombination plays an 
important role in the evolution of serotype 1 STs with over 95% of SNPs found 
occurring inside recombination regions. Studies have shown that different 
pneumococcal lineages differ in their rates of recombination (Chewapreecha et al., 
2014a, Croucher et al., 2013) and the current study has shown more recombination 
events occurring within Clade 3 isolates than seen in Clade 1 isolates. This may 
suggest that these events occurring within Clade 3, which is mostly made up of 
ST618 isolates, have led to distortion or loss of genes that compromised the fitness 
of ST618 isolates, thereby giving ST3081 a fitness advantage over ST618.  
Important regions within the genome where recombination events which were clade 
specific were found occurring in all clades in this study include the capsule locus. It 
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has been shown that recombination events occurring in the pneumococcal capsule 
locus and flanking regions including the penicillin binding proteins (PBPs) have led 
to capsule switching and development of penicillin non-susceptibility (Brueggemann 
et al., 2007, Golubchik et al., 2012). With the recent introduction in several African 
countries of the serotype 1-containing PCV13, findings from this study further 
emphasize the need for continuous post vaccination surveillance, in particular, for 
capsule switching events. In this study recombination events overlapping pbp2x 
which is found upstream of dexB flanking the capsule region was unique to Clade 2 
isolates, specifically ST303 isolates. Other genes undergoing recombination among 
study isolates in which changes occurring within genes could affect antibiotic 
susceptibility included ciaR, ciaH, mraY and mraW, all of which are involved in 
cell wall synthesis (Chewapreecha et al., 2014c). In chapter 4, we reported only 2 of 
1055 (0.19%) pneumococcal isolates in The Gambia demonstrating intermediate 
resistance to penicillin with neither of the two intermediate resistant isolates being 
serotype 1. However, this low level of penicillin non-susceptibility calls for on-going 
surveillance as changes over time in the patterns of antibiotic usage or changes in the 
affordability and availability of antibiotics in The Gambia may drive changes in the 
levels of resistance among the predominant pneumococci in circulation.  
In addition, differences in recombination blocks at the capsule locus between 
ST3081 and ST618 may offer some explanation on the observed clonal replacement 
seen in The Gambia in the recent past. It has been shown that capsule thickness 
provides some virulence advantage to pneumococci in invasive disease. It remains a 
possibility, therefore, that these observed differences between ST3081 and ST618 in 
recombination events at the capsule locus, may have an influence on the integrity of 
the pneumococcal capsule and virulence of these STs in invasive disease. Further 
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research along these lines will provide better clarity on the roles of these findings in 
the observed replacement between these serotype 1 STs. 
Additionally, regions with well characterized pneumococcal colonization factors 
such as ZmpB, NanA and NanB were seen in this study to have recombination 
occurring in isolates in Clade 3, but not in Clade 1 isolates. Similarly, amino acid 
sequence variability with ST clustering, i.e. different alleles were found between 
ST3081 and ST618 isolates in this study. In established models of infection, ST3081 
isolates were seen to be better adapted for nasopharyngeal carriage than ST618 
isolates (Brico-Monero, Ebruke et al., submitted manuscript). It is unclear if these 
differences in allele types have implications for a fitness advantage to ST3081. In a 
different protein, pneumolysin, differences in an amino acid allele between ST618 
and ST3081 isolates was associated with increased haemolytic activity which has 
been shown to an important mechanism during epidemic outbreaks (Brico-Monero, 
Ebruke et al., submitted manuscript).  
Within the accessory region, an important hub for exploring evolutionary 
mechanisms, some important observations were made from this study. Distinct 
clade-specific clusters were observed within the accessory region of isolates. 
Previous studies conducted on Gambian serotype 1 isolates, which represent a subset 
of isolates included in the current study, have highlighted significant differences 
between the predominant Gambian serotype 1 clones, ST618 and ST3081. These 
differences include the fucose metabolism operon, an important virulence factor of S. 
pneumoniae, and other important virulence factors such as XerD and FtsK (Cornick 
et al., 2015). In the current study, which has included a larger sample size and a 
longer period of sampling, the findings have remained consistent with these earlier 
reports. This study showed that recombination events were found occurring within 
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these operons in Clades 2 and 3 isolates but not in Clade 1 isolates. It is plausible 
that differences in operon types and patterns of recombination among pneumococcal 
serotype 1 strains may have contributed to clonal replacements observed in The 
Gambia. However, the precise role in fitness of these operons and their relative 
importance in the ecological fitness of the pneumococcus are yet to be fully 
understood.  
Also noted in the accessory region of isolates in this study, were clade specific 
differences in antibiotic resistance genes. The tetM genes, carried on Tn916 
transposon and responsible for resistance to tetracycline, were found among Clades 2 
and 3 isolates with differences in alleles but was not seen at all in Clade 1, ST3081 
isolates. In chapter 4, we report tetracycline resistance in both ST618 and ST3081 
isolates even though the level of resistance was higher in ST618 isolates. It is 
therefore not clear why the tetM gene was completely absent among ST3081 
isolates. However, the Int-Tn_1, a transposase from transposon Tn916 which 
confirms tetracycline resistance was conserved among all study isolates. In chapter 
4, phenotypic differences in co-trimoxazole was noted between the predominant STs. 
In the current study however, the genes associated with resistance to co-trimoxazole 
including folP and folA were not present. In addition, recombination events were 
found occurring in only five ST3081 isolates within the location of folP gene. 
Studies have shown a poor correlation between phenotypic resistance to 
cotrimoxazole and stains undergoing recombination in that region (Chewapreecha et 
al., 2014a). 
In phylogenetic analysis, we mentioned clusters of carriage isolates observed among 
the clades in this study, differences in accessory region are largely due to 
uncharacterized portions which will need further studies to enable a clear understand 
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their roles. Of the notable known genes are pneumococcal zeta toxin, pezT and xre 
which is a part of the toxin-antitoxin systems. These systems help maintain the 
integrity of the cell and the antitoxin helps to supress the action of the toxin. 
However, under circumstances of stress, the antitoxin can be degraded and allows 
the toxin to function. The pezT toxin present in ST618 carriage isolates but absent 
from invasive ST618 isolates and ST3081 invasive and carriage isolates has been 
shown to inhibit peptidoglycan wall synthesis (Mutschler et al., 2011).  
A few limitations to this study that should be considered in the interpretation of the 
findings include the following, other pneumococcal serotypes or closely related 
streptococci have not been included in this analyses. Some of these serotypes or 
bacterial species may have played a role in the observed clonal replacement and 
evolution of pneumococcal serotype 1 isolates cells since any observed differences 
in the predominant STs may depend on competition with STs of other serotypes or 
bacterial species that are known to co-exist with S. pneumoniae in the human 
nasopharynx. Additionally, mutagenesis experiments followed by animal infection 
experiments to ascertain if the selected determinants have a role in fitness of the STs, 
were not carried out. These experiments would have further strengthened the 
evidence for findings from the current study.  
In conclusion, this study has highlighted the possible roles of recombination, 
antibiotic resistance, virulence genes and colonization factors as possible key factors 
involved in the evolution of pneumococcal serotype 1 in the West Africa sub-region. 
These findings highlight important differences in circulating clones in West Africa 
of the predominant serotype 1 strains, ST3081 and ST618. Continuous surveillance 
would be helpful in providing additional evidence that will aid improvements in our 
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understanding of the evolutionary mechanisms behind observed changes among the 
predominant pneumococcal sequence types in circulation.  
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6. Discussion and future work 
6.1. Background 
This thesis describes the population structure and antibiotic resistance patterns of S. 
pneumoniae strains from the West African sub-region over two decades. It provides 
a description of the evolutionary biology of pneumococcal serotype 1, a leading 
cause of IPD in the sub-region, within the context of other pneumococcal serotypes 
over a period prior to and including the introduction of PCV in the West Africa sub-
region. This approach, to describe the molecular epidemiology of pneumococcal 
serotype 1 within the context of other serotypes, has provided a baseline that allows 
fora clearer understanding of the characteristics of pneumococcal serotype 1. Earlier 
studies have shown that evaluating the relationships between the predominant 
pneumococcal serotypes and genotypes circulating within a geographical setting in 
both invasive disease and carriage over the same time period provides a better 
understanding of the evolution of S. pneumoniae in that community (Brueggemann 
et al., 2003, Varon et al., 2015, Hanage et al., 2005).The importance of S. 
pneumoniae serotype 1 relates to its attributes. Various epidemiological studies 
carried out in different geographical locations on carriage and invasive strains at 
different times have provided evidence that pneumococcal serotype 1 is one of the 
leading causes of IPD globally and in the West African sub-region in particular, but 
paradoxically is rarely found in nasopharyngeal carriage (Adegbola et al., 2006, 
Brueggemann et al., 2013, Collard et al., 2013, Hill et al., 2006, Kronenberg et al., 
2006). In addition, S. pneumoniae serotype 1 has higher susceptibility to 
antimicrobial agents compared to other non-pneumococcal serotypes 1 isolates 
(Antonio et al., 2008). Furthermore, higher valency pneumococcal conjugate 
vaccines that have included this important serotype (PCV 10 and PCV 13) were only 
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recently introduced over the last few years and are now increasingly being used in 
routine immunization schedules across different parts of the world including in the 
West African sub-region. These reasons provide the background for this PhD. This 
study therefore characterized invasive and nasopharyngeal carriage pneumococci, 
and in particular pneumococcal serotype 1 isolates, providing relevant description in 
epidemiological and genotypic contexts, including patterns of antimicrobial 
resistance over a 20 year period pre- and post-PCV era. 
 
6.1. Research findings and implication for future studies 
 
In this thesis, while studying the population structure of pneumococcal serotypes, I 
have shown that use of PCVs in the Gambia reduced vaccine type serotypes with the 
exception of serotype 1 and 5. I have also shown clonal replacements occurring 
within serotype 1 STs prior to the introduction of PCV-7 and demonstrated serotype 
replacement by serotypes 12F and 35B following PCV-13 introduction. This study 
also exploited use of whole genome sequencing to reveal important differences 
between the predominant serotype 1 STs which provide insights into possible roles 
of recombination in the evolution of pneumococcal serotype 1 in the West Africa 
sub-region.   
6.1.1. S. pneumoniae population structure and vaccination 
In this thesis, a reduction in prevalence of vaccine type pneumococcal serotypes 
following the introduction of PCV was observed, the exception being serotypes 1 
and 5 both of which were rare in nasopharyngeal carriage but persisted into the post-
PCV era as predominant pneumococcal serotypes in invasive disease. This finding is 
consistent with the report by Mackenzie et al (Mackenzie et al, 2016) and other 
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reports (Cohen et al., 2016, Tin Tin Htar et al., 2015, von Mollendorf et al., 2017). In 
the population-based surveillance report by Mackenzie et al, which was carried out 
in the rural part of The Gambia which makes up a subset of isolates included in this 
study, there was no evidence of a significant reduction on serotype 1 disease by 
following PCV13 introduction, with the episodes of serotype 1 IPD remaining the 
same throughout the duration of the surveillance, whilst temporal fluctuations were 
seen for serotype 5 disease. The study reported that serotype 1 IPD was more 
prevalent in children aged 2-4years than it was in those age less than 2years. 
However, the rather short baseline period (16months) prior to PCV-7 introduction 
and only a 2-year post PCV-13 observation period might have limited the ability of 
the study to detect any appreciable effects on serotype 1 disease. Findings from the 
current study, which included pneumococcal isolates from both urban and rural parts 
of The Gambia and covered a slightly longer period of post PCV-13 observation than 
reported by Mackenzie et al, provide further evidence for the need for cautious 
optimism regarding expected benefits from PCV-13 on serotype 1 disease. These 
findings may also re-echo concerns that have been expressed previously regarding 
the need for a booster dose or consideration for alternative immunization schedules 
that would include children in the older age groups who are more at risk for serotype 
1 disease (Kwambana-Adams et al., 2016; Brueggemann et al., 2013, Ebruke et al., 
2015, Klugman et al, 2011). 
 
The emergence of non-vaccine type pneumococci, following introduction of PCV 
has been reported from other settings (Janoir et al., 2016, Del Amo et al., 2016). In 
particular, serotype 12F which was noted in this study to be an important cause of 
IPD in the post-PCV period, has been reported to cause epidemic outbreaks similar 
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to pneumococcal serotype 1in other parts of the world (Deng et al., 2016). Earlier 
studies on serotype 12F suggests this serotype has certain characteristics that are 
similar to pneumococcal serotype 1 including a high potential for causing epidemics 
and rarity in nasopharyngeal carriage (Zulz et al., 2013). The emergence of non-
vaccine pneumococcal serotypes that have epidemic potential suggest the possibility 
that expected gains in the ability of PCV-13 to cause reductions in future epidemic 
outbreaks due to pneumococcal serotype 1, may be diluted. Continuous population 
based post-vaccine surveillance of the circulating pneumococcal serotypes, and in 
particular monitoring of serotypes 1, 5 and 12F, would be needed to accurately 
assess the impact of PCV-13 and guide further development of effective 
interventions. 
 
Implications of the emergence of different genotypes of vaccine serotypes in the post 
PCV era seen in this study remain to be seen. The predominant STs for isolates 
belonging to serotypes 14 and 23F in the post-PCV era differed from the 
predominant STs of these serotypes that circulated in the pre-PCV period. It is yet 
unclear if these changes are related to the introduction of PCV or if they represent 
secular changes unrelated to the vaccine. This finding might be indicative of the 
potential for significant genetic and immunogenic variation that exists within a 
pneumococcal serotype, of which the impact on effectiveness of currently used 
pneumococcal conjugate vaccines remains to be seen. 
6.1.2. Antibiotic resistance patterns  
With over 99% of invasive isolates susceptible to penicillin, findings from this study 
contrasts with much higher rates of penicillin non-susceptibility (from above 20% to 
as much as 55%) that have been reported from other parts of Africa (Benbachir et al., 
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2001, El Mdaghri et al., 2012, Wasfy et al., 2005, Vallès et al., 2006). However, the 
low rates of penicillin non-susceptibility reported in the current study are consistent 
with findings from an earlier study in The Gambia (Adegbola et al., 2006), carried 
out in the pre-PCV era. Findings from this study, which included pneumococcal 
isolates collected through the pre- and post- PCV era, would indicate that the 
prevalence of penicillin non-susceptible pneumococci has remained low in The 
Gambia and may have decreased further over the recent few years. Access to 
antibiotics in The Gambia is generally poor in comparison to other countries and 
stems from a combination of many factors including higher drug costs and poorer 
disposable incomes in many families, and could explain the low rates of antibiotic 
resistance in The Gambia (Adegbola et al., 2006, Adetifa et al., 2012).   
Previous reports have provided evidence of decreases in the prevalence of resistant 
pneumococci following introduction of PCV in different parts of the world, driven 
largely by decreases in antibiotic-resistant vaccine serotypes (Richter et al., 2014, 
Janoir et al., 2016). In this study, the prevalence of resistant pneumococci to 
commonly used antibiotics in The Gambia remained largely unchanged from the pre- 
to the post-PCV era, with the exception of co-trimoxazole. However, the post PCV-
13 period of observation included in this study (2011-2015) might have been 
inadequate to allow for a full assessment of the vaccine impact on prevalence of 
antibiotic resistant strains and on-going surveillance would allow the appreciation of 
the true effect of PCV-13 on antibiotic resistance patterns. The high rates of non-
susceptibility to co-trimoxazole reported in this study align with studies in other 
parts of Africa and other developing country settings, where similarly high 
prevalence of co-trimoxazole resistant pneumococci, as high as 98.6%, have been 
reported (Kobayashi et al., 2017, Cornick et al., 2014, Jain et al., 2005). However, 
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with adoption in The Gambia of revised treatment guidelines, that recommend use of 
amoxicillin in place of co-trimoxazole as first line treatment for pneumonia (WHO, 
2012), it is not unlikely that changes in the patterns of antibiotic use may follow over 
the years and with it, changes in the patterns of selective antibiotic pressure on 
circulating pneumococci in The Gambia. It remains to be seen if these changes will 
happen and if they may affect the prevalence of co-trimoxazole resistant 
pneumococci, as has been reported elsewhere (Richter et al., 2014). Furthermore, 
WGS findings from this study revealed evidence of recombination events at 
locations within the capsule locus that could potentially lead to capsule switching 
and development of penicillin non-susceptibility. With the recent introduction of 
PCV in The Gambia, and reports from elsewhere that capsule switching have 
followed introduction of pneumococcal vaccines, cautious monitoring of the 
prevailing serotypes and any evidence of capsule switching and any changes in 
antibiotic resistance patterns would be appropriate to help clarify the roles of these 
findings in The Gambia and similar settings.  
Importantly, this study showed that the predominant emerging non-vaccine serotype 
in The Gambia, serotype 12F, demonstrated high levels of resistance to three of the 
four commonly used antibiotics included in this study. In contrast, isolates belonging 
to serotypes 1 and 5, the two leading vaccine serotypes seen in IPD in The Gambia, 
were seen to demonstrate high levels of resistance to fewer antibiotics in comparison 
to the NVT serotype 12F. Previous reports indicate that serotype 12F is an important 
emerging non-vaccine serotype that could play an important role in driving antibiotic 
resistance patterns in the post-PCV13 era (Janoir et al., 2016). This further buttresses 
the need for ongoing monitoring of the patterns of emerging pneumococcal serotypes 
and their antibiotic resistance profiles in the post PCV-13 era. in the sub-region. 
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However, the absence of any of the internationally disseminated antibiotic resistant 
clones, such as the PMEN1 lineage, ST81(Croucher et al., 2011), would be helpful 
for effective antibiotic treatment in this setting but would nevertheless require on-
going surveillance. It remains unclear why these internationally disseminated 
antibiotic resistant strains were absent in The Gambia but their absence may have 
contributed to the observed low levels of antibiotic resistance among pneumococci in 
The Gambia. 
6.1.3. S. pneumoniae serotype 1 sequence types and clonal replacement 
In The Gambia, the two major serotype 1 STs observed to be circulating, ST618 and 
ST3081, had been reported previously in other parts of West Africa and in 
neighbouring Senegal within Africa and in Oman in the MLST database. This study 
highlights the change in predominant clones of invasive and carriage serotype 1 
strains circulating in The Gambia, with ST3081 emerging as a new dominant clone 
in 2007, replacing ST618 which had predominated in The Gambia in the decade 
prior. These changes in dominant circulating genotypes might reflect adaptive 
changes by the pneumococcus in response to changes in the human population and 
human activity, such as antibiotic usage or vaccination. A carriage study of serotype 
1 in the context of a PCV-7 vaccine trial in The Gambia did not show any clear 
evidence that the observed changes in genotype were the results of vaccine selective 
pressure (Ebruke et al., 2015). Findings from this study indicate that the two 
predominant serotype 1 STs differed in their antibiotic resistance patterns with 
higher levels of antibiotic resistance to co-trimoxazole seen amongst ST3081 
isolates.  
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The availability of informative techniques such as whole genome sequencing has 
given us the opportunity to understanding of the key mechanisms involved in these 
clonal replacements observed in pneumococcal serotype 1. Below are important 
findings from the current study that may have possible roles in the evolution of 
pneumococcal serotype 1 among pneumococcal isolates from across the West Africa 
sub-region. We report the role of recombination in the evolution of S. pneumoniae in 
the sub-region. Clade and ST specific recombination events were occurring in the 
capsular locus and this suggests that this may have led to distortion of genes which 
may have resulted in a fitness advantage for ST3081 over ST618.  Another important 
implication of the recombination events noted to have occurred in the pneumococcal 
capsule locus, is how these events may impact on capsule switching and the 
development of penicillin resistance, as has been suggested in other studies 
(Brueggemann et al., 2007, Golubchik et al., 2012).  
In addition, observations in this study that the tetM genes, carried on Tn916 
transposon and responsible for resistance to tetracycline, were found only among 
ST618 isolates but not in ST3081 isolates as well as other resistance genes found, 
may be indicative of differences in the selective pressure of antibiotics on evolution 
of these STs in The Gambia. These findings further emphasize the need for 
continuous post vaccination surveillance of antibiotic resistance.  
Other findings in the current study include differences between the predominant 
serotype 1 STs in recombination events that involved well known colonization 
factors, such as ZmpB, NanA, NanB and in addition to important virulence factors 
such as the fucose metabolism operon (Cornick et al., 2015) reported by previous 
studies. Animal studies conducted on ST618 and ST3081 isolates showed that 
ST3081 was more virulent in well-established mouse models of infection and better 
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adapted for nasopharyngeal carriage. These findings provide additional evidence of 
possible mechanisms that could explain the observed clonal replacements seen in 
serotype 1 STs in The Gambia. 
6.2. Future work 
6.2.1. Continued epidemiological studies of S. pneumoniae population 
structure in West Africa 
In the light of recent introduction of pneumococcal conjugate vaccines in The 
Gambia and in other African countries, continued surveillance of the serotypes and 
sequence types in circulation would be an important follow-up to this work. This 
will help to confirm the findings described in the current study and identify any 
further changes that may occur over time. Surveillance over a longer period of time 
would allow for a more robust assessment of the impact of PCV-13 on the 
predominant serotypes and sequence types in circulation, such as the emergence of 
non-vaccine serotypes, and would also provide better clarity on how the patterns of 
antibiotic resistance may change in the long term, within countries in the region. 
 
6.2.2. Genomic characterization of S. pneumoniae serotypes  
Genomic studies on the circulating strains of S. pneumoniae in the broader context of 
other pneumococcal serotypes and sequence types, as well as other bacterial species 
that co-exist with pneumococci in nasopharyngeal carriage, would be appropriate as 
a follow-up to this research study. This would enable a more robust assessment of 
the evolutionary mechanisms of the predominant pneumococcal strains in circulation 
that takes into account relationships with other pneumococcal serotypes and other 
relevant bacterial species. Results from these studies could provide greater insights 
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into the key evolutionary mechanisms and potentially inform on development of 
newer strategies that will be relevant for effective control of pneumococcal disease 
in the West Africa region.  
 
6.2.3. Optimizing currently available interventions for control of 
pneumococcal disease in West Africa 
Efforts that aimed at a review of the timing of currently used PCVs, particularly in 
African countries where the burden of pneumococcal serotype 1 disease is in older 
children and adults, could result in greater levels of reduction in deaths from this 
serotype. Research to assess optimal timing for additional booster doses of currently 
used PCVs would be appropriate. 
 
In addition to on-going efforts to develop more effective pneumococcal vaccines and 
efforts at encouraging appropriate antibiotic use in treatment of pneumococcal 
disease, efforts to engage local and regional health authorities in intensifying public 
health campaigns on risk reduction strategies for control of pneumococcal disease in 
countries within the sub-region could have immediate impact on the prevalence of 
pneumococcal disease. Enlightenment campaigns that address known risk factors 
such as overcrowding and malnutrition, as well as the provision of improved medical 
care for persons with increased risk for pneumococcal disease including sickle cell 
anaemia and HIV positive persons, could bring result in immediate outcomes in 
reducing illness and deaths from pneumococcal disease.    
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6.3. Concluding remarks 
This study adds to our understanding of the population structure of invasive and 
carriage pneumococcal serotypes from the West African region, and the patterns of 
antibiotic resistance over the pre and post-PCV era. It also provides some clarity into 
some possible mechanisms behind evolution of the predominant circulating 
pneumococcal sequence types in the region. Knowledge gained from this study will 
be useful in informing appropriate preventive public health decisions in the region
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Appendix 
 Appendix 1.1 List of study isolates analysed in chapter 5 
Isolate ID ST Country Source 
Invasivecarri
ed 
Isolation 
year 
Gend
er 
10395_5_3
0 3081 
The 
Gambia Lung Aspirate Invasive 2010 M 
10395_5_6
2 217 Niger CSF Invasive 2012 M 
10395_5_7 303 Togo CSF Invasive 2009 M 
10395_5_9 303 Togo CSF Invasive 2009 F 
11658_1_2
3 618 
The 
Gambia Blood Invasive 1997 F 
11658_1_2
5 618 
The 
Gambia Blood Invasive 1999 M 
11658_1_3
2 3081 
The 
Gambia Blood Invasive 2011 M 
11658_1_3
3 618 Ghana CSF Invasive 2010 F 
11658_1_3
4 618 Togo CSF Invasive 2007 F 
11658_1_3
5 618 
The 
Gambia Lung Aspirate Invasive 2010 F 
11658_1_3
6 618 Senegal CSF Invasive 2010 F 
11658_1_3
7 618 Senegal CSF Invasive 2010 M 
11658_1_3
8 618 
The 
Gambia Blood Invasive 2010 F 
11658_1_4
0 618 
The 
Gambia CSF Invasive 2011 F 
11658_1_4
1 3575 Senegal CSF Invasive 2010 M 
11658_1_4
2 618 
The 
Gambia Blood Invasive 2011 F 
11658_1_4
6 618 
The 
Gambia Blood Invasive 2010 F 
11658_1_4
8 618 
The 
Gambia 
Pleural 
Aspirate Invasive 2010 F 
11658_1_5
0 618 Togo CSF Invasive 2008 F 
11658_1_5
3 618 Benin CSF Invasive 2010 M 
11658_1_5
4 618 Senegal CSF Invasive 2011 M 
11658_1_5
6 618 Senegal CSF Invasive 2010 M 
11658_1_5
7 618 
The 
Gambia Blood Invasive 2010 M 
11658_1_5
8 612 Senegal CSF Invasive 2010 F 
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11658_1_6
9 217 Niger CSF Invasive 2011 M 
11658_1_7
3 618 
The 
Gambia CSF Invasive 2001 M 
11658_1_7
4 618 
The 
Gambia Blood Invasive 1996 M 
11658_1_7
5 618 
The 
Gambia Blood Invasive 1996   
11658_1_7
9 618 
The 
Gambia CSF Invasive 2007 F 
11658_1_8
1 3579 
The 
Gambia Blood Invasive 1998 M 
11658_1_8
5 618 
The 
Gambia Blood Invasive 1998 M 
11658_1_8
8 612 
The 
Gambia Blood Invasive 1999 M 
11658_1_9
0 618 
The 
Gambia Blood Invasive 1996 F 
11658_8_2
0 618 Nigeria CSF Invasive 2010 F 
11658_8_2
3 618 
The 
Gambia Blood Invasive 1996 M 
11791_1_2
7 303 Togo CSF Invasive 2010 M 
11791_1_3
0 618 Senegal CSF Invasive 2010 F 
11791_1_3
2 618 Senegal CSF Invasive 2010 F 
11791_1_3
3 618 Togo CSF Invasive 2009 M 
11791_1_3
4 618 Togo CSF Invasive 2007 M 
11791_1_3
6 618 
The 
Gambia 
Pleural 
Aspirate Invasive 2010 M 
11791_1_3
8 3575 
The 
Gambia Lung Aspirate Invasive 1996 F 
11791_1_4
0 303 
The 
Gambia Blood Invasive 2010 F 
11791_1_4
2 618 
The 
Gambia Blood Invasive 1997 M 
11791_1_4
4 618 
The 
Gambia Blood Invasive 2003 M 
11791_1_4
5 618 
The 
Gambia Blood Invasive 2002 F 
11791_1_5
1 612 
The 
Gambia 
Joint fluid 
aspirate Invasive 1998   
11791_1_5
5 618 
The 
Gambia Blood Invasive 1996 F 
11791_1_5
6 618 
The 
Gambia Blood Invasive 1996 M 
11940_1_1
0 618 
The 
Gambia Blood Invasive 2011 F 
11940_1_1
2 618 
The 
Gambia Blood Invasive 2000 F 
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14410_4_1 3081 
The 
Gambia Lung Aspirate Invasive 2010 M 
14410_4_1
0 3081 
The 
Gambia Blood Invasive 2013 F 
14410_4_1
1 3081 
The 
Gambia Blood Invasive 2011 M 
14410_4_2
0 3081 
The 
Gambia Lung Aspirate Invasive 2012 F 
14410_4_2
7 
1177
9 
The 
Gambia Blood Invasive 2013 F 
14410_4_3
1 3081 
The 
Gambia Blood Invasive 2012 M 
14410_4_4 3081 
The 
Gambia Blood Invasive 2013 F 
14410_4_4
3 3081 
The 
Gambia Blood Invasive 2012 F 
14410_4_5
1 3081 
The 
Gambia Blood Invasive 2012 F 
14410_4_5
2 3081 
The 
Gambia CSF Invasive 2012 M 
14410_4_5
4 3081 
The 
Gambia Blood Invasive 2013 M 
14410_4_5
6 3081 
The 
Gambia Blood Invasive 2012 F 
14410_4_6
0 
1177
9 
The 
Gambia Blood Invasive 2013 F 
14410_4_6
1 3081 
The 
Gambia CSF Invasive 2012 F 
14410_4_6
3 217 
The 
Gambia Blood Invasive 2012 F 
14410_4_6
4 3081 
The 
Gambia CSF Invasive 2012 F 
14410_4_7
1 3081 
The 
Gambia Blood Invasive 2010 F 
14410_4_8
1 3081 
The 
Gambia Lung Aspirate Invasive 2011 M 
14410_4_8
2 3081 
The 
Gambia Lung Aspirate Invasive 2012 M 
14410_4_8
5 3081 
The 
Gambia Blood Invasive 2013 F 
14410_5_1
8 3081 
The 
Gambia Blood Invasive 2013 M 
14410_5_2
1 3081 
The 
Gambia Blood Invasive 2010 F 
14410_5_2
4 3081 
The 
Gambia Lung Aspirate Invasive 2010 M 
14410_5_3
0 3081 
The 
Gambia Blood Invasive 2012 F 
14410_5_3
5 3081 
The 
Gambia Lung Aspirate Invasive 2009 M 
14410_5_3
9 3081 
The 
Gambia Lung Aspirate Invasive 2008 M 
14410_5_4
2 3081 
The 
Gambia Lung Aspirate Invasive 2009 M 
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14410_5_4
3 3081 
The 
Gambia Blood Invasive 2009 F 
14410_5_4
4 3081 
The 
Gambia Blood Invasive 2009 M 
14410_5_4
5 3081 
The 
Gambia Lung Aspirate Invasive 2009 M 
14410_5_4
7 3081 
The 
Gambia Blood Invasive 2010 M 
14410_5_4
8 3081 
The 
Gambia Blood Invasive 2009 M 
14410_5_4
9 
1064
9 
The 
Gambia Blood Invasive 2008 M 
14410_5_5
0 3081 
The 
Gambia Lung Aspirate Invasive 2010 F 
14410_5_6
7 3081 
The 
Gambia CSF Invasive 2012 M 
14410_5_7 3081 
The 
Gambia Lung Aspirate Invasive 2013 F 
14410_6_1 
1064
9 
The 
Gambia Blood Invasive 2013 M 
14410_6_1
4 3081 
The 
Gambia Blood Invasive 2011 M 
14410_6_1
9 3081 
The 
Gambia Blood Invasive 2011 M 
14410_6_2
6 3081 
The 
Gambia Lung Aspirate Invasive 2010 M 
14410_6_3
0 3081 
The 
Gambia Blood Invasive 2013 F 
14410_6_3
3 3081 
The 
Gambia Blood Invasive 2011 M 
14410_6_3
8 3081 
The 
Gambia Blood Invasive 2009 M 
14410_6_3
9 3081 
The 
Gambia Blood Invasive 2012 M 
14410_6_4 3081 
The 
Gambia Blood Invasive 2013 M 
14410_6_4
1 3081 
The 
Gambia Blood Invasive 2011 F 
14410_6_4
8 217 
The 
Gambia Blood Invasive 2013 M 
14410_6_5
6 3081 
The 
Gambia Blood Invasive 2013 M 
14410_6_6
4 3081 
The 
Gambia Lung Aspirate Invasive 2011 F 
14410_6_7
6 618 
The 
Gambia Blood Invasive 2003 M 
14410_6_8 3081 
The 
Gambia Blood Invasive 2012 F 
14410_6_8
0 618 
The 
Gambia Blood Invasive 2002 F 
14410_6_8
1 3581 
The 
Gambia 
Pleural 
Aspirate Invasive 2002 F 
14410_6_8
2 3081 
The 
Gambia Blood Invasive 2008 M 
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14410_6_9 3081 
The 
Gambia 
Joint fluid 
aspirate Invasive 2009 M 
14410_7_1 3081 
The 
Gambia Blood Invasive 2007 M 
14410_7_1
1 3081 
The 
Gambia CSF Invasive 2008 F 
14410_7_1
2 217 
The 
Gambia Blood Invasive 2003 M 
14410_7_1
3 2084 
The 
Gambia Blood Invasive 2002 M 
14410_7_1
4 217 
The 
Gambia Blood Invasive 2003 M 
14410_7_1
9 618 
The 
Gambia Blood Invasive 2003 F 
14410_7_2
5 618 
The 
Gambia Blood Invasive 2002 F 
14410_7_2
6 618 
The 
Gambia Blood Invasive 2003   
14410_7_3
3 618 
The 
Gambia Blood Invasive 2002   
14410_7_3
8 618 
The 
Gambia Blood Invasive 2002 F 
14410_7_3
9 618 
The 
Gambia Blood Invasive 2002 F 
14410_7_4
6 3081 
The 
Gambia Blood Invasive 2008 F 
14410_7_5
2 3081 
The 
Gambia Lung Aspirate Invasive 2007 M 
14410_7_5
4 217 
The 
Gambia Blood Invasive 2007 M 
14410_7_6 3581 
The 
Gambia CSF Invasive 2002 M 
14410_7_6
0 618 
The 
Gambia Blood Invasive 2002 F 
14410_7_6
1 217 
The 
Gambia Blood Invasive 2003 M 
14410_7_6
9 3081 
The 
Gambia Blood Invasive 2008 F 
14410_7_7
5 618 
The 
Gambia Blood Invasive 2003 F 
14410_7_7
6 217 
The 
Gambia Blood Invasive 2003 M 
14410_7_7
9 2084 
The 
Gambia Blood Invasive 2002 M 
14410_7_8
3 3081 
The 
Gambia Blood Invasive 2007 M 
14410_7_9 217 
The 
Gambia CSF Invasive 2003 F 
14520_6_6
1 303 Ghana Blood Invasive 2011 F 
14520_6_6
3 3081 Senegal 
Joint fluid 
aspirate Invasive 2012 M 
14520_6_7
3 3081 Senegal CSF Invasive 2012 F 
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14520_6_7
9 217 Togo CSF Invasive 2012 M 
14520_6_8
1 303 Niger CSF Invasive 2009   
14520_6_8
2 3081 
The 
Gambia Blood Invasive 2010 M 
14520_7_5 3081 Senegal CSF Invasive 2010 M 
14520_7_6 3081 Senegal CSF Invasive 2010 M 
14520_7_7
7 3081 
The 
Gambia Blood Invasive 2012 M 
14520_7_7
8 3081 
The 
Gambia Blood Invasive 2012 M 
14520_7_7
9 3081 Senegal Blood Invasive 2012 F 
14520_7_8
1 303 Niger CSF Invasive 2012 M 
14520_7_8
9 303 Niger CSF Invasive 2010 M 
15378_2_3
0 3081 
The 
Gambia Lung Aspirate Invasive 2010 F 
15378_2_4
9 3081 
The 
Gambia 
Joint fluid 
aspirate Invasive 2008 F 
15378_2_5
0 3081 
The 
Gambia Blood Invasive 2010 M 
15531_4_5
0 3081 
The 
Gambia Lung Aspirate Invasive 2011 M 
15531_4_6
4 3081 
The 
Gambia 
Joint fluid 
aspirate Invasive 2008 F 
15531_4_6
5 3081 
The 
Gambia 
Joint fluid 
aspirate Invasive 2008 F 
15531_4_8
9 3081 
The 
Gambia Lung Aspirate Invasive 2011 F 
15531_4_9
1 217 
The 
Gambia Blood Invasive 2009 M 
15531_5_1
0 3081 
The 
Gambia Blood Invasive 2010   
15531_5_1
5 3081 
The 
Gambia Blood Invasive 2008   
15531_5_3
1 3081 
The 
Gambia CSF Invasive 2004   
15531_5_3
5 3575 
The 
Gambia Blood Invasive 1999   
15531_5_4
0 3081 
The 
Gambia Blood Invasive 2012   
15531_5_5
3 3081 
The 
Gambia Lung Aspirate Invasive 2012   
15531_6_1
8 3081 
The 
Gambia Blood Invasive 2014 M 
15531_6_2
2 3081 
The 
Gambia Blood Invasive 2014 F 
15531_6_2
4 3081 
The 
Gambia Lung Aspirate Invasive 2014 M 
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15531_6_2
9 3081 
The 
Gambia Blood Invasive 2014 F 
15531_6_3
2 3081 
The 
Gambia Blood Invasive 2014 F 
15531_6_3
4 3081 
The 
Gambia Lung Aspirate Invasive 2014 F 
15531_6_3
7 3081 
The 
Gambia Blood Invasive 2014 F 
15531_6_4
5 3081 
The 
Gambia Blood Invasive 2014 F 
15531_6_5
4 3081 
The 
Gambia Blood Invasive 2014 M 
15531_6_5
8 3081 
The 
Gambia Blood Invasive 2014 M 
15531_6_6
0 3081 
The 
Gambia Blood Invasive 2014 M 
15531_6_6
3 3081 
The 
Gambia Blood Invasive 2014 M 
15531_6_7
0 3081 
The 
Gambia Blood Invasive 2014 M 
15531_6_9
3 3081 
The 
Gambia NP swab Carriage 2009 F 
15531_7_2
2 3081 
The 
Gambia NP swab Carriage 2009 M 
15531_7_3
2 618 
The 
Gambia Blood Invasive 2005   
15531_7_3
6 618 
The 
Gambia Blood Invasive 2005   
15531_7_4
0 618 
The 
Gambia Blood Invasive 2004   
15873_2_5
7 3081 
The 
Gambia Blood Invasive 2014 M 
15873_2_5
9 3081 
The 
Gambia Blood Invasive 2007 F 
15873_3_1
0 3081 
The 
Gambia Lung Aspirate Invasive 2012 M 
15873_3_1
2 217 Niger CSF Invasive 2010 M 
15873_3_1
5 2084 
The 
Gambia Blood Invasive 2003 F 
15873_3_9 217 Togo CSF Invasive 2011 M 
15873_4_5
8 3081 
The 
Gambia Blood Invasive 2014 M 
15873_4_5
9 3081 
The 
Gambia Lung Aspirate Invasive 2014 F 
15873_5_2
3 3081 
The 
Gambia CSF Invasive 2012 M 
15873_5_6
6 3081 
The 
Gambia Blood Invasive 2014 F 
16399_5_1
3 217 
The 
Gambia NP swab Carriage 2009 M 
16399_7_5
0 3081 
The 
Gambia NP swab Carriage 2009 M 
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16399_7_6
3 3081 
The 
Gambia NP swab Carriage 2009 M 
16399_7_8
0 3081 
The 
Gambia NP swab Carriage 2009 M 
16453_2_3 3081 
The 
Gambia NP swab Carriage 2009 F 
17794_7_1
53 
1231
0 
The 
Gambia NP swab Carriage 2013 M 
17794_8_1 3081 
The 
Gambia NP swab Carriage 2009 M 
17794_8_1
14 3081 
The 
Gambia NP swab Carriage 2009 M 
17794_8_9
3 3081 
The 
Gambia NP swab Carriage 2010 F 
19183_3_2
6 618 
The 
Gambia NP swab Carriage 2007   
19183_3_2
7 618 
The 
Gambia NP swab Carriage 2007   
19183_3_2
8 618 
The 
Gambia NP swab Carriage 2007   
19183_3_2
9 618 
The 
Gambia NP swab Carriage 2007   
19183_3_3
0 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_3
1 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_3
2 618 
The 
Gambia NP swab Carriage 2007   
19183_3_3
5 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_3
6 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_3
7 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_3
8 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_3
9 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_4
0 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_4
1 303 
The 
Gambia NP swab Carriage 2007   
19183_3_4
2 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_4
3 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_4
4 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_4
8 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_4
9 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_5
0 618 
The 
Gambia NP swab Carriage 2008   
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19183_3_5
3 217 
The 
Gambia NP swab Carriage 2007   
19183_3_5
4 618 
The 
Gambia NP swab Carriage 2007   
19183_3_5
5 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_5
6 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_5
7 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_5
8 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_6
0 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_6
1 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_6
2 618 
The 
Gambia NP swab Carriage 2007   
19183_3_6
3 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_6
4 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_6
5 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_6
6 618 
The 
Gambia NP swab Carriage 2007   
19183_3_6
7 618 
The 
Gambia NP swab Carriage 2007   
19183_3_6
8 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_6
9 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_7
1 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_7
2 618 
The 
Gambia NP swab Carriage 2007   
19183_3_7
3 618 
The 
Gambia NP swab Carriage 2007   
19183_3_7
4 618 
The 
Gambia NP swab Carriage 2007   
19183_3_7
5 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_7
6 303 
The 
Gambia NP swab Carriage 2007   
19183_3_7
7 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_7
8 618 
The 
Gambia NP swab Carriage 2007   
19183_3_8
3 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_8
4 3081 
The 
Gambia NP swab Carriage 2008   
19183_3_8
5 3081 
The 
Gambia NP swab Carriage 2008   
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19183_3_8
6 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_8
7 3081 
The 
Gambia NP swab Carriage 2007   
19183_3_8
9 3081 
The 
Gambia NP swab Carriage 2008   
19341_1_1
58 3081 
The 
Gambia Lung Aspirate Invasive 2015 M 
19341_1_1
64 3081 
The 
Gambia Blood Invasive 2015 M 
19341_1_1
65 3081 
The 
Gambia Blood Invasive 2015 M 
19341_1_2 
1219
7 
The 
Gambia CSF Invasive 2015 F 
20402_4_1
06 3081 
The 
Gambia Blood Invasive 2015 M 
20402_4_1
56 3081 
The 
Gambia NP swab Carriage 2014 F 
20402_4_1
81 3081 
The 
Gambia NP swab Carriage 2011 F 
20402_4_2 
1219
7 
The 
Gambia CSF Invasive 2015 F 
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Appendix 1.2 List of genes unique to clades in the accessory region of the 
genome 
Unique to clade 1     
Gene 
Non-unique Gene 
name Annotation 
prtR   HTH-type transcriptional regulator PrtR 
group_3915   hypothetical protein 
bspRIM   Modification methylase BspRI 
sugB   Trehalose transport system permease protein SugB 
group_3901   hypothetical protein 
fucA   L-fuculose phosphate aldolase 
rnhB   Ribonuclease HII 
rafA_1   Alpha-galactosidase 
group_223   hypothetical protein 
group_3197   hypothetical protein 
araP   L-arabinose transport system permease protein AraP 
group_136   hypothetical protein 
rhaB   L-Rhamnulokinase 
group_3905   hypothetical protein 
repN   Replication initiation protein 
group_3907   hypothetical protein 
group_3909   hypothetical protein 
group_3910   hypothetical protein 
group_3911   hypothetical protein 
group_660   hypothetical protein 
group_3914   hypothetical protein 
hsdR   Type-1 restriction enzyme R protein 
Int-Tn_1   Transposase from transposon Tn916 
group_3898   hypothetical protein 
sftA   DNA translocase SftA 
group_3921   hypothetical protein 
group_3922   hypothetical protein 
hmo   4-hydroxymandelate oxidase 
      
Unique to clade 3     
group_808   putative HTH-type transcriptional regulator 
group_1811 recX Regulatory protein RecX 
bglA_2   Aryl-phospho-beta-D-glucosidase BglA 
group_1789   Arylsulfatase 
glcA   Glucan endo-1,3-beta-glucosidase A1 
group_514 glnP_1 Glutamine transport system permease protein GlnP 
group_4999 mutX_1 8-oxo-dGTP diphosphatase 
xerC_1   Tyrosine recombinase XerC 
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tcyB   hypothetical protein 
      
      
Unique to clade 1 
ad 2     
glnP_2   
putative glutamine ABC transporter permease protein 
GlnP 
mutX_2   8-oxo-dGTP diphosphatase 
gutB   Sorbitol dehydrogenase 
group_807   putative HTH-type transcriptional regulator 
butA   Aminoglycoside 3'-phosphotransferase 
leuA_1   2-isopropylmalate synthase 
recX   Regulatory protein RecX 
bglH_1   Aryl-phospho-beta-D-glucosidase BglH 
group_397 natA_1 ABC transporter ATP-binding protein NatA 
msmE_2   Multiple sugar-binding protein 
eabC   Blood-group-substance endo-1,4-beta-galactosidase 
      
Unique to clade 2     
capA   Capsule biosynthesis protein CapA 
      
      
Unique to clade 2 
ad 3     
group_410 hmo 4-hydroxymandelate oxidase 
group_539 ecfT_1 
Energy-coupling factor transporter transmembrane 
protein EcfT 
msbA_2   putative ABC transporter ATP-binding protein 
doc   Toxin Doc 
group_572 fucA L-fuculose phosphate aldolase 
group_542 ykoD_1 Putative HMP/thiamine import ATP-binding protein YkoD 
fucU   L-fucose mutarotase 
group_431 manX_3 PTS system mannose-specific EIIAB component 
group_1497 eabC Blood-group-substance endo-1,4-beta-galactosidase 
soxS   Regulatory protein SoxS 
group_3293 manZ_3 Mannose permease IID component 
levE   
Fructose-specific phosphotransferase enzyme IIB 
component 
group_1499 rhaB L-Rhamnulokinase 
group_3356 rnhB Ribonuclease HII 
manY_2   Mannose permease IIC component 
group_428 fucI L-fucose isomerase 
irtA   Iron import ATP-binding/permease protein IrtA 
group_873 adhB Alcohol dehydrogenase 2 
      
      
 Appendix 
 
232 | P a g e  
 
Unique to clade 1 
ad 3     
bglA   6-phospho-beta-glucosidase BglA 
group_3507   hypothetical protein 
group_582   hypothetical protein 
group_140   hypothetical protein 
group_1758   hypothetical protein 
licC_2   Lichenan permease IIC component 
lacF_1   
Lactose-specific phosphotransferase enzyme IIA 
component 
licB_1   
Lichenan-specific phosphotransferase enzyme IIB 
component 
group_3918   hypothetical protein 
licR_1   putative licABCH operon regulator 
group_75   hypothetical protein 
group_1021   hypothetical protein 
group_139   hypothetical protein 
ricR   Copper-sensing transcriptional repressor RicR 
iscS_1   Cysteine desulfurase IscS 
 
 
